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Chapter 1: Introduction 11 Introduction
1.1 Inflammatory bowel diseases, a complex disorder
Numerous mucosal inflammatory diseases which, before the 20th century, were either rare
or completely absent in populations of industrialized countries (Bach et al., 2002), have sig-
nificantly increased over recent decades due to different life-style and environmental fac-
tors. Most prominent examples are CD, which was unknown until 1920 (Crohn et al., 1984),
atopic eczema (OMIM 603165), and asthma (OMIM 600807). This increase in barrier organ
diseases suggests infectious or toxic agents associated with the concomitant changing living
conditions. An altered composition of the commensal bacterial flora that is due to hygiene,
antibiotics, and different nutrition, is also thought to be a key trigger of an inflammatory bar-
rier disease but the precise mechanisms at work are not clear yet. Known and proposed bar-
rier disease susceptibility factors involve barrier integrity (Palmer et al., 2006), immuno-
regulatory (Valentonyte et al., 2005), and pathogen defense related genes (Hugot et al., 2001).
In contrast to Mendelian or near-Mendelian inherited diseases, complex diseases, such as
inflammatory bowel diseases, result from many predisposing variants across the genome.
Diseases are said to be complex, if their etiology is based on the complex interplay of several
predisposing genetic factors with the environment and the microbial metagenome and they
are common, if the prevalence is higher than 0.1% (100 cases per 100,000) in the general pop-
ulation.
Similar histological appearance, cellular activation patterns, and common susceptibility loci
identified by genome-wide linkage studies (Becker et al., 1998), all indicate that there are
common mechanisms at work in inflammatory disorders, which make them particularly
suited to joint analyses.
The most intimate contact with the outside world takes place at the 5,000 square meter sur-
face of the intestines. Considering the often hostile environment, this contact usually seems
to take place without any troubles. Inflammatory bowel diseases (IBD) is characterized by
perturbed control of inflammation in the gut, and in its interaction with bacteria, and dam-
age to the gut wall (Schreiber et al., 1998). IBD (OMIM 601458) is divided into the the main
subphenotypes CD (CD; OMIM 266600) and ulcerative colitis (UC; OMIM 191390) and as
many as 1.4 million persons in the United States and 2.2 million persons in Europe suffer
from these diseases (Loftus et al., 2004). Although mortality is low, morbidity associated with
these diseases is substantial. IBD is also considered a prototype, which will help in the under-
standing of other chronic inflammatory disorders, e.g. rheumatoid arthritis (RA), where the
phenotype is less clear and the disease organ less accessible.
Chapter 1: Introduction 21.1.1 Pathogenesis and pathophysiology
IBD is the result of an abnormal immune response of the gut mucosa triggered by one or
more environmental risk factors in people with predisposing gene variations. The median
age of onset is 26.5 years for sporadic cases of CD and 22.0 years for familial CD, as deter-
mined by Colombel and colleagues (1996). Given this low age of onset and the unpredictable
fluctuating symptons, CD imposes a substantial personal burden, with time off work, need
for expensive drugs, or surgery and multidisciplinary care. In addition, annual costs for in-
flammatory bowel diseases drugs are a major economical factor for public health systems,
e.g. yearly 7.0 million US dollars in Sweden (Blomqvist et al., 2001).
CD and UC have a combined prevalence of 200–300 per 100,000 in the United States and the
life-time risk has been calculated to be 0.15% for CD and 0.3% for UC. With almost twice as
many people suffering from UC than from CD, incidence of IBD is about 3–20 new cases per
100,000 each year (Probert et al., 1996; Shivananda et al., 1996) and is rising worldwide (see
also fig. 1-1). Furthermore, a north-south gradient across Europe was reported, with the
highest prevalence being in Iceland and Stockholm and the lowest in Portugal and Greece
(Shivanda et al., 1996). Significant differences in prevalence exist among different ethnic
groups living in the same geographic region, displayed by the two- to eightfold higher prev-
alence in Ashkenazi Jews versus non-Jews (Roth et al., 1989).
Fig. 1-1 Inverse relation between the Incidence of prototypical infectious diseases (A) and the incidence of immune disorders (B) after
World War II. Reprinted from Bach et al. (2002).
Chapter 1: Introduction 3Clinical features include abdominal pain, chronic diarrhea, rectal bleeding, weight loss, in-
testinal stenoses, fistulae, growth retardation, fever, and anaemia. A severe course of UC is
the formation of a toxic megacolon, a sudden sessation of bowel function leading to toxic di-
latation and eventual perforation of the bowel. While some patients develop a chronically ac-
tive disease, others come to a complete clinical remission between active episodes. IBD is
also associated with extraintestinal manifestations, such as arthritis and uveitis (Nordgren et
al., 1992). Patients of UC have an increased risk to develop primary sclerosing cholangitis and
vice-versa (Cullen et al., 2003), an inflammatory disorder of the bile duct. In addition, IBD is
frequently found in well-defined genetic diseases, such as Turner’s syndrome (Price et al.,
1979; Kohler et al., 1981; Scarpa et al., 1996), Hermansky-Pudlak syndrome (Shanahan et al.,
1988; Schinella et al., 1980; Mahadeo et al., 1991), and glycogen storage disease type Ib, which
is characterized by neutropenia and abnormal neutrophil function (Yang et al., 1995). IBD,
in particular UC, is also associated with several other immune-mediated disorders such as
ankylosing spondylitis thyroiditis and multiple sclerosis (Satsangi et al., 1997; Parkes et al.,
1997).
Fig. 1-2 Clinical characteristics of Crohn’s disease. (A) Bowel of healthy individual; (B) heavily inflamed bowel with ulcers of a patient;
(C) extraintestinal inflammation of the skin of a patient. By courtesy of Dr. Susanna Nikolaus.
Some investigators have argued that CD and UC are at opposite ends of a continuous range
of disease, but more and more evidence suggests that they are distinct disorders that share
some genetic and environmental risk factors and differ in others (Ferguson et al., 1994; Sha-
nahan et al., 2001). In approx. 10% of cases, definitive classification of CD or UC cannot be
made and these are designated as “indeterminate colitis”. The discrimination between CD
and UC is based on clinical, endoscopic, radiological, and histopathological features (Podol-
sky et al., 1991; Lennard-Jones et al., 1989; Truelove et al., 1976). Recently, gene expression
profiling has added further evidence to define CD and UC as distinct molecular entities
(Warner et al., 2002). The following table briefly summarizes the important differences be-
tween CD and UC:
Chapter 1: Introduction 4Since its first description in 1913, the cause of CD is still largely unknown. Except for cigarette
smoking (Andus et al., 2000), uncertainty still exists around other environmental (risk) fac-
tors, such as diet (e.g. fiber, sugar, milk, fast food; see also Persson et al., 1992), stress (for re-
view see Mawdsley et al., 2005), and domestic hygiene (e.g. hot running water). Endogenous
modifiers of disease activity – such as the effect of the brain-gut axis and psychological stress
– are still under investigation. Breastfeeding is supposed to provide protection against CD
and UC according to Klement et al. (2004). In contrast to CD, tobacco smoking is protective
for UC (Shanahan et al., 2002). In one study, the relative risks of developing UC in heavy ex-
smokers, all ex-smokers, non-smokers, and smokers were 4.4, 2.5, 1.0, and 0.6, respectively
(Lindberg et al., 1988). Nicotine is probably the main active ingredient in this association
(Birrenbach et al., 2004), but the mechanisms remain unknown.
An interesting hypothesis was made by Hugot et al. (2003), who described an association of
CD with refrigeration. This cold chain hypothesis is based on the observation that psy-
chotrophic bacteria Yersinia spp and Listeria spp can exist and grow at temperatures be-
tween -1°C and 10°C and that cold-chain development paralleled the outbreak of CD during
the 20th century. Chronic ingestion of psychotrophic bacteria by genetically pre-disposed
individuals might invoke an over-active immune reaction, assuming the loss of tolerance
owing to the lack of exposure to microbial antigens during childhood. Several arguments can
be made to emphasize the critical role of the commensal microflora. First, the bacterial flora
is modified by behavioral changes influencing immune responses, not only locally, but also
systemically. Second, animal models of intestinal inflammation demonstrate that germ-free
conditions can completely abrogate the development of “spontaneous” IBD. A third argu-
ment is the close association between exposure to microbial matter and disease develop-
ment. The earlier the exposure to microbes, the higher the expression levels of PAMP
receptors and the lower the risk of disease development and “overreactions” (Shanahan et
al., 2002; Bach et al., 2002). The physical barrier of the intestine consists of a thick glykocalyx
Crohn’s disease Ulcerative colitis
inflammation is transmural and discontinuous 
(“skip lesions”)
continuous inflammation starting from the rectum that 
is restricted to superficial layers (mucosa)
any part of the gastrointestinal tract may be involved, 
most frequently the terminal ileum and colon
inflammation is limited to rectal (proctitis) and colonic 
mucosal layers
presence of granulomas, stenoses, intestinal/peria-
nal fistulas
no fistulaes, stenoses, or granulomas observed
more often associated with psoriasis and thrombotic 
vascular complications
more often associated with ankylosing spondylitis, ar-
thritis, primary sclerosing cholangitis, increased risk of 
colon carcinoma
Table 1-1 Major differences between the two IBD subphenotypes CD and UC. According to Yang et al. (2001).
Chapter 1: Introduction 5mucous layer coating the apical surface of the epithelial cells. Epithelial cells are laterally
joined by tight and adherens junctions. Defects in this protective lining allows the influx of
outside components, such as bacteria, which can result in an exagerrated immune response.
The bacteria within the enteric lumen have a complex open ecosystem that is continuous
with the external environment, and there are up to ten times more bacteria (1012 bacteria/g
faeces in the colon) than there are cells in the human body. With over 400 bacterial species,
identified by 16S rRNA, accounting for over one kilogram of intestinal contents (Farrell et al.,
2002; Shanahan et al., 2002) and anaerobes predominating, this dynamic complex has been
described as a neglected organ (Bocci et al., 1992). However, progress in such investigations
has been hampered by gaps in our knowledge of the normal flora. At least half of the bacterial
species cannot be cultured. Reports of qualitative changes have been inconsistent or con-
flicting (Sartor et al., 1997; Shanahan et al., 2000).
Finally, a possible link exists between de-worming and the emergence of immunological dis-
ease (Weinstock et al., 2005; Korzenik et al., 2005). Recent studies suggest that it is possible to
downregulate aberrant intestinal inflammation in humans with the porcine whipworm Tri-
churis suis (Summers et al., 2003; Summers et al., 2005). Eggs of this helminth are orally ad-
ministered to patients. As especially Crohn's disease probably results from failure to
downregulate a chronic Th1 intestinal inflammatory process, induction of a Th2 immune re-
sponse by intestinal helminths diminishes Th1 responsiveness.
Fig. 1-3 Current knowledge of the etiology of IBD. CD and UC have an overlapping phenotype, and changes in diagnosis are quite
frequent. Disease-causing factors can either lead to an increased risk or protect individuals from an outbreak. It is widely accepted that
different combinations of susceptibility factors can result in the same disease (“phenocopies”).
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1.2.1 Genetic evidence from family and twin studies
Strong familial clustering has been observed for CD and UC in the late 1980s (Kuster et al.,
1989; Mayberry et al., 1989; Colombel et al., 1996; Peeters et al., 1996) and systematic inves-
tigations have yielded relative sibling risks of 6–9 for UC (Orholm et al., 1991; Meucci et al.,
1992) and 15–50 for CD (Tysk et al., 1988; Satsangi et al., 1994; Schreiber et al., 2005; Fielding
et al., 1986).
Besides familial risk data and segregation analysis (Duerr et al., 2002; Orholm et al., 1993),
strong genetic support was corroborated by twin studies. Tysk and colleagues (1988) used the
Swedish twin registry and inpatient hospital records to identify twins affected by inflamma-
tory bowel diseases. Monozygotic twins with UC had a proband concordance of 6.3%. None
of the dizygotic twins with UC were concordant. Monozygotic twins with CD had proband
concordance of 58.3% while dizygotic twins had proband concordance of 3.9%. A total of 80
twin pairs were considered (including 34 monozygotic) and despite discordance for pres-
ence or absence of inflammatory bowel diseases, no pair was affected by both UC and CD.
Thomson et al. (1996) traced 144 twin pairs with inflammatory bowel diseases from 16,000
members of the National Association for Colitis and Crohn’s Disease. Six of 38 monozygotic
twins with UC and five of 25 with CD were concordant for the disease. The relative risk for an
unaffected identical twin to develop inflammatory bowel diseases compared with that for a
non-identical twin was 3.49 (p = 0.03). Once again, in the majority of cases only one twin had
developed overt inflammatory bowel diseases; however, there was no pair of twins with
mixed inflammatory bowel diseases.These studies and case reports all indicate a higher con-
cordance for inflammatory bowel diseases in monozygotic than in dizygotic twins, suggest-
ing that genetic factors rather than environmental factors play the primary role in disease
pathogenesis. Since Tysk et al. calculated the heritability of liability for UC to be 0.53 and that
for CD to be 1.0, this suggests a much larger genetic influence in CD. The existing difference
in disease prevalence among distinct ethnical groups in some populations and, therefore,
the same exposure to environmental factors, also hints at a genetic component in the etiolo-
gy of IBD (Jayanthi et al., 1992; Probert et al., 1996). The relative contribution of genetic fac-
tors to the pathogenesis of CD may be greater than in schizophrenia, asthma, hypertension,
or longevity, and at least equivalent to that in insulin-dependent diabetes.
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The human DNA sequence differs only by approx. 1.2% from the chimpanzee genome (Chen
et al., 2001) and there is an 0.1% difference between two individual human genomes. The sin-
gle nucleotide polymorphisms and other variants contribute mainly to these differences and
they have become the toolkit of the geneticists. Polymorphic markers, which are not neces-
sarily involved in a specific trait themselves, are often used as proxies for susceptibility loci
that contribute to the disease. The four main types of DNA markers are restriction fragment
length polymorphisms (RFLPs), variable number of tandem repeat polymorphisms (VNTRs),
microsatellites (short tandem repeats, STRs), and single nucleotide polymorphisms. Only re-
cently, a major role for copy number polymorphisms (CNV) has been suggested.
SNPs are single base-pair differences between genomic sequences and are highly abundant
in the human genome. In 2001, the International SNP Map Working Group published a SNP
map consisting of 1.42 million SNPs, or approximately one SNP per 1.9 kb (Sachidanandam
et al., 2001). In August 2006, the same database (dbSNP build 126) contained a total of 11.96
million SNPs, from which 5.65 million were annotated as validated. However, not all SNPs in
public databases are truly polymorphic for a given population. Botstein and Risch (2003) ar-
gue that there are probably more than 15 million SNPs with a frequency of at least 1%, which
corresponds to almost 1 SNP per 200 base-pairs. SNPs are mostly biallelic and, therefore, less
informative than microsatellite markers. However, as they are much more frequent, less
prone to undergo mutation, and can also be scored more easily with automatic methods
than microsatellites, SNPs are regarded as the state-of-the-art tool for fine mapping in com-
plex diseases.
There is a clear relationship between the severity of amino acid replacement and the likeli-
hood of clinical observation. As compared with a conservative amino acid substitution, a
nonsense change is 9.0 times more likely to present clinically (Krawczak et al., 1998). Corre-
sponding ratios for radical, moderately radical, and moderately concervative changes are 3.0,
2.3, and 1.8, respectively. This useful classification of SNPs according to their codon replace-
ment was first described by Grantham et al. (1974), and is therefore termed the Grantham
scale. Other used terms to classify SNPs are nonsense (generates stop codon), missense, in-
tronic, non-synonymous (amino acid sequence changes), synonymous (no sequence change
of gene product), silent, neutral, coding, and non-coding. Missense and nonsense SNP are
significantly less abundant than synonymous or intronic SNPs, reflecting evolutionary selec-
tion against radical changes (Stephens et al., 2001).
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Once a genetic background is assumed for a disease, the next important step is to reduce the
vast number of genes, approximately 28,000 to 35,000 genes (Roest Crollius et al., 2000; Ew-
ing et al., 2000), to a few susceptibility regions in the genome. One method that was devel-
oped for already in the 1980s for that purpose is genome-wide linkage analysis.
Alleles close to each other on a chromosome tend to be inherited together, i.e. they are
linked. Linkage analysis tests if co-segregation between a phenotype and a genetic marker
exists within a pedigree of many generations, or in many independent families. If only one
disease locus exists for a given disease, it will be located in a region of the genome that is
shared by all affected individuals. The most common approach in genetically complex dis-
eases is the affected sib-pair linkage analysis. Many (hundreds of) pairs of siblings who are
affected by a specific disease are genotyped to determine the proportion of parental alleles
shared at each marker. If the marker allele sharing between affected siblings is significantly
different from the expected ratio (under the assumption of no linkage) of 25%, 50%, and 25%
sharing of 2, 1, and 0 parental alleles respectively, the region surrounding the markers is
linked to the disease. The resolution relies on detecting crossovers between markers and the
disease locus within families and there will be only few such events close to the locus among
affected sib-pairs; hence the candidate interval will be large. On the other hand, it is possible
to pick up the effect of a disease locus at longer distances and, therefore, the spacing between
markers in a linkage scan can be relatively wide (typically 5–10 cM with 1 cM = 1% recombi-
nation rate). This is what made whole genome linkage scans possible. A whole genome link-
age scan usually includes typing of about 300–800 evenly-distributed microsatellites. These
short tandem repeats are di-, tri-, and tetranucleotide repeats (e.g. [CA]n or [CAG]n) that are
abundant in the human genome (approx. 10,000). The LOD (logarithm of odds) score, which
is the favoured measure for linkage analysis, is the decadic logarithm of the probability that
two markers are linked with a given recombination value divided by the probability that they
are unlinked (see also Lander and Kruglyak criteria, 1995).
Numerous independent linkage scans have been performed for inflammatory bowel diseas-
es by different groups, giving rise to several identified susceptibility loci, with some replicat-
ing more consistently than others. IBD1 on chromosome 16 is the most widely and
consistently replicated linkage region among the detected regions. A summary of the most
important linkage regions is shown in table 1-2, page 9 and a detailed review of the the IBD
linkage literature can be found at the end of this thesis (9.1 on page 173) or in Zheng et al.
(2003). Although there are striking discrepancies among the genome-wide scans in respect
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age loci, indicating that multiple genes are involved in the pathogenesis of IBD.
Because Hugot et al. (1996) and Satsangi et al. (1996) detected strong evidences for linkage
on chromosomes 16, 12, 6, and 3, subsequent studies mainly focused on these candidate re-
gions. Thus, later identified, though being attractive loci as well, such as 14q, 19p, and 1p,
were less investigated. Collectively, genome scans have shown that CD and UC are distinct
disorders, which is most apparent in CD-specificity of the 16q12 (IBD1) locus. An additional
complexity is the variable role that different susceptibility loci might have in different ethno-
geographic populations, reflecting true genetic heterogeneity. More than three studies (Ri-
oux et al., 2000; Brant et al., 2000; Akolkar et al., 2001) reported significant differences
between Jewish and non-Jewish patients. Mwantembe et al. (2001) noted also that IBD is
more prevalent among South African whites than among blacks, a pattern observed else-
where as well. They concluded that the inflammatory process leading to IBD may be distinct
in different population groups. Besides genetic heterogeneity, the discrepancies between the
results of the various screens and follow-up linkage studies may be related to the difficulties
in detection of genes of modest effects in complex traits (Risch et al., 1996). Positive linkage
results are typically observed over very broad regions for genes of major effect (Cho et al.,
2000). Mapping resolution depends on both sample size and marker density, and even the
largest studies typically have a rather poor resolution of 5–10 cM, corresponding to approx.
5–10 Mb (Clark et al., 2003), although a high-resolution linkage study was reported just re-
cently (McKnight et al., 2006). Once the region of interest has been narrowed down to a suf-
ficiently small region, fine mapping is usually carried out in cases and controls by association
studies.
Name Locus Known disease genes
IBD1 16p12–q13 CARD15
IBD2 12p13.2–q24.1 –
IBD3 6p MHC region
IBD4 14q11–12 –
IBD5 5q31–33 SLC22A4/SLC22A5
IBD6 19p13 –
IBD7 1p32–36 –
IBD8 16p12 –
IBD9 3p21–26 –
Table 1-2 IBD linkage regions.
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Classical linkage analysis and positional cloning clearly remain the methods of choice for
identifying rare, high-risk, disease-associated mutations, owing to the clear inheritance pat-
terns they display. Although more than 1,200 genes (Botstein et al., 2003) have been charac-
terized for highly penetrating Mendelian phenotypes, only a small number of human genes
that contribute to complex diseases were identified by this classical “positional cloning” ap-
proach. Greater statistical power and finer resolution is achieved by SNP association studies
in a case-control setting. By using unrelated individuals, the information of numerous mei-
otic events throughout the multigenerational pedigree is indirectly extracted, thus leading to
significant narrowing of the region of interest (Nordborg et al., 2002; Botstein et al., 2003).
Owing to this physical narrowing and the lower level of informativity of biallelic SNPs, hun-
dreds of thousand SNPs are necessarys to carry out a genome-wide scan of sufficient cover-
age compared to max. 800 STRs for a genome-wide linkage scan. Precise SNP numbers are
still under debate and vary from 100,000 to 1,000,000 SNPs (Botstein et al., 2003). Discussions
will probably end with the availability of the 1000$ genome (Bennett et al., 2005) that extracts
genetic variation in toto. As millions of validated SNPs (see 1.2.2 on page 7) are annotated in
public databases, merely methodological problems limit coverage, albeit throughput contin-
uously increases (see fig. 1-4). Furthermore, a standard genome-wide scan for 400 cases and
400 controls still costs more than half a million Euro, posing a major obstacle for many re-
search groups.
Fig. 1-4 SNP genotyping method market overview. Whole genome SNP genotyping (WGG) methods exist since 2003 and the
throughput is increasing with time (y-axis). Genotypes per assay and DNA are shown on a logarithmical scale along the x-axis.
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more often than expected by chance. To investigate whether phenotypes are associated or
not, one usually collects two groups of individuals, e.g. patients and a control sample for
case-control design. In each group the proportion of interest is then determined. The usual
chi-square test for 2 x 2 tables is subsequently applied to determine statistical significance.
The strength of an association is often measured by the relative incidence or relative risk (RR)
or the correlation coefficient. However, potential effects that are unrelated to disease, such
as ethnic, social, or geographical stratification, could generate systematic differences be-
tween patients and controls. This problem of population stratification is generally overcome
by using a family-based association design, e.g. the transmission disequlibrium test (TDT;
Spielmann et al., 1993). Unfortunately, this design is expensive and computationally ineffi-
cient (Morton et al., 1998).
Botstein and Risch (2003) distinguish between two different types of genome-wide associa-
tion studies, namely a map-based (LD-based, indirect) and sequence-based (functional
SNPs, direct) approach, both being unbiased in terms of involved genes. A third and com-
monly employed association study is the so-called candidate gene approach. To this end,
genes are selected for genotyping based on their possible role in disease-associated path-
ways, animal models, or other characteristics.
Until recently, only few genome-wide association studies have been reported. A significant
number of large multi-center association studies are ongoing and a flood of related publica-
tions is expected within the next years. Early successes of genome-wide association studies,
showing the feasibility and power of this approach, are listed in the following table:
Reference Disease No. of SNPs Identified gene(s)
Martins Silva et al., 2003 Multiple sclerosis 3,974 MHC region
Smyth et al., 2006 Type I diabetes 6,500 IFIH1
Hu et al., 2005 Esophageal cancer 11,555 GASC1, EPHB1, PIK3C3
Namkung et al., 2005 Alcoholism 15,878 GABRA1
Nakamura et al., 2005 Crohn’s disease 72,738 TNFSF15
Ozaki et al., 2005 Myocardial infarction 92,788 LTA
Klein et al., 2005 Age-related macular degeneration 116,204 CFH
Herbert et al., 2006 Obesity 116,204 INSIG2
Maraganore et al., 2005 Parkinson disease 198,345 SEMA5A, PARK10+11 locus
Table 1-3 Early successes in disease-finding utilizing genome-wide association studies. Ordered by number of genotyped SNPs.
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“slopped over” to other organisms as well, e.g. mice (Liu et al., 2006).
1.2.5 Known susceptibility genes
Early segreation analyses suggested a major recessive gene for CD and a major dominant
gene for UC. However, CD and ulcerative are now considered polygenic traits. Support
comes from an increasing amount of published susceptiblity genes and several replicated
linkage loci. In IBD, disease genes involved in the regulation of the innate immune system,
mucosal integrity, and cell-cell interactions are all clearly plausible candidate genes. The
most important IBD genes and regions are briefly described in the next sections. For review
see also Noble et al. (2006) and Yamada et al. (2005).
1.2.5.1 CARD15
The first susceptibility locus for CD, which has received greatest support in replicative stud-
ies worldwide, is on the pericentromeric region of chromosome 16, and designated IBD1 lo-
cus. Mutations of the CARD15 (caspase activating recruitment domain, 15) gene in this
region have been conclusively associated with CD (Hugot et al., 2001; Ogura et al., 2001;
Hampe et al., 2001). NOD2 (nucleotide oligomerization domain), the protein product of
CARD15, functions as an intracellular sensor of muramyl dipeptide (MDP), a highly con-
served peptidoglycan (PGN) motif, common to many intraluminal bacteria. Therefore,
NOD2 is part of the pattern-associated molecular pathogen (PAMP) recognition system
(Hugot et al., 2001) and it is further a member of the CATERPILLER (CARD, transcription en-
hancer, R[purine]-binding, pyrin, lots of leucine repeats) protein family. Thus, CARD15 is
part of the evolutionary ancient innate immune system. Besides intestinal epithelial cells, it
is expressed in monocytes and activates nuclear factor κB (NF-κB), which is a key transcrip-
tional factor involved in initiation of immunoinflammatory responses (van Heel et al., 2001;
Mahida et al., 2001).
Besides a frameshift mutation 1007insC (“SNP 13”) that leads to a truncation of the transcript
in the leucine-rich repeat region, Hugot and others (2001) identified the two missense muta-
tions Arg702Trp (“SNP 8”) and Gly908Arg (“SNP 12”). Of the patients with CD, 10–30% were
heterozygous and 3–15% homozygous or compound heterozygous for the CARD15 muta-
tions; the corresponding proportions from the control population were 8–15% and 0–1% re-
spectively. Hugot and colleagues (2001) determined the relative risk of CD for heterozygous,
homozygous, or compound heterozygous individuals for the mutations to be 3-fold, 38-fold,
and 44-fold higher than for normal controls, respectively. Later, Croucher et al. (2003) con-
firmed that the disease-associated SNPs occur independently and share a common back-
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and more strongly predisposing muation.
In 2002, Lesage et al. sequenced all CARD15 exons plus flanking splice sites in 453 CD pa-
tients, 159 UC patients, and 103 healthy controls (1,430 chromosomes in total). They identi-
fied 67 SNPs, of which 31 were potential disease-causing mutations (DCM). SNP 8, 12, and 13
represented 32%, 18%, and 31% respectively, whereas the total of the rare mutations repre-
sented 19% of DCMs, thus they were categorized as “private mutations”. Interestingly, 93%
of all mutations were located in the distal third of the gene, once more highlighting the cru-
cial role of the leucine-rich repeat domain (LRR). CARD15 also plays a role in the susceptibil-
ity to Blau syndrome (Miceli-Richard et al., 2001), Psoriasis (Lee et al., 1990; Rahman et al.,
2003), early-onset sarcoidosis (Kanazawa et al., 2005), although sometimes different se-
quence variants are relevant than in CD (see fig. 1-5). Sarcoidosis is a granulomatous relaps-
ing inflammatory disease that mainly affects the lung, while Blau syndrome is a rare disease
typically defined by granulomatous arthritis, skin eruption, and uveitis occurring in the ab-
sence of lung or other visceral involvement.
Fig. 1-5 Different mutations in CARD15 contribute to distinct inflammatory disorders. Although CD-associated variants are mainly
found within the LRR domain, mutations linked to other diseases are predominantly situated in the nucleotide-binding domain found in
NACHT (NAIP, CIITA, HET-E and TP1), and the NAD (NACHT-associated domain). The CARD domains have been implicated in apoptosis
and NF-kB activation, the NBD (NACHT + NAD) domain in oligomerization, and the LRR in bacterial recognition. Purple: Blau syndrome;
light blue: early-onset sarcoidosis; yellow: CD. Brown ovals depict the binding site of the magnesium-nucleotide complex. From Schreiber
et al., 2005.
CARD15 variants seem to account for less than 20% of CD and they have not been found to
be associated with collagenous colitis, another rare subphenotype of IBD (Madisch et al.,
2006). The CD-associated mutations arose about 40,000 years ago (Schreiber et al., 2005),
suggesting that positive selective evolutionary pressure (Akey et al., 2002) is missing, high-
lighting the role of just recently changed living conditions due to “Westernization”.
“SNP” dbSNP ID nt change aa change Exon fCo fCa OR
8 rs2066844 C14772T R702W 4 4.7% 10.5% 2.33 (95%CI: 1.81 – 3.00)
12 rs2066845 G25386C G908R 8 1.3% 4.0% 3.12 (95%CI: 2.03 – 4.78)
13 rs2066847 32629insC 1007insC 11 3.9% 15.5% 4.17 (95%CI: 3.22 – 5.39)
Table 1-4 Summary of the three major mutations in the CARD15 coding sequence. Minor allele frequencies for cases and controls
were calculated based on 1091 healthy German controls and 1150 German CD patients. Odds ratios and 95% confidence intervals
were calculated for carriership of the risk allele, i.e. 11 + 12 vs. 22 (unpublished data).
Chapter 1: Introduction 14Fig. 1-6 Effects of CARD15 mutations on the NOD2 protein and the intestinal epithelial barrier. (A) MDP is recognized intracellularly
by the LRR of NOD2. This leads to self-oligomerization and RIP2-mediated NF-κB activation. Regulated chemokine secretion and defensin
release contribute to mucosal homeostasis. (B) A defect in the MDP-sensing LRR, as caused by the CD-associated variants, leads to loss-of-
barrier function, as expression of protective chemokines and defensins is reduced. Illustration from Schreiber et al., 2005.
As Yamazaki et al. (2002) showed that CARD15 variants do not play a significant role in the
pathogenesis of Japanese CD patients (see also Inoue et al., 2002) and it is further known that
mutations are absent or very rare in Chinese (Leong et al., 2003) and Koreans (Lee et al.,
2005), once more an ethnic difference in genetic susceptibility to CD is suggested. Low fre-
quencies of CARD15 risk alleles have also been observed in the New Zealand Maori (Gearry
et al., 2006), a population in which IBD is uncommon (Wigley et al., 1962; Schlup et al., 1986)
and in African colored patients (Zaahl et al., 2005; Kugathasan et al., 2005). The contribution
of CARD15 variants to disease susceptibility is also much lower in northern Europe (Finland,
Ireland, Scotland, Sweden, Iceland, and Norway) than elsewhere in Europe (Arnott et al.,
2004; Idestrom et al., 2005; Medici et al., 2006). A meta-analysis of 42 case-control studies ex-
amined the ORs for development of CD for carriers of one mutant allele (Economou et al.,
2004) of SNP 8, 12, and 13 and risk was increased by a factor of 4, 3, or 2, respectively.
In summary, the discovery of NOD2/CARD15 has dramatically changed the focus of IBD re-
search to the role of the innate immune system (Schreiber et al., 2005). Was the disease
pathophysiology initially considered a merely T cell-driven process, it is now mainly viewed
as a barrier disorder.
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The protein NOD1, a structural homologue of NOD2, is encoded by the CARD4 gene on chro-
mosome 7p14. Because of its homology to NOD2, its expression in epithelial cells, its ability
to recognize Shigella flexneri LPS (Girardin et al., 2001) and to activate NF-κB, plus a known
linkage peak on 7p14–p15 (Satsangi et al., 1996), association of CARD4 with IBD was exhaus-
tively tested by several groups. Zouali et al. (2003) found five non-conservative changes in the
CARD4 coding sequence, of which E266K (MAF = 0.28) was the only non-private mutation.
This nsSNP was not associated with UC, CD, or IBD in their sample, though. In 2005, Hysi and
others found an insertion-deletion polymorphism (ND1+32656) near the beginning of
intron 9 that was associated with the presence of asthma and elevated immunoglobulin E
levels. They further showed that the variant influences the binding of an unknown nuclear
factor. In contrast to asthma, the more common allele of ND1+32656 was found to be associ-
ated with IBD in a British panel (McGovern et al., 2005). ND1+32656 was further significantly
associated with early age of onset CD and IBD. McGovern et al. (2005) also observed the pres-
ence of a strong protective two-marker haplotype (ND1+32656*2/rs2907748*1).
1.2.5.3 TNF-α
The pro-inflammatory cytokine TNF-α plays a crucial role in mucosal inflammation and is
likely to be at the apex of the inflammatory cascade in CD (Murch et al., 1993; Satsangi et al.,
1998), as TNF-α can induce apoptosis and activate NF-kB through signaling cascades ema-
nating from TNFR1. The TNF locus, which maps to the IBD3 locus on chromosome 6 within
the class III region of MHC, between HLA-B and HLA-DR, is a good site to look for genotype-
phenotype relationships (Sashio et al., 2002). Many polymorphisms described in the TNF
gene have already been studied in IBD (Fowler et al., 2005; Bouma et al., 1996 and 1998; Louis
et al., 2000). TNF levels are elevated in the serum, mucosa, and stool of IBD patients, and in-
fusion of monoclonal anti-TNF antibody is a highly efficacious IBD therapy (Komatsu et al.,
2001; Braegger et al., 1992; Breese et al.; 1994; D’Haens et al., 1999). In 2002, van Heel et al.
identified a polymorphism in the TNF-α promoter as a marker of IBD susceptibility in the UK
population. However, it remains unclear whether the TNF-857 variant is a true disease allele
or a marker allele in LD with a neighbouring functional polymorphism. Interestingly enough,
TNF-α has been found to upregulate NOD2 in epithelial cell lines (Rosenstiel et al., 2003).
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In 2001, John Rioux and colleagues described a systematic approach for LD mapping in the
IBD5 linkage region (Rioux et al., 2000; Ma et al., 1999) for CD on chromosome 5q31. This led
to the finding of a strongly disease-associatied haplotype, spanning 250 kb and comprising
11 discrete haplotype blocks (Daly et al., 2001). However, analogous to the HLA region, tight
LD across the region hindered them to identify a single causative mutation. Instead, Rioux et
al. (2001) identified 11 significant SNPs that carry equivalent genetic information and are
strongly associated with CD, a finding that was later replicated in several populations (Gial-
lourakis et al., 2003; Mirza et al., 2003; Negoro et al., 2003). Three years later, Peltekova et al.
(2004) detected 10 new SNPs by resequencing the IBD5 interval, of which two were found to
have functional effects. The first is a C→T missense substitution in exon nine of solute carrier
family 22 member four (SLC22A4) that causes the amino acid substitution L503F at an evolu-
tionarily conserved position in the 11th transmembrane domain of OCTN1. The second SNP
is a G→C transversion in the SLC22A5 promoter (-207G→C), which disrupts a functional pro-
moter element. SLC22A4 and SLC22A5 are within a single haplotype block (block 7; see
fig 1-7, page 17) and encode for the organic cation transporter proteins OCTN1 and OCTN2,
respectively. The protein OCTN1 has a length of 551 amino acids, is strongly expressed in kid-
ney, trachea, bone marrow, and to a lesser extent in the small bowel, and has been charac-
terized as a carnitine transporter (Tokuhiro et al., 2003). OCTN2, that is 557 aa long, is 75.8%
homologous to OCTN1, and functional studies have shown it to be a high affinity sodium car-
nitine transporter, expressed in kidney, smooth muscle, and heart tissue (Tamai et al., 1998).
In contrast to most of the studied populations, where the two-allele risk haplotype “TC” is
prevalent (e.g. 54% in affected vs. 42% in unaffected; Peltekova et al., 2004), the previously
identified variants of IBD5 have been found to be extremely rare in the Japanese population
(Negoro et al., 2003; Yamazaki et al., 2004). An intronic SNP rs2268277 of SLC22A4 has been
reported to be associated with another chronic inflammatory disorder, namely rheumatoid
arthritis (Tokuhiro et al., 2003).
The observation that the frequencies of L503F and -207G→C in individuals who do not carry
the general IBD5 risk haplotype are not significantly different in cases and controls (Torok et
al., 2005; Fisher et al., in press), led to an ongoing debate whether the real disease-causing
mutation(s) remain(s) to be identified. Though Peltekova et al. (2004) showed an altered
function or expression of the OCTN1 and OCTN2 cation transporterts, it is generally agreed
that the link between aberrant OCTN function and CD remains to be established.
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above the line are transcribed from left to right and those below the line are transcribed from right to left. (B) 11 blocks numbered 1 to 11
(between 3 kb and 92 kb) each of limited genetic diversity are punctuated by sites of recombination. (C) D’ scores are shown to demonstrate
the tight linkage disequilibrium between the SNPs that were analyzed. The lowest D’ (D’ = 0.959) was observed between IGR2096 and
the OCTN2 variant (-207G→C). (D) Location of the SNPs that were analysed, IGR2222 representing the OCTN2 variant (-207G→C) and
IGR3002 representing the OCTN1 variant (1672C→T). IGR2078, which was used by Peltekova and colleagues (2004) to represent the
extended IBD5 haplotype, is located in block 4. Illustration from Noble et al. (2005).
1.2.5.5 DLG5
Refining the linkage peak of Hampe et al. (1999) on chromosome 10q23, led to the associa-
tion finding between the discs large homolog 5 (DLG5; 79,220,557–79,356,354 bp) and IBD
(Stoll et al., 2004). Since then, several investigations have led to controversial findings and
ongoing discussions concerning the validity of the initial finding.
SNP 113G→A (rs1248696), which results in the amino acid substitution R30Q in the DUF622
domain, is the only haplotype tagging SNP of the significantly overtransmitted haplotype D
in the DLG5 gene. R30Q is completely absent, i.e. monomorphic, in Greek (Gazouli et al.,
2005) and Japanese (Yamazaki et al., 2004) patients. Failure of replication of the positive as-
sociation of R30Q and of the negative association with haplotype A with IBD and CD was re-
ported by Torok et al. (2005), Noble et al. (2006), and Vermeire et al. (2005) for other European
populations. Although not seeing the negative haplotypic association with IBD, Daly et al.
(2005) replicated the positive association of the nsSNP R30Q in a Candian and Italian patient
panel, but not in a panel from the United Kingdom. In 2006, Friedrichs et al. determined
DLG5 as a male-specific CD susceptibility locus by using multivariate logistic regression
analyses on the previous datasets of Stoll et al. (2004) and Daly et al. (2005). This finding is
consistent with the observation of Fisher et al. (2002), who identified the linkage region 10q
as a male-specific locus. Similar to the observation made by Tenesa et al. (2006), the observed
gender-specificity is a result of divergent allele frequencies in healthy controls and not in the
CD patients. Friedrichs et al. (2006) argument that this transmission ratio distortion of the Q
allele among controls is likely to be the consequence of prenatal processes. The question re-
mains why the observed gender-dependent disparity in Q allele frequencies is offset in male
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CARD15risk and CARD15nonrisk group with no association seen in the latter and an increased
association in the first (Stoll et al., 2004; Vermeire et al., 2005).
The DLG5 protein belongs to the group of membrane-associated guanylate kinases
(MAGUKs) and as such contains 4 PDZ domains, one SH3 domain followed by one guanylate
kinase (GUK) domain. Additionally, DLG5 contains an N-terminal domain DUF622 of un-
known function. All domains are assumed to be involved in protein-protein interactions,
supporting the notion that DLG5 serves as a multi-functional adapter and scaffold protein
which is involved in the maintenance of epithelial integrity (Friedrichs et al., 2006). In addi-
tion, DLG5 has been reported to be involved in maintaining cell shape and polarity (Humbert
et al., 2003), and to be located at cell-cell contact sites (Wakabayashi et al., 2003). The R30Q
variant is thought to disturb binding to Rab GTPase and thus is likely to have functional im-
plications (Stoll et al., 2004).
1.2.5.6 TNFSF15
TNFS15 was identified as a susceptibility gene for CD by Yamazaki et al. in 2005. They con-
ducted a multi-stage genome-wide association study in 94 unrelated Japanese patients and
752 controls using 72,738 gene-centric SNPs. A highly significant association (p = 1.71 x 10-
14) of SNPs and haplotypes within the TNFS15 (tumor necrosis factor superfamily, member
15) gene was replicated in the second stage using an additional 390 CD samples. The most
significant SNP (tnfsf15_28) resides in intron 3 of the gene. In the third stage, the association
was confirmed in a large family-based and case-control IBD panel from the UK, with p-val-
ues ranging between 0.01 and 0.05.
TNFSF15 is located on 9q32 (114,631,166–114,647,962 bp), a linkage locus that was first con-
nected with CD by Cho and colleagues (1998). The protein is a novel TNF-like factor, ex-
pressed primarily in endothelial cells (Yue et al., 1999). Upregulation of transcript and
protein levels of TNFSF15 have recently been reported for macrophages and CD4+/CD8+
lymphocytes of the intestinal lamina propria of CD patients (Bamias et al., 2003).
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Evidence suggests that CARD15 is only associated with CD (Hugot et al., 2004), however, a
stronger association exists between genes of the human leukocyte antigen (HLA, involved in
regulating the immune response) region and UC than for CD (Satsangi et al., 1996; van Heel
et al., 2004; Yap et al., 2004). A review by Zheng et al. (2003), who summarized 18 studies pub-
lished since 1995, describes DRB1 and DQB1 as the key regions for UC and CD.
Regarding the class II genes, the most consistent positive association in UC is with
DRB1*1502 across multiple ethnicities (Ahmad et al., 2003; Yoshitake et al., 1999; Trachten-
berg et al., 2000) and the susceptibility to extensive disease conferred by the DRB1*0103–
DQB1*0501 haplotype (Ahmad et al., 2003, Roussomoustakaki et al., 1997). However, both
these haplotypes are rare (UC frequencies ~2% and ~8%, respectively), implicating impor-
tance in subgroups of UC patients only (Ahmad et al., 2003). The most consistent negative
class II association in UC is with the DRB1*0401–DQB1*0301 haplotype of approximately the
same magnitude (OR ~0,5) as the DRB1*0401 association in PSC (Stokkers et al., 1999). To
what extent these class II associations in UC are biologically important in themselves, or only
serve as markers for other candidate polymorphisms elsewhere in the HLA-complex is cur-
rently not known. For the individual class III and class I genes (of which TNF-α, LTA, HSP-70,
MICA and HLA-B are the most studied), there is less consistency. In sum, TNF-α variants (es-
pecially at promoter positions -308 and -857) may confer susceptibility to UC (van Heel et al.,
2002; Yamamoto-Furusho et al., 2004; O’Callaghan et al., 2003), LTA associations seem to be
in LD with TNF-signals (Coss et al., 2000), particular MICA and HLA-B alleles can only be
demonstrated in Japanese patients (Ahmad et al., 2002; Nomura et al., 2004) and the role of
HSP-70 polymorphisms is still unclear (Ahmad et al., 2002). Thus, the primary associations
may be located outside and in LD with loci studied so far, and systematic mapping of the en-
tire HLA-complex in UC is ongoing (Stenzel et al., 2004).
Within the MHC region, the identification of a causative mutation is complicated through
the high density of genes and polymorphisms and the extent of LD (Shiina et al., 2004). Stud-
ies are further limited due to the great number of possible haplotypes as well as the variation
of haplotypes between different populations (Kawasaki et al., 2000). The majority of the re-
ported associations for UC and CD differ (Ahmad et al., 2002; Ahmad et al., 2003), and possi-
bly the region contains more than one IBD susceptibility locus (Yap et al., 2004; Hampe et al.,
1999).
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Several other susceptibility genes have been previously described, but in contrast to the
CARD15, 5q31, or HLA locus, none of the preliminary findings was consistently replicated by
other groups. A diverse range of reasons can be claimed for this discrepancy among associa-
tion studies, for example false-positive findings, missing power, population stratification, or
genetic heterogeneity. In the light of discordant data-sets, it is difficult to ascertain whether
genes impact clinical outcome or not.
Toll-like receptors (TLRs) are transmembrane glycoproteins which recognize conserved
products unique to microbial metabolism and signal via a number of downstream mole-
cules, e.g. MyD88, IL-1R-associated kinases, TGF-β, and TNF-receptor associated factor 6
(Takeda et al., 2003). Eleven members of the TLR family have been identified to date (Akira et
al., 2004) and two mutations in the TLR4 gene, Asp299Gly and Thr399Ile, have been associ-
ated with CD and/or UC (Franchimont et al., 2004; Gazouli et al., 2005; Torok et al., 2004;
Brand et al., 2005). Although TLR4 antagonists prevent mice from developing colitis (Fort et
al., 2005), no associations with IBD and the two SNPs were seen by other groups (Arnott et
al., 2004). Identification of a protective polymorphism in the gene coding for flagellin-sens-
ing TLR5 (Gerwitz et al., 2005) is of great pertinence, as recent studies report synergism be-
tween NOD2 and TLR5 signaling (Netea et al., 2005).
The anterior gradient 2 gene (AGR2) is located on chromosome 7p21.3, a region implicated
as a susceptibility region for IBD in a previous genome-wide linkage scan (Satsangi et al.,
1996), with stronger evidenve for linkage in UC patients. According to this fact, plus the ex-
istence of a loss-of-function mouse model, which spontaneously develops symptoms of di-
arrhea and goblet cell dysfunction, AGR2 was selected as a good UC candidate gene by Zheng
and colleagues (2006). Genotyping German and British patient samples yielded a moderate
but consistent association between SNP hCV1702494 in the 5’ region of AGR2 and IBD.
It is evident that genetic association studies alone will not decipher the etiology of inflamma-
tory bowel diseases. Therefore, investigators have successfully employed a broad range of
molecular techniques in parallel, including e.g. gene expression studies with microarrays
(Heller et al., 1997; Dieckgraefe et al., 2000; Lawrance et al., 2001; Langmann et al., 2004; Oka-
hara et al., 2005; Costello et al., 2005), protein-protein interaction studies by the yeast two-
hybrid system (Barnich et al., 2005), or proteome expression profiling using serum of patients
(Sauer et al., 2005; Din et al., 2005). Exploiting and combining the results gathered on the ge-
nomic, transcriptional, and protein level will lead to a further understanding of complex dis-
eases.
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Investigations of intestinal inflammation in animals have shown the association between ge-
netic, bacterial, barrier function, and immunological contributions to pathogenesis of CD
(Blumberg et al., 1999; Wirtz et al., 2000). However, there has been no de novo identification
of orthologous genes that contribute to IBD predisposition in humans. Although no animal
is an exact replica of CD, owing to the polygenic and complex etiology, the spontaneous dis-
ease in SAMP1/Yit mice (Kosiwicz et al., 2001) seems to be closest. Spontaneous intestinal
disease that occurs in C3H/HeJBir mice is partly due to their TLR4 deficiency (Brandwein et
al., 1997) and, thus, susceptible to bacterial invasion. It is common to all IBD animal models
that the expression of a disease depends on colonization with bacterial flora, irrespective of
the underlying genetic defect. Under sterile conditions, susceptible animals do not develop
IBD-like symptoms. Chronic intestinal inflammation of the bowel that mimics some charac-
teristics of human CD can be chemically induced in mice by ad libitum administration of e.g.
2,4,6-trinitrobenzene sulfonic acid (TNBS; Neurath et al., 1996) or dextrane sodium sulfate
(DSS; Vowinkel et al., 2004). All exogenous IBD-causing chemicals have in common that they
destroy the intestinal epithelial lining leading to massive bacterial invasion and inflamma-
tion. 
One good mouse model that adds to the key role of TNF-α and its therapeutical implication
is that the increased TNF-α biosynthesis, due to deletion of 3’ regulatory elements from the
TNF transcript, results in a CD-like phenotype (Kontoyiannis et al., 1999). Moreover, TNF-/-
mice show marked reduction in chemically induced intestinal inflammation (Neurath et al.,
1997).
In addition to innumerable studies on rodents, few investigations focus on higher mammals,
though mostly suffering from limited numbers of animals. The cotton-top tamarin (CTT;
Saguinus oedipus) is an endangered New World primate that develops a highly prevalent and
spontaneous idiopathic colitis resembling human UC if kept in captivity (Chalifoux et al.,
1985). A study by Mansfield and others (2001) found that enteropathogenic Escherichia coli
(EPEC) caused acute colitis in CTTs, which was associated with UC. Saunders and colleagues
(1999) describe a novel Heliobacter species that is associated with UC in CTTs. Colitis-affect-
ed animals entered remission when returned to their natural habitat (Wood et al., 2000). Be-
sides cotton-top tamarins, siamang gibbons tend to develop colitis (Stout et al., 1969) when
kept in captivity and colitis has been as well reported for chimpanzees (Fremming et al.,
1955). Further evidence that stress increases disease activity is provided by studies of Gue et
al. (1997), who showed that stress may exacerbate experimental colitis in rats, provoked
through intracolonic 2,4,6-trinitrobenzenesulfonic acid instillation. Chronic colitis has also
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lis silvestris f. catus) [Cave et al., 2003; Feinstein et al., 1992].
In conclusion, animal models of inflammatory bowel diseases (IBD) have been useful in the
identification of those immune responses involved in IBD pathogenesis and in defining the
important roles of environmental influences, such as the bacterial flora, but models have
proven to be inappropriate for unravelling the predisposing genetic factors.
More details concerning IBD mouse models can be found in the reviews of Byrne et al. (2006)
and Blumberg et al. (1999).
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The etiology of inflammatory bowel diseases (IBD) is mostly unkown and complex, as both
genetic and environmental factors are involved. This complexity presents a major challenge
to the efforts to identify the underlying mechanisms behind IBD. As only a limited number
of IBD susceptibility genes have been described so far, and as more are thought to exist, the
approach of this thesis aimed to identify, map, and study further existing gene variants that
contribute to the disease, in other words to connect phenotype with genotype. Two unbiased
genome-wide association studies of direct and indirect nature were carried out to find such
additional susceptibility variants in a large sample collection of German CD patients. To this
end, a cSNP-based scan with approximately 20,000 non-synonymous SNPs using SNPlex™
technology plus an LD-based scan with over 100,000 genome-wide distributed SNPs was per-
formed. Rather than correcting for multiple testing (e.g. Bonferroni correction), different lev-
els of replication were employed. Once an associated mutation was determined, further
studies were carried out to investigate its potential effect. In addition, full mutation detection
and subsequent fine mapping was carried out for a detected susceptibility region. A summa-
ry of the experimental approach is shown in the following flow chart:
Fig. 1-8 Experimental workflow of this thesis. Two unbiased association screenings generate a great wealth of significant results. Due
to massive multiple testing, which leads to a high rate of false positive associations, further genotyping is necessary to “filter” the initial results.
Sample sizes are significantly larger in the replication studies, yielding a higher power to detect an association. Finally, causative SNPs
are found by resequencing the regions of interest in many individuals.
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While this project was part of a collaborative effort, the following techniques were estab-
lished during this PhD thesis by me:
❏ Automation of SNPlex™, which included the setup of robotic scripts and liquid classes.
LIMS Integration of SNPlex™ was done in collaboration with the bioinformatic group.
❏ Automation of whole-genome amplification (WGA) and its applicability for the in-
house genotyping platform (TaqMan® and SNPlex™). Several quality checks were per-
formed to check for allelic imbalance and other possible pitfalls.
❏ Development of statistical analysis tools for genome-wide data sets.
2.1 Laboratory information management system (LIMS)
An in-house available database was used to systematically store and retrieve information.
Microsoft’s SQL Server 7 was the database management system (DBMS) of choice and the
name of the used database was ’ibdbase’. Various in-house Visual Basic client applications
were used to facilitate lab processes and the analysis of genotyping data (Hampe et al., 2001;
Teuber et al., 2005) plus to further enhance quality control. In the database, the following in-
formation is integrated: pedigree and phenotype information, sample and microtiter plate
information, marker information, genotypes.
Data protection of private information such as the patient’s name or address was ensured by
using anonymized identifiers. For the POPGEN individuals, an even more sophisticated an-
onymization was used as described in Krawczak et al. (2006).
Since the database has to meet constantly changing demands, it has an open design.
Throughout the years, the LIMS has grown, thus to meet for example the requirements of SN-
Plex™. More information is available at http://www.ikmb.uni-kiel.de/research.html under
“Bioinformatics”. An older database scheme can be found here:
http://www.ikmb.uni-kiel.de/research/bioinformatics/db_schema.pdf.
Genotype data was exported in the standard Linkage Pedigree format (pre-file) as required
by the used analysis programs. The file did not have a header line (i.e. the first line should be
for the first individual, not the names of the columns):
3 128 91 2 1 2    3 3    0 0    4 2
a b c de f    -----------g------------- 
a. pedigree name: A unique alphanumeric identifier for this individual's family. Unrelated
individuals should not share a pedigree name.
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his family (see above).
c. father's ID: Identifier corresponding to father's individual ID or "0" if unknown father.
Note that if a father ID is specified, the father must also appear in the file.
d. mother's ID: Identifier corresponding to mother's individual ID or "0" if unknown
mother Note that if a mother ID is specified, the mother must also appear in the file.
e. sex: Individual's gender (1 = male, 2 = female).
f. affectation status: Affectation status to be used for association tests (0 = unknown, 1 =
unaffected, 2 = affected).
g. marker genotypes: Each marker is represented by two columns (one for each allele, sep-
arated by a space) and coded either “ACGT” or “1–4” where: 1=A, 2=C, 3=G, T=4. A “0” in
any of the marker genotype position (as in the the genotypes for the third marker above)
indicates missing data.
2.2 Recruitment
An overview of the patient and control samples used in this study is provided in table 2-1. The
German patient panels A, B, D, E, and F were collected at the Charité University Hospital
(Berlin, Germany), the Department of General Internal Medicine at the Christian-Albrechts-
University (Kiel, Germany) with the support of the German Crohn and Colitis Foundation
(DCCV).
Clinical, radiological and endoscopic (type of lesions, distribution) examinations were re-
quired to unequivocally confirm the diagnosis of CD (Lennard-Jones et al., 1989; Truelove et
al., 1976). Histological findings also had to be confirmative or compatible with this diagnosis.
In case of uncertainty, the diagnosis of indeterminate colitis was assigned and the patient ex-
cluded from the study. The sample has been used in several previous studies within the col-
laborative group (Croucher et al., 2003; Curran et al., 1998; Hampe et al., 1999; Hampe et al.,
1998); the respective publications provide a more extensive account of the phenotyping
techniques employed.
German control individuals were obtained from the German population biobank PopGen as
described (Krawczak et al., 2006; Lamina et al., 2005). Popgen targets the population of
northern Schleswig-Holstein (1.1 million people) that is enclosesed by the Danish border
(North), the North Sea and Elbe river (West), the Baltic Sea (East), and the Kiel Canal (South).
The latter can only be crossed by a limited number of ferries and bridges. There is no histor-
ical, demographic or genetic evidence suggesting that etiological factors relevant in the
present context differ substantially between this and other regions of Germany (Krawczak et
al., 2006).
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collected at the Institute of Transfusion Medicine in the clinic of Kiel. Health status of all
blood donors was categorized by questioning and standard diagnostic blood parameters.
Patients for panel E were mostly and controls (Popgen) completely from Northern Germany.
Furthermore, patients with familial CD, early age of onset and a clear diagnosis were prefer-
entially selected. This was done to provide a “genetically enriched” sample for the initial
screening, as it is more likely that genetic factors play a major role in the etiology of such “ex-
treme” phenotypes.
The UK patients were collected as described previously by the collaborating centre (Onnie et
al., 2006). UK Population controls were obtained from the 1958 British Birth Cohort
(http://www.b58cgene.sgul.ac.uk). Recruitment protocols were approved by ethics commit-
tees at all participating centers prior to commencement of the study and participants gave
written, informed consent (9.9 on page 197) besides a detailed questionnaire (9.8 on
page 191). The 382 French-Canadian parent-parent-child (PPC) trios were collected through
the collaborator Genizon Biosciences. Patients were older than 18 years, had 4 French-Cana-
dian grandparents, and diagnosis were obtained by either colonoscopy, radiological exami-
nation with barium, abdominal surgical operation, or exploratory biopsies. Patients with UC
or any other form of bowel disease were excluded.
Study Panel Patients Controls Trios
cSNP
Crohn’s disease (Germany) - A 735 368 –
Crohn’s disease (Germany) - B 498 1032 380
100k
Crohn’s disease (Germany) - C 393 399
Crohn’s disease (Germany) - D 567 1082 375
Common
Ulcerative colitis (Germany) - E 788 1032 439
Crohn’s disease (UK) - F 509 656 –
Ulcerative colitis (UK) - G 442 521 –
Crohn’s disease (French-Canadian) - H – – 382
Table 2-1 IBD patient and control samples used for association analysis. The patient samples are organized in 'panels' that corre-
spond to successive steps of the study. Index cases from trios were also used in the case-control analyses so that, for example, a total of
878 cases (498 + 380) were available for the case-control comparison in panel B. The controls from CD panel B and D were also used
for the analysis of UC (E). Panels A and B overlap with C and D, which is valid, as these are used in two independent studies.
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After recruitment of individuals, genomic DNA was isolated from the leukocytes of donated
blood samples. DNA samples were quality checked on an agarose gel and used for whole ge-
nome amplification. Amplified products were arrayed on 96 well microtiterplates (MTP),
thus increasing the throughput for downstream processes. The latter was even increased by
merging 4 x 96 well MTPs into a 384 well MTP.
2.3.1 DNA extraction from blood
Genomic DNA (gDNA) was extracted from EDTA whole blood samples, using the Invisorb®
Blood Giga Kit for DNA isolation. Only a few modifications were made to the manufacturer’s
protocol. Blood samples were stored at -80°C and thawed in a cold water bath with the lid
sticking right out of the water.
Lysis of erythrocytes, while leukocytes stayed intact, was performed by incubating 9 ml of
blood for 10 min with 30 ml of cold buffer 1 at room temperature. Afterwards, the suspension
was centrifuged for 3 min at 3,000 rpm and the supernatant was carefully discarded. This step
was repeated with 20 ml buffer 1 until the leucocyte containing pellet was free of haem. A
DNA contamination with haem causes problems during downstream experiments, as haem
inhibits PCR reactions (Heath et al., 1999). The pellet was resuspended in 3 ml of buffer 2 and
50 µl of Proteinase K and incubated for 2 hours in a 60°C water bath under continuous shak-
ing (95 turns/min) to increase the lysis efficiency. This step leads to the lysis of the leukocytes
and their nuclei and therefore to a release of DNA into the suspension. To seperate the DNA
from cell and protein fragments, 1.8 ml of buffer 3 were added. Vigorous mixing and a 5 min
incubation on ice were subsequently carried through. Then, the mix was centrifuged for 15
min at 5,000 rpm. Afterwards, the cleared supernatant was transferred into a 15 ml centrifuge
tube. For the precipitation of the DNA, 10 ml of 96% ethanol (according to Bearden et al.,
1974; Shapiro et al., 1981; Wilcockson et al., 1975) were added and the tube carefully inverted
several times. If precipitation did not take place, the tube was incubated for 2 h at -20°C. The
precipitated DNA was obtained by centrifugation for 3 min at 5,000 rpm and was then col-
lected with a pipette tip and transferred into 2 ml reaction tubes containing 1 ml of 70% eth-
anol. The DNA pellet was rinsed by vortexing and subsequently centrifuged for 2 min at
13,000 rpm. Finally, the ethanol was removed with a pipette and samples were dried for 10
min at room temperature.
All samples were quantified by measuring the concentration with PicoGreen® as described
in 2.4 on page 29. The purified gDNA was resuspended in 500 µl of 1x TE buffer and stored at
+4°C for short periods or at -20°C for long periods. Average yields were 200 ng/µl, which cor-
responds to an amount of 100 µg DNA. If no pellet was visible or DNA concentration was be-
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two to three blood samples. If no DNA was left, individuals were contacted for an additional
blood sample. In addition to a label on the lid, each 2 ml reaction tube received a barcode for
tracking it in the LIMS.
2.3.2 Plate design
For genotyping, 92 DNA samples were arranged in a 96 well format according to a pre-de-
fined plate layout. Individual of the same pedigree were kept on the same plate. Four wells
were used for internal controls and quality control, such as three empty wells (no template
controls [NTCs]) and one positive control, the so called CEPH (Fondation Jean Dausset -
Cenre d’Etude du Polymorphisme Humain, Paris, France) control. Negative controls were
used to reveal potential contaminations. As four 96 well plates were merged into a single 384
well plate, there were four positions with CEPH cell-line DNA in the final plate layout. Geno-
type concordance was checked for every assay among these four wells holding the same
DNA. A low genotype concordance indicated an assay problem or a contamination problem.
Each MT plate was labeled with a unique plate name for database storage to allow unmistak-
able identification. SNPlex™ plates received the prefix “X”, e.g. XG01.
Fig. 2-1 New ICMB plate layout. Wells D3 and D10 were used as negative controls for TaqMan® genotyping and for allelic ladder in
case of SNPlex™.
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The most commonly used technique for measuring nucleic acid concentration is the deter-
mination of absorbance at 260 nm (A260). The major disadvantages of the absorbance meth-
od are the large relative contribution of nucleotides and single-stranded nucleic acids to the
signal, the interference caused by contaminants commonly found in nucleic acid prepara-
tions, the inability to distinguish between DNA and RNA and the relative insensitivity of the
assay (an A260 of 0.1 corresponds to a 5 µg/mL dsDNA solution).
Concentrations of the genomic DNA were measured using the PicoGreen® method (Ahn et
al., 1996; Rengarajan et al., 2002). The PicoGreen® reagent is a proprietary, unsymmetrical
cyanine dye. Free dye is essentially nonfluorescent and exhibits >1000-fold fluorescence en-
hancement upon binding to dsDNA (with excitation and emission maxima of ~500 nm and
~520 nm, respectively). The assay displays a linear correlation between dsDNA concentra-
tion and fluorescence and has a detection range extending from 25 pg/mL to 1 µg/mL dsDNA
using a single dye concentration. The assay is highly selective for dsDNA over RNA, single-
stranded DNA (ssDNA) and oligonucleotides. Furthermore, there is essentially no base selec-
tivity and assay results are not compromised by proteins, nucleotides and other common
sample contaminants (Singer et al., 1997; see also fig. 2-2).
Fig. 2-2 Fluorescence enhancement of PicoGreen® reagent upon binding dsDNA, ssDNA and RNA. Samples containing 500 ng/mL
calf thymus DNA, M13 ssDNA or E. coli ribosomal RNA were added to cuvettes containing PicoGreen® reagent in TE. Samples were
excited at 480 nm and the fluorescence emission spectra were collected using a spectrofluorometer. Emission spectra for samples containing
dye and nucleic acids, as well as for dye alone (baseline), are shown. Illustration taken from the manufacturer’s protocol.
Pipetting, dilution, and normalization steps were fully automated using a TECAN pipetting
robot (Genesis RSP 150). With the in-house software SampleTool, 96 samples can be mea-
sured in parallel. 32 samples were arranged in duplicates in a 96 well optical Sarstedt plate,
as shown in fig. 2-3. Thus, the worktable of the robot has capacity for three of such plates.
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After a 5 min incubation in the dark, plates were read in a TECAN Spectrafluor Plus fluorom-
eter. Concentrations and dilution factors were calculated using the average of the two mea-
surements for each DNA and a standard curve. Normalized DNA concentrations were
verified by a second measurement. If single tubes were measured without SampleTool, the
Gemini scripts WL_Fluoro_V2.gem and WL_dDNA_Eppi_V2.gem were used.
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Since the yield of DNA from individual patient samples is limited and as larger experiments
require larger amounts of DNA (Lasken et al., 2003), whole-genome amplification was estab-
lished and used for genotyping plate production. The multiple displacement amplification
(MDA, see fig. 2-4) method, which relies on isothermal amplification using the DNA poly-
merase of the bacteriophage φ29 from Bacillus subtilis, is a recently developed technique for
high performance WGA (Lovmar et al., 2006). MDA was first described by Dean et al. (2002).
Fig. 2-4 Multiple displacement amplification reaction. DNA synthesis is primed by random hexamers. Exponential amplification occurs
by a ‘hyperbranching’ mechanism. Unlike PCR, which requires thermal cycling to repeatedly melt template and anneal primers, the φ29
DNA polymerase acts at 30°C to concurrently extend primers as it displaces downstream DNA products.
The yield of a MDA reaction is less dependent on the amount of input DNA, but because the
reaction is self-limited, the yield will depend on the reaction conditions and amount of re-
agents and hence on the reaction volume (Dean et al., 2002). Consequently, varying DNA
concentrations in the initial sample will plateau during MDA, which is a potential benefit for
MDA in large-scale genotyping applications because it unifies and increases the DNA con-
centrations of the samples (Lovmar et al., 2006). Therefore, besides a 100-fold amplification
of the DNA, a resource-consuming normalization step with PicoGreen® becomes pointless
after the WGA. In contrast, if genomic DNA was used for genotyping, a measurement was
necessary (see 2.4 on page 29).
1 µl of stock DNA was used as an input for the reaction, with concentrations ranging from 50
ng/µl to as much as 300 ng/µl. More input DNA was used than recommended by the manu-
facturer (10 ng recommended) as it was shown that higher amounts of input DNA signifi-
cantly increase genotyping performance and concordance rates (Bergen et al., 2005).
The kits GenomiPhi v1 and v2 were used for amplification of DNA. All steps were carried out
according to the kit’s protocol. Pipetting robots were used to set up the WGA reactions
(Scripts Pipet_WGA_nach_SNPlex.gem and _Verduennung_nach_WGA_Andre.gem).
Version 1 is an overnight reaction while version 2 yields the same amount after two hours re-
action time. Furthermore, there is no random amplification in empty wells thus no artefacts
are generated. Generated fragments range between 10 and 100 kb.
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way:
1. 1:5 with 1x TE-buffer, final volume of 100 µl (~50 ng/µl)
2. The 100 µl were split (2x 50 µl) to two fresh 96 well MT plates
3. One plate was used for SNPlex™ and the other for TaqMan® plate production.
4. In case of SNPlex™, the WGA-DNA was fragmented for 5 minutes according to the
SNPlex™ protocol and then diluted 1:2 with 1x TE-buffer to a final volume of 100 µl (~25
ng/µl).
5. For TaqMan®, the 50 µl WGA-DNA were further diluted 1:80 to a final volume of 4 ml
(~0.63 ng/µl).
6. Four 96 deepwell microtiter plates were then merged to one 384 deepwell MTP using
the script Merge_Deepwells.gem (if necessary, merging was undone with the script
Unmerge_Deepwells.gem). This was accomplished with a 96-needle multi pipetting
device (Te-MO, TECAN) on a TECAN pipetting robot.
Aliqouts of 5 µl were dispensed via a 384-channel Robbins Scientific Hydra microdispenser
to fresh 384 MT PCR plates. For TaqMan®, the “copied” plates were dried down at 60°C for
one hour and subsequently sealed. In case of SNPlex™, the plates were left to dry overnight
in a closed cupboard. Dried plates were sealed and ready-to-use for genotyping.
TaqMan® PCR plates were kept for two years while SNPlex™ PCR plates were usable for six
months (based on empirical experiences). Each plate received a unique barcode label for da-
tabase tracking.
Various studies have shown that there almost no differences (i.e. no allelic imbalance) exist
between genotyping results of genomic compared to WGA DNA, thus making MDA a reliable
provider of nearly unlimited amounts of DNA. A good overview of various studies that exam-
ined the genotype concordance of WGA-DNA and genomic DNA is given in Lovmar et al.
(2006). Own results of such a comparison are listed in section 3.5.5.1 on page 115.
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PCR fragments, depending on the expected size, were separated in 1–2% agarose gels (Taka-
hashi et al., 1969). The smaller the expected product, the higher the concentration of agarose
should be for a better seperation and resolution (table 2-2). In case of genomic DNA, as nec-
essary for the quality control of gDNA, an agarose concentration of 0.8% was used.
To visualize DNA-bands ethidiumbromide was added to the gels (1.5 µl EtBr per 100 ml gel
solution; 10 mg/ml). 0.5x TAE (Tris-acetate-EDTA) buffer or 0.5x TBE (Tris-borate-EDTA)
buffer was used as a running buffer. Pouring gels was done by boiling the buffer/agarose mix-
ture in a microwave, letting it cool down to approx. 60°C, adding EtBr under the hood, pour-
ing it into the casting device, and leaving it there for approx. 30 min until polymerization had
finished. Large gels were made using 250 or 300 ml, medium ones using 100 ml and small
ones with 50 ml buffer. 2x DNA-loading buffer (0.25% bromphenol blue + 0.25% xylene cy-
anol FF + 30% glycerol in water) was added to the samples (5 µl for 10 µl sample). In 1% aga-
rose gels, bromophenol blue migrates with 300 bp linear double-stranded DNA fragment,
whereas xylene cyanol FF migrates at approximately the same rate as linear double-stranded
DNA 4 kb length. These relationships are not significantly affected by the concentration (0.5
to 1.4%) of agarose in the gel.
Fragments were separated in horizontal gel chambers electrophoretically at 110 V for 70 min
(for large TBE gels up to 150 V possible) until complete band seperation. The size of DNA
fragments was estimated under UV-illumination with the Bio-Rad Gel Doc XR gel documen-
tation system according to the comigrating DNA-size standards such as 100 base pair ladder.
A single clear band of the expected size and only a low amount of primer-dimers indicated
optimal PCR conditions.
Agarose in gel Efficient range of separation
0.3% 60.0 kb – 5.0 kb
0.6% 20.0 kb – 1.0 kb
0.7% 10.0 kb – 0.8 kb
0.9% 7.0 kb – 0.5 kb
1.2% 6.0 kb – 0.4 kb
1.5% 4.0 kb – 0.2 kb
2.0% 3.0 kb – 0.1 kb
Table 2-2 DNA seperation in agarose.
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For the follow-up of candidate gene studies, knowledge of all variations in a limited amount
of sequence (e.g. a gene) is needed. In the present study, all exons plus splice sites of ATG16L1
and NELL1 were resequenced in 47 CD patients. This methodology of SNP verification and
finding is termed mutation detection.
2.7.1 Primer design
Primers for exonic sequences were designed in introns, with the amplicon covering the exon
itself, splice sites, and at least 50 bp of flanking intronic sequence. For longer exons or diffi-
cult GC-rich regions, primers generating overlapping amplicons were designed. Sequencing
was performed for both orientations (forward and reverse), to circumvent sequencing arte-
facts. The webinterface Primer3 (Rozen et al., 2000) was used for the design. Modifications to
the default settings were as follows:
❏ Mispriming Library (repeat library): HUMAN
Only a single specific binding site was allowed for each primer, therefore repeating ele-
ments in the DNA were excluded by choosing this option.
❏ Product Size Ranges: 100–850
Amplicon lengths need to be less than 850 bp, which is the maximum read of the 3730xl
sequencer.
❏ Primer Size: min = 18; opt = 24; max = 30
❏ Primer Tm: min = 55; opt = 65; max = 75
High annealing temperatures facilitate specific hybridization.
❏ Primer GC%: min = 40; opt = 50; max = 60
❏ CG Clamp: 1
A “C” or “G” residue at the 3’ end supports binding and elongation of the polymerase.
❏ Max Poly-X: 4
Only four repetitive mononucleotides were allowed to avoid mispriming and frame-
shifts.
Primer sequences were checked for potential hairpin and primer dimer formations. Finally,
an in silico PCR was made at the UCSC webpage (Kent et al., 2002) to check whether a single
amplicon is generated.
All primers were ordered through Eurogentec (Seraing, Belgien) on a 40 nmol scale. The qual-
ity was ensured by mass spectrometry by the manufacturer. Primer stocks were diluted to a
concentration of 100 µM with DDW, e.g. for 40 nmol of primers, 400 µl water were added.
Chapter 2: Methods 352.7.2 Polymerase chain reaction (PCR)
The polymerase chain reaction (PCR) is based on the three repeating steps:
❏ denaturation of double-stranded template by high temperature
❏ annealing of two oligonucleotides (primers) to template
❏ elongation by a thermostable DNA polymerase and dNTPs
The transcript is exponentially amplified by cycling through the above steps (Saiki et al.,
1985; Mullis et al., 1987). This is accomplished by switching between the specific tempera-
tures for each step. Therefore programmable thermocyclers are used. Reactions terminate if
either the template has reached a critical concentration, resources are used up (dNTPs,
primers) or if the enzymatic activitiy of the polymerase has vanished. A linear amplification
was done by using only one primer. According to Mülhardt (2002), the mother of all PCR pro-
grams is the following:
A typical protocol for a PCR master mix is given in table 2-4, page 36.
2.7.3 DNA sequencing
Sequencing of DNA, which basicly means to determine the order of nucleotides in a given
DNA fragment, was performed by means of a modified protocol of the chain terminating
technique that was developed by Frederick Sanger et al. in 1977. Rather than using labelled
primers, labelled terminators, the so-called di-deoxynuleotides (ddNTPs) were used. The
major advantage of this approach is the complete sequencing set can be performed in a sin-
gle reaction, rather than the four needed with the labeled-primer approach. This is accom-
plished by labelling each of the dideoxynucleotide chain-terminators with a separate
fluorescent dye, which fluoresces at a different wavelength.
Temperature Time Cycle(s)
94°C 5 min 1
94°C 30 s
3055°C 30 s
72°C 90 s
72°C 5 min 1
4°C ∞ 1
Table 2-3 Standard PCR protocol.
Chapter 2: Methods 36Primer optimization and PCR
To determine the optimal melting temperature (Tm) of the primers and the perfect PCR con-
ditions, a gradient (12°C across 12 positions) PCR was carried out using the following reac-
tion mix:
Specificity was enhanced by using a touchdown thermoprofile (Don et al., 1991).
If no or many bands were seen on the gel, the MgCl2 concentration was either in- or de-
creased and the PCR repeated. In GC-rich regions, the Qiagen Taq DNA Polymerase Kit was
used and steps were carried out according to the protocol. The kit included Q-solution,
which facilitates amplification of difficult templates by modifying the melting behavior of
nucleic acids.
Reagent volume [µl] final conc.
GeneAmp® 10x PCR buffer II 2.50 1x
MgCl2 [25 mM] 2.00 2 mM
dNTPs [10 mM each] 0.50 200 µM each
Forward Primer [10 µM] 0.10 0.04 µM
Reverse Primer [10 µM] 0.10 0.04 µM
Ampli Taq Gold® [5 U/µl] 0.15 0.03 U/µl
DNA [5 ng/µl] 1.00 0.75 U
Water 18.65
Total 25.00
Table 2-4 PCR mix for a single reaction.
Temperature Time Cycle(s) Comment
95°C 5 min 1 AmpliTaq Gold® is activated
95°C 30 s
1664°C 30 s
recommended annealing temperature of manufacturer + 8°C
td=-0.5°C/cycle
72°C 1 min elongation time depends on length of template: 1000 nt/min
95°C 30 s
1556°C 30 s recommended annealing temperature of manufacturer
72°C 1 min elongation time depends on length of template: 1000 nt/min
72°C 10 min 1 filling up the ends, especially needed for TA-cloning
4°C ∞ 1
Table 2-5 Primer optimization PCR program.
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a gradient, the optimum Tm was used. All reactions were carried out in 96 well plates with 5
ng of liquid or dried DNA. Forward and reverse reactions were performed together on a 96
well MTP for 47 samples. One well was used as a negative control to check for (cross-)con-
taminations.
Digest
5 µl of PCR product were tested on an 1.5% agarose gel (in 300 ml TBE, 1% EtBr, 150 V for 50
min). If a sharp band was visible, the PCR product was cleaned using an enzymatic digest.
Highly concentrated PCR products were diluted 1:5 with water before the digest. The enzy-
matic digest was performed in a new plate and to remove superfluous primers. For the digest,
8 µl PCR product were mixed with 0.30 µl shrimp alkaline phosphatase (SAP; 1 U/µl), 0.15 µl
exonuclease I (ExoI; 10 U/µl), and 1.55 µl water and incubated at 37°C for 15 min. SAP digests
single-stranded DNA molecules as described by Berthold et al. (1976). Remaining dNTPs
were also destroyed as a dephosphorylating SAP was used (Sauer et al., 2000). Thus, a possi-
bly resulting dNTP/ddNTP imbalance was avoided that could disturb the sequencing reac-
tion. The reaction was stopped by a subsequent heat step of 72°C for 15 min. This is an
essentiel step as an active SAP could negatively effect the sequencing reaction.
Sequencing reaction
Sequencing reactions were carried out according to the kit’s protocol. 2 µl of the digested
PCR product were used for the sequencing reaction. Furthermore, 1.0 µl primer [3.2 µM] (ei-
ther forward or reverse), 1.0 µl BigDye™ Terminator Ready Reaction Mix version 1.1 from the
kit, 0.5 µl 5x sample buffer and 5.5 µl water were added to the reaction (total of 10 µl). The fol-
lowing cycle protocol for the sequencing reaction was used:
To lower the background fluorescence noise, unincorporated nucleotides and primers were
removed using a Sephadex spin column plate. The latter was prepared by adding Sephadex
powder to a fresh MAHVN 4550 plate with the aid of a multi-screen column loader. Sephadex
is cross-linked dextran composed of polyglucose (Mort et al., 1998). 300 µl of water were add-
Temperature Time Cycle(s) Comment
95°C 30 s
25Tmopt 15 s optimized annealing temperature
60°C 4 min chain termination reaction
4°C ∞ 1
Table 2-6 Sequencing thermoprofile. As the BigDye Reaction Mix has its temperature optimum at 60°C, the upper limit for the optimized
annealing temperature was 60°C to avoid premature termination stops (Wen et al., 2001).
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ture, as a result of which a three-dimensional network and pores (20–80 µm) are formed, the
plate was centrifuged for 5 min at 2100 rpm. This was necessary to dry the column. Another
150 µl of water were added to the columns and the plate was immediately centrifuged at 2100
rpm for 5 min. The sequencing product was diluted to a final volume of 30 µl with 10 µl PCR
water and pipetted into the centre of the spin column. The column plate was fitted into a Mi-
croAmp® Optical 96-well reaction plate and centrifuged for 5 min at 2100 rpm. The flow
through contained the purified sequencing product and the plate was sealed with an alumi-
num adhesive cover. The sequence detection was performed with an automated, high-
throughput 96-capillary fluorescence detection system, the 3730xl DNA Analyzer.
2.7.3.1 Sequence analysis
Traces were manually inspected with Sequencher 4.2 and 4.5 and variation discovery was
carried out with novoSNP (Weckx et al., 2005) that allows automated detection of sequence
variations from sequence trace files in a fast and reliable manner. A relatively low cut-off
score of 10 was used, to eliminate the risk of false-negative variations, as recommended by
the developers. Besides biallelic single nucleotide polymorphisms, novoSNP is capable of
detecting insertion-deletion polymorphisms (INDELs). The latter have gained attention just
recently in context of complex diseases (McGovern et al., 2005; McCarroll et al., 2006; Hind
et al., 2006; Conrad et al., 2006).
Fig. 2-5 novoSNP’s graphical user interface. The main frame is centered on the “A/G” SNP rs2241880 as seen in Exon nine of
ATG16L1: table 3-8, page 92.
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The key method of this study was genotyping, which refers to the process of determining the
genotype of an individual with a biological assay. Depending on the requirements of the ex-
periment, one of the following three genotyping methods were used: TaqMan®, SNPlex™, or
Affymetrix SNP chips. 
2.8.1 TaqMan®
For genotyping only a small number of SNPs or for follow-up of SNPs that did not work with
SNPlex™, the robust genotyping method TaqMan® was chosen. TaqMan® is a single-tube
PCR assay (De La Vega et al., 2005; Holland et al., 1991; Livak et al., 1995; Livak et al., 1999;
McGuigan et al., 2002) that exploits the 5’ exonuclease activity of DNA polymerase.
The assay includes two locus-specific PCR primers that flank the SNP of interest, and two al-
lele-specific oligonucleotide TaqMan® probes. These probes have a fluorescent reporter dye
at the 5’ end, and a non-fluorescent quencher (NFQ) with a minor groove binder (MGB; N-
methylpyrrolecarboxamide) at the 3’ end (Afonina et al., 1997).
An intact probe emits little fluorescence when excited, because the close physical proximity
of the 5’ fluorophore to the 3’ quencher causes the fluorescent (or better: Förster) resonance
energy transfer (FRET) effect to quench the fluorescence emitted by the fluorophore (Livak
et al., 1995). A fluorescent signal is generated when the intact probe, which is hybridized to
the target allele, is cleaved by the 5’ exonuclease activity of Taq DNA polymerase during each
cycle of the PCR reaction. The PCR primers amplify a specific locus on the genomic DNA
template, and each fluorescent dye-labeled hybridization probe reports the presence of its
associated allele in the DNA sample (see fig 2-6, page 40). In each PCR cycle,  cleavage of one
or both allele-specific probes produces an exponentially increasing fluorescent signal by
freeing the 5’ fluorophore from the 3’ quencher. The use of two probes, one specific to each
allele of the SNP and labeled with two fluorophores, allows detection of both alleles in a sin-
gle tube. TaqMan® probes were labelled with the fluorescent dyes FAM™ (6-carboxyfluores-
cein) or VIC® (proprietary dye from Applied Biosystems) and with the quencher TAMRA™
(6-carboxytetramethylrhodamine, succinimidyl ester). Old non-MGB assays were labeled
with TET (5'-Tetrachloro-Fluorescein) instead of VIC®. The passive reference dye ROX (6-
carboxy-X-rhodamine, succinimidyl ester) was included in every well for normalization.
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Allelic discrimination is achieved by the selective annealing of matching probe and template sequences, which generates an allele-specific
(fluorescent dye-specific) signal.
Fluorogenic probes with an MGB produce enhanced allelic discrimination, because the MGB
stabilizes the double-stranded probe template structure, thereby increasing the probe Tm
without increasing probe length (Kutyavin et al., 2000). This provides enhanced mismatch
discrimination between these shorter probes, resulting in improved allele specificity. These
probes also increase the signal-to-noise ratio of an assay, because the reduced distance be-
tween the 5’ fluorophore and the 3’ quencher provides more efficient quenching of an intact
probe. Furthermore, a non-fluorescent quencher replaces the TAMRA™ quencher, reducing
the background fluorescence and improving the spectral discrimination for MGB assays.
Most of the genotyping assays were Assays-on-Demand (AoD), a pre-designed and validated
assay format offered by the manufacturer. If pre-designed assays were not availabe, Assays-
by-Design (AbD) were ordered, i.e. the manufacturer made the design according to a user-
defined sequence. Both types of assays needed no further optimization.
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tings (Dieffenbach et al., 1993; Lowe et al., 1990). Probes were manually selected according
to the following criteria:
❏ Polymorphism in middle or last part of probe (minimum of two bases before the 3’ end
of the probe)
❏ No guanine (G) on the 5’ end
❏ Melting temperature (Tm) must be 7°C higher than the highest primer Tm (65–67°C)
❏ Difference in probe Tms must be smaller than 1°C
❏ Length of 13–20 bases
❏ Less than four contiguous G’s; no G on the 5’ end; less Gs than Cs (cytosines)
❏ No repetitive elements in the target region (http:\\www.repeatmasker.org)
❏ Only one SNP per probe is allowed
Primers were chosen that had a GC-content of 30–80% and that generated an amplicon be-
tween 50 and 150 bp in length. Less than 2°C Tm difference were allowed between the two
primers. Further primer design requirements included:
❏ Length of 9–40 bases
❏ Maximum of two Gs or Cs inside the last five bases of the 3’ end
❏ 3’ end of primer as close to the probe as possible without overlapping
❏ Presence of SNPs at primer binding sites is not allowed, absence of repetitive elements is
desirable
In the primer test panel of the software, primers were tested for dimerization and hairpin
loops (secondary structure formation). Not more than three self-annealing or loop-bonds in
a row were accepted, primer dimerisation for up to four bonds was allowed. Tms were calcu-
lated using an oligonucleotide concentration of 50 nM and a salt concentration of 50 mM.
An annealing temperature optimization was carried through for self-designed TaqMan®-
MGB assays. The experiment was performed with half 96 well MTPs (47x 2.5 ng control sam-
ple DNAs) for different annealing/elongation (AE) temperatures. In the first round, 60°C or
62°C were chosen. If the assay failed to discriminate, 58°C and 64°C were tested. Further op-
timization steps included variable amounts of MgCl2 or longer AE times.
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5 µl of the reaction mix were added to the 384 well plates with the dried genomic DNA by a
TECAN Genesis RSP 150 multipipetting robot. This process was executed and tracked with
the in-house software Pipettor which is part of the integrated LIMS (Hampe et al., 2001). For
all three assay types, the same two-step PCR protocol was used (table 2-8, page 42).
The endpoint fluorescence measurement was carried out with the ABI Prism® 7900 HT Se-
quence Detection System. If 96 well MTPs were used, they were read in the ABI Prism® 7700
Sequence Detection System. Allele calling for each plate was done manually to ensure data
quality. Markers passing a call rate of 95%, and not deviating from Hardy-Weinberg equilib-
rium, were used in downstream analyses.
Reagent
Assay-by-Design Assay-on-Demand self-designed Assay
volume [µl] volume [µl] volume [µl]
TaqMan® PCR master mix 2.500 2.500 2.500
FAM™ probe [10 µM] – – 0.100
VIC® probe [10 µM] – – 0.100
Forward Primer [20 µM] – – 0.225
Reverse Primer [20 µM] – – 0.225
Ready-to-use assay mix 0.063 0.250 –
H2Odest. 2.437 2.250 1.850
Total 5.000 5.000 5.000
Table 2-7 TaqMan® pipetting scheme.
Temperature Time Cycle(s) Function
95°C 10 min 1 activation of Ampli Taq Gold®
95°C 15 s
45
denaturation step
60°C 1 min annealing, elongation, nucleolytic cleavage of hybridised probes
4°C ∞ 1 storage
Table 2-8 Universal TaqMan® PCR protocol. If a mastermix with AmpErase UNG was used (prevents contamination), a 2 min step at
50°C was added in the beginning.
Chapter 2: Methods 43Fig. 2-7 TaqMan® cartesian cluster plot of 384 samples including controls. (A) Normalized VIC®-fluorescence is plotted along the x-
axis, while FAM™ is plotted along the y-axis. All three clouds seperate nicely and were manually called with the SDS software, i.e. manual
allele assignment. (B) Assignment of genotypes to the positions on the plate. Homoyzygotes for allele 1 are shown in red, heterozygotes in
green (both dyes are measured), and homozygotes for allele 2 in blue. The black squares close to the origin are the negative controls,
which control for potential contamination, and black crosses are undefined genotypes that were excluded from subsequent analyses. 
Given the level of automation, a throughput of 22,000 genotypes per day can be achieved at
the Kiel SNP genotyping platform. This corresponds to fifty-seven 384 well MTPs or 20,976
different DNA samples. At the end of the process, genotyping data is imported into the SQL
database ’ibdbase’.
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As hierarchical genome-wide scans demand a follow-up of hundreds and more significant
SNPs, a high-throughput genotyping platform using SNPlex™ was established which is now
also used throughout Germany’s National Genome Research Network (NGFN). The current
extent of automation yields a throughput of 280,000 genotypes per day, which corresponds
to fifteen 384 MTPs that are run with 48plex pools. In contrast to the simple and robust Taq-
Man® method, multiple pipetting steps are needed for SNPlex™ and the entire process
stretches over three days. To avoid contaminations, as universal primers are used to amplify
the purified ligation product, pre-PCR steps are physically seperated from post-PCR reac-
tions, i.e. they are carried out in two distinct laboratories. The principle of the oligonucle-
otide ligation reaction (OLA), which is the allele-discriminating step, is based upon a method
developed around the 1990's: the ligation chain reaction (LCR; Barany et al., 1991; Landegren
et al., 1988; Weiss et al., 1991). In contrast to LCR, SNPlex™ uses a normal PCR step to expo-
nentially amplify the ligation products. Furthermore, oligonucleotides are designed and syn-
thesized for only one DNA strand by Applied Biosystems. Hence, SNPlex™ takes advantage
of ligation's specificity and PCR's increase in sensitivity.
Assays for the SNPlex™ Genotyping System are designed by Applied Biosystem’s automated
high-throughput pipeline. The pipeline combines SNP-specific assays into compatible mul-
tiplex pools. These steps include (according to De La Vega et al., 2005):
❏ Screening the SNP context sequences against the target genome to avoid designing
assays for SNPs in repetitive or duplicated genomic regions thatwould lead to lowspeci-
ficity (this step can be omitted for organisms without an assembled genome at hand).
❏ Selection and design of the SNPspecific ligation probes by applying assay and probe-
manufacturing rules to select the more suitable strand and probe sequence.
❏ Assignment of ZipCode sequences to each ASO probe of an assay.
❏ Separating the assays into compatible multiplex pools that are screened for
probe/probe interactions, spurious ligation templates, and unintended probe combina-
tions that may have a significant genomic target.
Each assay includes three SNP-specific ligation probes: Two of the probes are allele-specific
oligos (ASOs). These are designed specifically for the detection of polymorphisms by having
the discriminating nucleotide on the 3' end. Each ASO probe sequence also contains one of
96 unique ZipCode™ sequences for ZipChute™ probe binding. In a multiplex reaction, the
universal ZipCode sequences on each ASO are unique. Therefore, in a 48-plex reaction, there
are 96 ASOs (two for each SNP), and 96 different ZipCode sequences. The third probe is a lo-
cus-specific oligo (LSO). Its sequence is common to both alleles of a given locus and anneals
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primer binding site. In a 48-plex reaction, there are 48 LSOs. All 144 probes for a 48-plex re-
action are shipped together as an ASO/LSO probe pool. It is this pool that confers genotyping
specificity to the SNPlex™ System assay. All other reagents are universal and not SNP
specific.
The assay workflow is outlined in fig. 2-9 and in brief the procedure is as follows:
Day 1 - OLA laboratory
SNPlex™ is based on the oligonucleotide ligation/PCR assay (OLA/PCR). After an initial ki-
nase step to phosphorylate linkers and ligation probes, the activated oligonucleotides are
combined with fragmented whole-genome amplified DNA (100–150 ng per well, i.e. 2–3 ng
per assay) to perform genotyping in separate reactions. Only 384 well MTPs are used
throughout the process. During the “OLA reaction”, which is the allele-discriminating step,
the genotype information is encoded by highly specific ligation of the ASO probes to the LSO
probes using genomic DNA as the target. ASO and LSO linkers connect to the corresponding
ASO and LSO probes.
Day 2 - OLA laboratory
After the ligation reaction, unligated and incompletely ligated oligonucleotides, as well as the
genomic DNA templates, are removed by an enzymatic digestion using exonuclease I and λ-
exonuclease (“purification step”). This reduces the background noise of the signal. Following
dilution of the digested material, an aliquot is subjected to a PCR reaction with two universal
primers, one of which is biotinylated (“PCR setup”). The plates with the PCR mix are then put
into the thermocyclers of the PCR laboratory.
Day 3 - PCR laboratory and capillary electrophoresis (CE)
After PCR, biotinylated amplicons are incubated with streptavidin-coated microtiter plates.
Exponential amplification of the ligation products yields higher signals and a better discrim-
ination. Upon removal of the non-biotinylated amplicon strands, a mixture of 102 pre-opti-
mized, universal ZipChute™ probes is added to each well for hybridization and to decode
the genotypic information. Of these, 96 ZipChute™ probes correspond to all 96 possible al-
leles of the 48 addressable SNPs in the multiplex. The six remaining ZipChutes™ are needed
for internal controls, such as the positive and the negative hybridization control (PHC/NHC).
ZipChute™ probes are fluorescently labeled oligonucleotides, with each probe having a
unique size (so-called mobiliy modifiers). The ZipChute™ probes are eluted after stringent
washing and detected by electrophoretic separation on Applied Biosystems 3730xl DNA An-
alyzers. An allelic ladder containing all available ZipChute™ probes is also analyzed to cor-
rect run-to-run sizing variations.
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plates. Auto-calls were manually inspected for faulty genotype assignments before the data
was exported from GeneMapper® and then imported into the in-house database ’ibdbase’.
Additional software tools, e.g. the OLAtool, and database tables were created to meet the re-
quirements of SNPlex™.
Fig. 2-8 SNPlex™ polar cluster plots. The same SNP is shown for three different types of DNA (genomic, amplified, and diluted ampli-
fied DNA). There are no apparent quality differences concerning clustering. The legend below the plots shows the meaning of each symbol.
Along the x-axis, the intensity is plotted on a log-scale. Data points above 3.0 are considered to have a good signal intensity and quality.
The angle in radians (angle of the vector from the origin in the cartesian plot) is plotted along the y-axis.
All necessary master mixes were prepared manually, while all other pipetting steps were car-
ried out on four different TECAN multipipetting robots.
Chapter 2: Methods 47Fig. 2-9 SNPlex™ workflow and chemistry. The key step is the oligo ligation assay, which is the allele-discrimnating step. For a descrip-
tion see text above and for more details see the protocol from Applied Biosystems.
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For the first follow-up round of the genome-wide screenings, lead SNPs were selected that
were below a certain p-value threshold. Further steps, which included the fine mapping of
ATG16L1 and NELL1, required a more thorough SNP selection. Only validated HapMap SNPs
were chosen by means of Haploview that passed the following quality criteria: call rate >95%,
p-value for HWE >0.01, less than 3 Mendel errors, minor allele frequency >1%. Tagging SNPs
were chosen as described in 2.9.5.1 on page 69.
If more SNPs were required to fill in gaps or if additional cSNPs were needed, validated SNPs
from the NCBI dbSNP database were selected according to the descriptions of Fredman et al.
(2006). In their publication, Fredman et al. state that the best validation criteria is that the db-
SNP entry has more than two submitter handles (“rationalized ssID count” >2). Therefore,
the cSNP selection of the present study is biased towards records with many submitters.
Finally, if there were still gaps, SNPs from the Celera Genome Project were chosen with the
help of Applied Biosystem’s SNPbrowser™ software (De La Vega et al., 2005).
2.8.4 Design of coding SNPlex™ pools by Applied Biosystems
Full detail regarding the construction of the panel of 19,779 nsSNPs is provided in 9.2 on
page 176. In brief, SNPs from the dbSNP database build 117 (Sherry et al., 2001) were com-
bined with variants from the Applera exon resequencing project (Adams et al., 2002) together
with the SNPs discovered by shotgun sequencing of the human genome by Celera Genomics
(Venter et al., 2001). Variants that mapped uniquely to the human genome assembly (Celera
R27) were then further filtered based on their measured or expected (i.e. "double-hit" SNPs)
heterozygosity in populations of European and African descent. Putative functional SNPs
were then defined as non-synonymous variants that altered the amino-acid sequence of an
annotated NCBI RefSeq, Celera or ENSEMBL transcript. For the resulting 28,709 nsSNPs,
context sequence and allele information was submitted to the assay design pipeline of the
SNPlex™ Genotyping System v. 1.0 (Tobler et al., 2005). Context sequence was masked for
adjacent double-hit SNPs to avoid probes overlapping with other common SNPs. Finally a
total of 19,779 SNPlex™ assay designs that were manufactured and partitioned in 428 multi-
plex pools of up to 48 SNPs each (mean: 45 SNPs per assay pool). The full list of SNPs and their
annotations are provided in Supplemental_Table_01.xls on the DVD.
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Parallel genotyping of thousands of SNPs was first reported by Carrasquillo et al. (2002), Fan
et al. (2000) and Wang et al. (1998). The 100k GeneChip® is a further development of the 10k
GeneChip (Matsuzaki et al., 2004) by Affymetrix. Both combine reduction in genome com-
plexity with the allele-discriminating specificity of oligonucleotide arrays (Kennedy et al.,
2003). Using Platinum Pfx polymerase (Invitrogen) instead of normal Taq polymerase results
in the preferential amplification of fragments in the size range between ~250 bp and ~2000
bp. This represents ~300 megabases (Mb) of sequence complexity, compared to the five-fold
lower complexity generated with Taq polymerase. This correspondingly increases the num-
ber of SNPs in the hybridization targets (Matsuzaki et al., 2004).
Fig. 2-10 Example of an Affymetrix GeneChip miniblock. (A) SNP miniblock showing hybridization in three individuals, demonstrating
the three possible genotypes “AA”, “AB”, and “BB”. Probes are synthesized as perfect-match (PM) 25-mers and as one base mismatches
in the center (MM). Probes for both “A” and “B” alleles on both sense and antisense strands are synthesized, for a total of 40 probes per
SNP miniblock(B) Sequence prototypes of the oligonucleotide probes. Twenty-five-mer oligonucleotides which are complementary to SNP
sites and flanking sequences are synthesized on the surface of the array. The 13th nucleotide is the interrogative position where the probe
sequences are either perfectly matched (PM) or mismatched (MM) to one of the two alleles of the SNP. The PM and MM probe pairs provide
a basis for signal vs. noise measurements. The two probe pairs corresponding to the two alleles are grouped as probe quartets. Shown are
the prototype sequences of the probe quartet at the SNP site, where the probe sequences differ only at the SNP site which is also the
interrogative position. To provide data redundancy, four additional probe quartets are offset from the SNP site by one to four nucleotides
in either direction. Also shown are prototype sequences for the probe quartet offset by4. In this offset probe quartet, the SNP site has shifted
to position 17 of the 25-mer. The probe sequences in this quartet are different at 4 (PM vs. MM) and at the SNP site (allele “A” vs. “B”).
Each SNP is represented by five probe quartets (one at the SNP site and four offset) in both orientations, for a total of 40 oligonucleotide
probes.
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sisting of more than one million copies of a 25 bp oligonucleotide probe of a defined se-
quence, synthesized in parallel by proven photolithographic manufacturing. Each SNP is
interrogated by 10 probe quartets see (fig 2-10, page 49, A) where each probe quartet is com-
prised of a Perfect Match and a Mismatch probe for each allele. In total, there are 40 different
25 bp oligonucleotides per SNP (see fig 2-10, page 49, B).
Affymetrix arrays were hybridized in collaboration with Peter Nürnberg and Christian Becker
(Cologne Center for Genomics).
In total, 116,161 SNPs were present on the Affymetrix 100k GeneChip® that actually consists
of two 50k chips. Average intermarker distance was 23.6 kb. Genotyping of 393 cases and 399
controls was done on the Affymetrix GeneChip® Human Mapping 50K XbaI and HindIII Ar-
rays. About 250 ng of genomic DNA were digested with the two restriction enzymes XbaI and
HindIII and processed according to the Affymetrix protocol. In brief, the following steps were
carried out:
Genome complexity reduction
Sample DNAs should not be highly degraded nor contain PCR inhibitors, such as high con-
centrations of heme or chelating agents. For each individual assayed, 250 ng of genomic DNA
are digested separately with 10 U of XbaI or HindIII (New England BioLabs) in volumes of 20
µl for 2 hours at 37°C. Following heat inactivation at 70°C for 20 minutes, 0.25 µM of XbaI
adaptor (5’-ATT ATG AGC ACG ACA GAC GCC TGA TCT-3’ and 5’phosphate –CTA GAG ATC
AGG CGT CTG TCG TGC TCA TAA- 3’)(Affymetrix), or HindIII adaptor (5’-ATT ATG AGC ACG
ACA GAC GCC TGA TCT-3’ and 5’phosphate –AGC TAG ATC AGG CGT CTG TCG TGC TCA
TAA-3’) (Affymetrix) are ligated to the digested DNAs with T4 DNA Ligase (New England Bi-
oLabs) in 25 µl for 2 hours at 16°C. The ligations are stopped by heating to 70°C for 20 min-
utes, and then diluted 4-fold with water. For each ligation reaction, two to three PCRs are run
in order to generate >40 µg of PCR products. Each PCR contains 10 µl of the diluted ligation
reactions (25 ng of starting DNA) in 100 µl volumes containing 1.0 µM of primer (5’-ATT ATG
AGC ACG ACA GAC GCC TGA TCT-3’), 0.30 mM dNTPs, 1.0 mM MgSO4, 5 U Platinum
® Pfx
Polymerase (Invitrogen), PCR Enhancer (Invitrogen) and Pfx Amplification Buffer (Invitro-
gen). 30 cycles of PCRs are run with the following cycling program: 94°C denaturation for 15
seconds, 60°C annealing for 30 seconds, and 68°C extension for 60 seconds. As a check, 3 µl
of PCR products are visualized on 2% TBE agarose gels to confirm the size range of ampli-
cons.
The PCR products are purified over MinElute 96 UF PCR Purification plates (Qiagen), and re-
covered in 40 µl of EB buffer (Qiagen). PCR yields are measured by absorbance readings at
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to 25-mer oligonucleotide probes, the PCR products are fragmented to <100 bp with DNAse
I. 0.20 U of DNAse I (Affymetrix) is added to 40 µg of purified PCR amplicons in a 55 µl volume
containing Fragmentation Buffer (Affymetrix) for 35 minutes at 37°C, followed by heat inac-
tivation at 95°C for 15 minutes. Fragmentation products are visualized on 4% TBE agarose
gels.
The 3’ ends of the fragmented amplicons are biotinlyated by adding 214 µM of a proprietary
DNA labeling reagent (Affymetrix) using Terminal Deoxynucleotidyl Transferase (Affyme-
trix) in 70 µl volumes for 2 hours at 37°C, followed by heat inactivation at 95°C for 15 minutes.
Allele specific hybridization to oligonucleotide arrays
The fragmented and biotinylated PCR amplicons are combined with 11.5 µg/mL human Cot-
1 (Invitrogen) and 115 µg/mL herring sperm (Promega) DNAs. The DNAs are added to a hy-
bridization solution containing 2.69 M tetramethylamonium chloride (TMACl), 5.77 mM ED-
TA, 56 mM MES, 5% DMSO, 2.5x Denhardt’s solution, and 0.0115% Tween-20 in a final
volume of 260 µl. The hybridization solution was heated to 95°C for 10 minutes then placed
on ice. After warming to 48°C for 2 minutes, 200 µl of the hybridization solution is injected
into cartridges housing the oligonucleotide arrays (Affymetrix GeneChip® 100K Mapping
Set: 50K Array Xba 240 and 50K Array Hind 240). Hybridizations are carried out at 48°C for 16
to 18 hours in a rotisserie rotating at 60 rpm. Following the overnight hybridization, the ar-
rays are washed with 6x SSPE and 0.01% Tween-20 at 25°C, then more stringently washed
with 0.6x SSPE and 0.01% Tween-20 at 45°C. Hybridization signals are generated in a three
step signal amplification process: 10 µg/mL streptavidin R-phycoerythrin (SAPE) conjugate
(Molecular Probes) is added to the biotinylated targets hybridized to the oligonucleotide
probes, and washed with 6x SSPE and 0.01% Tween-20 at 25°C; followed by the addition of
5µg/mL biotinylated goat anti-streptavidin (Vector) to increase the effective number of bi-
otin molecules on the target; and finally SAPE is added once again and washed extensively
with 6x SSPE and 0.01% Tween-20 at 30°C. The SAPE and antibody were added to arrays in 6x
SSPE, 1x Denhardt’s solution and 0.01% Tween-20 at 25°C for 10 minutes each. Following the
final wash, the arrays are kept in Holding buffer (100 mM MES, 1 M [Na+], 0.01% Tween-20).
The washing and staining procedures are run on Affymetrix fluidics stations. Arrays are
scanned using GCS3000 scanners with AutoLoaders (Affymetrix).
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Genotypes were called by the GeneChip® DNA Analysis Software (GDAS v2.0, Affymetrix) us-
ing the implemented dynamic model (DM; Di et al., 2005) algorithm and a confidence score
cutoff of 0.25. The Dynamic Model Mapping algorithm is a likelihood model based algorithm
using Wilcoxon’s signed rank test. It provides a genotype call for each SNP, along with quality
information for the call (for more details see GDAS User’s guide).
To ensure that no samples were confused, the 31 identical SNPs placed on both chips were
checked whether they yielded the same genotype for the same individual.
We verified genders by counting heterozygous SNPs on the X chromosome. Experimental de-
tails concerning the genotyping of the 100K SNP set are provided in Matsuzaki et al. (2004).
Genotype data of all 50k SNPs was exported for 96 chips (corresponding to 96 different
DNAs/individuals) into a single file per chip. These large and inscrutable files were converted
with the Converter.jar of GENOMIZER (2.9.3 on page 63) into the computational efficient
“chromosome data files”.
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A genotyping error occurs when the observed genotype of an individual does not correspond
to the true genotype (Bonin et al., 2004). Erroneous genotypes markedly decrease the power
for detecting associations (Goring et al., 2000; Abecasis et al., 2001; Terwilliger et al., 1990;
Gordon et al., 1999). Several levels of checks were applied to the data as suggested by Pom-
panon et al., (2005) to ensure reliability of the results.
Human errors
Human subjectivity during manual scoring (TaqMan® and SNPlex™) represented a main
problem that can hardly be avoided. Obviously, the risk of human scoring error strongly de-
pends on the quality of the data. Other sources of human errors were minimized by a maxi-
mum of automization. This included the use of barcodes and scanners for plates and
samples.
Low quantity or quality of DNA
Only a few or low-quality target DNA molecules favour allelic dropouts and false alleles (Tab-
erlet et al., 1996). Furthermore, the risk of contamination is increased. Therefore, each DNA
sample was quality checked on a gel (2.6 on page 33), normalized to a specific concentration
(2.4 on page 29), and an excess amount was used for genotyping and the whole-genome am-
plification (2.5 on page 31).
Call rate and Hardy-Weinberg equilibrium
All assays were checked for a high call rate (cases and controls) and for HWE (only controls)
as described in 2.9 on page 55 and by Hosking et al. (2004) and Xu et al. (2002). HW disequil-
brium can also arise from selection, inbreeding, or population admixture (Morton et al.,
1995).
Checking for Mendelian inheritance
In family-based studies, genotypes were checked for Mendelian errors, i.e. the genotype of a
child is incompatible with the genotypic constitution of the parents, e.g. the child has the
genotype “AA”, but the parents have the genotype “AA” and “BB” (Douglas et al., 2002; Ewen
et al., 2000). For most of the Mendelian errors, non-paternity was the cause, as always the
same pedigrees were affected. Since the assumed rate of non-paternity is <10% in Germany
(according to the Max Planck Institute in Munich), assays that produced more than 10%
Mendelian Error, i.e. more than one error per hundred trios, were excluded. This was done
because Mendelian errors can also indicate a genotyping or contamination problem (Gor-
don et al., 2004; Lange et al., 2001). If the number of Mendelian errors was below this thresh-
old or if the error-causing genotype(s) had ambiguous positions in the cluster plot, the
genotypes of all pedigree members were set to “0”.
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Another quality control for the assays and the genotyping process was the inclusion of posi-
tive and negative controls as described in 2.3.2 on page 28. In addition, each genotyping
method had its own internal controls . For a description, see the corresponding chapters
(TaqMan®: 2.8.1 on page 39; SNPlex™: 2.8.2 on page 44; Affymetrix Arrays: 2.8.5 on page 49).
Technical replication
Due to the paricular biochemical nature of each genotyping method, a technical replication
with a different method was performed before trusting new significant associations (see e.g.
page 104).
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Association studies can be family- or population-based resulting in two different analysis
methods, the transmission disequilibrium test (TDT) for family-based studies (Spielman et
al., 1993) and the case-control analysis for population-based studies. Genetic analyses were
performed using the diagnostic disease categories IBD, CD, and UC as described in 1.1.1 on
page 2. All tested SNPs had to pass several generally employed quality tests, such as call rate,
being polymorphic, and being in Hardy-Weinberg equilibrium. The latter is a fundamental
principle in population genetics stating that the genotype frequencies and gene frequencies
of a large, randomly mating population remain constant provided immigration, mutation,
and selection do not take place (American Heritage Dictionary).
All markers were tested for Hardy-Weinberg equilibrium (HWE) in controls using a χ2 test be-
fore inclusion in the association statistics (p > 0.01 threshold; variables as in table 2-14,
page 62 and with p1 and p2 being the allele frequencies):
If SNPs with significant deviations from HWE would be included, unacceptable high type I
error (false positives) rates would be the case (Sasieni et al., 1997; Schaid et al., 1999). Only
biallelic markers passing a call rate (CR) of >95% in cases and controls were used in down-
stream analyses. Quality assessments, single locus and transmission disequilibrium tests
(TDT) were performed using Haploview (Barrett et al., 2005) and GENOMIZER (Franke et al.,
2006; for more details see 2.9.3 on page 63). In families with multiple affected individuals,
one trio was randomly extracted for TDT analysis as implemented by Haploview. For case-
control analyses, one affected child was randomly extracted per trio using an in-house avail-
able Perl script create_case_controls_random.pl. Significance assessment of associa-
tions with or between single locus genotypes was performed using χ2 or Fisher's exact test for
2 x 3 contingency tables.
Haplotype frequency estimates among singletons were obtained using an implementation of
the EM algorithm in COCAPHASE (Dudbridge et al., 2003). Significance testing of haplotype
frequency differences were also performed with COCAPHASE and TDTPHASE. For details
see 2.9.5 on page 67.
Standardized coefficients r2 and D’ were computed with Haploview for pair-wise linkage dis-
equilibrium (LD) estimation between markers (2.9.1 on page 56).
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The population genetics term linkage disequilibrium is used for the non-random association
of alleles at two or more loci (Goldstein et al., 2001), not necessarily on the same chromo-
some.
Example according to Ott (1999), see also fig. 2-12:
A non-polymorphic gene (wt/wt) is in close proximity to a biallelic marker on the same chro-
mosome. The SNP has the alleles “A” and “B”, where “A” is the more frequent allele. At this
stage, the haplotypes “wtA” and “wtB” exist in the population. Then a mutation occurs, “wt
→ mut”, and this is statistically more likely to take place on the chromosome with the allele
having the higher population frequency, which is in this case allele “A”. At this point, the pop-
ulation contains three haplotypes, the two common ones considered above and a new one,
“mut/A”. As the population grows, recombinations occur between the two loci and slowly a
fourth haplotype, “mut/B”, emerges. There is then a marked difference between two classes
of haplotypes, those carrying a “wt” allele and those carrying a “mut” allele. The former con-
tains marker alleles “A” and “B” in approximately equal frequencies. However, haplotypes
carrying a mut allele contain far more “A” than “B” alleles (originally only “A”). This situation
is referred to as linkage disequilibrium. If “mut” is a disease allele, there must be a marked
difference of marker allele frequencies between affected and unaffected individuals. The ex-
tent of LD varies largely, there are “hot” and “cold” spots of recombination in the genome.
Fig. 2-12 History of two neighbouring alleles. (A) Alleles that exist today arose through ancient mutations. (B) One allele arose first and
then the other. The “C–C” haplotype will either die out or “drift” to an appreciable frequency in the population, with or without selective
pressure. (C) Recombination creates new arrangements for ancestral alleles. Illustration from http://www.sph.umich.edu/csg/abeca-
sis/class/
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quencies are pA, pa, pB, and pb with pA + pa = 1 and pB + pb = 1. The following haplotypic con-
figurations are possible:
In the presence of linkage equilibrium, the expected haplotype frequencies are equal to the
product of the allele frequencies. The deviation from the exptected frequency is determined
by calculating the disequilibrium parameter D:
pAB = pA · pB + D → D = pAB - (pA · pB).
The equilibrium state is characterized by D = 0 and is called gametic phase equilibrium or
linkage disequilibrium, and values >0 are referred to as positive disequilibrium or associa-
tion. For all four possible haplotypes, deviations are the same in case of biallelic loci. To dif-
ferentiate the LD between the locus pairs, the measure D is normalized. The most commonly
used normalizations are D’ and r2:
D’ = D/Dmax for D > 0 and D’ = D/Dmin for D < 0
with Dmax = min(pA · pb, pa · pB) and Dmin = max(-pA · pB, -pa · pb) [Hartl et al., 1988]
r2 = ∆2 = D2/(pA · pB · pa · pb)
A D’ value of one means that there is no evidence for recombination between the two mark-
ers. If allele frequencies are similar, high D’ values mean that the markers are good surrogates
for each other.
As recombination occurs between two loci, an existing LD between them gradually breaks
down (decay of disequilibrium). If one has determined a value of D’ between disease and a
marker locus and is willing to assume that the marker has not changed in past generations,
it is of interest to estimate the number of generations t from the given value of D’:
t = log(D’)/log(1-r), where r is the recombination fraction between the two loci.
In the present study, pairwise LD between SNPs was computed using Lewontin’s standard-
ized deviation coefficient D’ (Lewontin et al., 1963 and Lewontin et al. 1988) and r2 (Hill et al.,
1968). The algorithm, as implemented in Haploview (Barret et al., 2005), compares estimated
two-marker haplotypes with expected haplotypes in each population.
Haplotype Independence Observed
A______B pA · pB pAB
A______b pA · pb pAb
a______B pa · pB paB
a______b pa · pb pab
Table 2-9 Haplotypic configurations. “p” denotes the frequency of the corresponding genotype.
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The single-marker case-control statistic served as the main analysis method, especially for
the initial genome-wide screenings. Summarizing the method, allele and genotype frequen-
cies are compared between unrelated healthy individuals (controls) and unrelated patients
(cases). In contrast to this study design, a family-based approach was used, the TDT, which
is described in 2.9.4 on page 65. The main advantage of the case-control approach is the less
difficult and faster recruitment process and the higher statistical efficiency (TDT: only 1/6 on
the null hypothesis; Morton et al., 1998) and power. A major disadvantage of the case-control
design is its susceptibility to population substructure. Therefore, matching cases and con-
trols needs careful consideration to avoid stratification. Three distinct methods were used
for calculating case-control statistics, which are described in the following sections.
2.9.2.1 Genotype-based case-control comparison (CCG)
Genotype counts were obtained by cluster plot analyses of TaqMan® (2.8.1 on page 39) and
SNPlex™ (2.8.2 on page 44) data. Observed genotypes frequencies were compared to the ex-
pected frequencies, under the null hypothesis (H0) that no differences exist between cases
and controls.
If homozygotes for one allele are missing, then the 2 x 3 contingency table is narrowed down
to a 2 x 2 table and the χ2 value is calculated according to 2.9.2.2 on page 59.
Genotype Cases Controls Sum
11 n11 m11 w
12 n12 m12 x
22 n22 m22 y
Sum n m z
Table 2-10 Two-by-three contingeny table for genotype-based analyses.
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1. Expected values are computed: 
2. Differences to the observed values are calculated:
3. Chi square is finally computed: 
A chi square value greater than 3.84 is considered significant at the α = 0.05 level and with one
degree of freedom.
GENOMIZER was used to calculate the genotypic case-control p-value. If sex-matching was
required, an in-house Perl script (snp_cc_significance.pl) was used.
2.9.2.2 Allele-based case-control comparison (CCA)
Besides the genotypic case-control test, the allele-based test was used as the second major
test for association. Using the values from table 2-10, the following formulas were applied to
construct table 2-11:
n1 = 2 · n11 + n12; m1 = 2 · m11 + m12; n2 = 2 · n22 + n12; m2 = 2 · m22 + m12
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Allele Cases Controls Sum
1 n1 m1 x
2 n2 m2 y
Sum n m z
Table 2-11 Two-by-two contingeny table for allele-based analyses.
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1. Expected values are computed: 
2. Differences to the observed values are calculated:
3. Chi square is finally computed: 
A chi square value greater than 3.84 is considered significant at the α = 0.05 level and with one
degree of freedom. The general rule to calculate the degrees of freedom is to multiply the de-
grees of freedom for the rows and columns [i.e., d.f. = (rows-1) · (columns-1)] .
GENOMIZER (Franke et al., 2006) and Haploview (Barret et al., 2005) were used to calculate
the allelic case-control p-value in the present study. If sex-matching was required, an in-
house Perl script (snp_cc_significance.pl) was used. Permutation testing, as imple-
mented in Haploview, was used to verify significant p-values. This means that the affection
status of the individuals is reassigned and the same calculation is repeated, for the current
study 10,000 times. After bootstrapping, the output summarizes how many of the permuted
data sets had a higher maximum value compared to the non-randomized dataset..
a n x⋅z--------- b;
m x⋅
z
----------- c; n y⋅z--------- d;
m y⋅
z
-----------= = = =
e
n1 a–( )2
a
-------------------- f
m1 b–( )2
b
---------------------- g
n2 c–( )2
c
-------------------- h
m2 d–( )2
d
----------------------=;=;=;=
χ2 e f g h+ + +=
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The odds ratio is often used in retrospective studies as an approximation to the relative risk
(for pospective or cohort studies) and is referred to as the approximate relative risk or simply
as relative risk (Armitage et al., 1987). The ratio of the odds of an event in the experimental
(intervention) group to the odds of an event in the control group is defined as the odds ratio.
Odds are the ratio of the number of people in a group with an event to the number without
an event. Thus, if a group of 100 people had an event rate of 0.20, 20 people had the event and
80 did not, and the odds would be 20/80 or 0.25. An odds ratio of one indicates no difference
between comparison groups. For undesirable outcomes an OR that is less than one indicates
that the intervention was effective in reducing the risk of that outcome, i.e. a protective effect:
Relative risk and odds ratio are computed in the following way:
When the incidence rate is small, i.e. a is very small compared to b, which is the case for a rare
disease, odds ratios are a good estimate of the relative risks (Gordis, 2004):
[(a + b) ≈ b and (c + d) ≈ d], then OR ≈ RR
Relative Risk Exposure
≤0.3 strong protective effect
0.4 – 0.8 protective effect
0.9 – 1.1 no effect
1.2 – 2.5 risk effect
≥2.6 strong risk effect
Table 2-12 Relative risk and exposure. According to Sachs (2003).
Disease
+ (yes) - (no)
Factor
+ (Allel 1) a b
- (Allel 2) c d
n
Table 2-13 Typical two by two table for odds ratio calculation. According to Sachs (2003).
RR
a
a b+
-----------
c
c d+
-----------
----------- a c a d⋅+⋅a c b c⋅+⋅------------------------- OR;
a
c
-
b
d
--
--
a
b
--
c
d
--
--= a d⋅
b c⋅---------= = = =
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et al., 2000):
Table 2-13 gives the descriptive effect for the exposure. Whether the observed effect is signif-
icant on the chosen level of significance, is tested with the χ2 test according to Pearson, Man-
tel, and Haenszel et al. (1959):
In cases of low frequency SNPs, Fisher’s exact test was used to compute the case-control sta-
tistics. This was done by means of the webinterface SISA (Daan Uitenbrook, Hilversum, The
Netherlands).
Eight different odds ratios (table 2-15) can be calculated under assumptions of different ge-
netic models with the data of the following table:
Genotype Count
11 n11
12 n12
22 n22
Sum z
Table 2-14 Genotype counts.
Type of odds ratio High risk factor Low risk factor
Allelic #1 2 · n11 + n12 2 · n22 + n12
Allelic #2 2 · n22 + n12 2 · n11 + n12
Carriership #1 n11 + n12 n22
Carriership #2 n22 + n12 n11
Homozygotes #1 n11 n22
Homozygotes #2 n22 n11 
Heterozygotes #1 n12 n11 
Heterozygotes #2 n12 n22
Table 2-15 Different types of odds ratios. The most commonly used odds ratio is carriership of the minor allele, i.e. homozygous and
heterozygous carriers of the rare allele are assumed to have the disease.
95 CI OR( ) 1 96 1
a
-- 1
b
-- 1
c
-- 1
d
--+ + +,⎝ ⎠⎛ ⎞±ln=
χ2 n 1–( ) a d b c⋅–⋅( )
2⋅
a b+( ) c d+( ) a c+( ) b d+( )⋅ ⋅ ⋅--------------------------------------------------------------------------------=
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At the beginning of this study, no integrated and readily applicable software was available to
administer and analyze the large amounts of disease association data, which were going to
be generated in the two genome-wide experiments.
Therefore, a public-domain software, namely GENOMIZER (Franke et al., 2006), was devel-
oped. GENOMIZER implements the workflow of an association experiment, including data
management, single-point and haplotype analysis, ‘‘lead’’ definition, and data visualization.
The software comes with a complete user manual, and is open-source software licensed un-
der the GNU Lesser General Public License. The use of this software facilitated the handling
and interpretation of the genome-wide association data.
The functionality of the package is available both from the command-line and through a
graphical user interface. A given genome-wide association experiment is defined in terms of
its study population (cases and controls) and the marker set used. Individual genotypes are
reorganized in ‘‘chromosome data files’’ that represent a compact and memory-efficient in-
termediate data format. Using these files, the following analyses can be performed on a per-
chromosome basis:
1. Assessment of general marker characteristics including call rate, minor allele frequency,
and deviation from Hardy-Weinberg equilibrium (HWE). In addition to a χ2 goodness-
of-fit test, a recently proposed exact test of HWE has been implemented (Wigginton et
al., 2005).
2. Calculation of single-point allelic and genotypic association statistics (e.g., odds ratios)
and significance levels using recessive and dominant models.
3. Calculation of sliding-window haplotype statistics and randomization p-values using
the expectation maximization (EM)-implementation provided by the WHAP or COCAP-
AHSE programs (Dudbridge et al., 2003; Dudbridge et al., 2000). The actual program
used can be selected by the user.
4. Assessment of pairwise LD over user-defined ranges of the physical map; significance
levels are calculated using an efficient EM-implementation limited to two-marker hap-
lotypes (Morton et al., 2001).
5. Sex-specific analysis of X-chromosomal genotypes in which female data are treated as
in the autosomal case. Male genotypes are treated as direct haplotype observations and
analyzed using a randomization algorithm similar to WHAP/COCAPHASE.
For more details of the software package see Franke et al. (2006) or visit the homepage:
http://www.ikmb.uni-kiel.de/genomizer. A sample output plot is shown in fig 9-4, page 182.
Chapter 2: Methods 64Fig. 2-13 Screenshot of the GENOMIZER graphical user interface (GUI). (A) The main window is based upon a tab interface, which
reflects the logical order of a typical association study. (B) GENOMIZER stores multiple experiments based upon the same set of markers
in the same database. (C) For each chromosome, various analysis types are performed, each resulting in one unique analysis run. (D) The
table shows the analysis results for the selected run. (E) The multifunctional status bar and toolbar for user interaction.
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The suggestion to use family-based, rather than population-based controls, arises out of
concern over the effects of inmeasured population stratification (Spielman et al., 1993), i.e.
control individuals may not be well matched to cases, particularly for ethnic origin. Differ-
ences in allele frequencies between cases and controls will be interpretetd as evidence for LD
even though they may just be the result of differences in ethnic origin. Family-based cases
and “internal” controls are able to overcome this problem. Spielman et al. (1993 and 1996)
coined the term transmission/disequilibrium test using McNemar’s test, describing it as “a
test for linkage in the presence of association”. It is further a meausure of LD in the presence
of linkage. The idea that underlies TDTs is that, in the presence of association between a ge-
netic marker and disease susceptibility , the probability of transmission of a marker gene
from parents to an affected offspring is significantly increased (over-transmission) or de-
creased (under-transmission) from the 0.5 value (50% transmission is expected if no linkage
and no LD) predicted by Mendelian inheritance.
In the TDT study design, healthy parents with at least one affected offspring (so-called
monoplex or nuclear families; Falk and Rubinstein et al., 1987) are used. The number of
transmitted alleles from heterozygous parents to affected children is compared to the num-
ber of untransmitted alleles (table 2-16). Transmission events from homozygous parents are
not informative (fig 2-14, page 65) and these pedigrees are therefore excluded from the TDT
test.
Fig. 2-14 Informative and non-informative trios. Circles denote females and squares denote males, thus mother, father and their dis-
eased child are shown. Only heterozygote parents are informative.
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al. (1995) made the observation that the TDT tends to furnish an excess of false-positive re-
sults in such cases. However, it is only feasible to trace and genotype both parents of cases
for diseases with an early age of onset. In such cases, the use of unaffected sibling controls
has been advocated (Spielman et al., 1998).
As a test statistic, the McNemar test was used (Agresti et al., 1996), which corresponds to an
asymptotic chi square distribution under one degree of freedom (dof): 
In terms of efficiency, the TDT study design is inferior compared to the case-control design.
Each trio is scored for 2 transmisssions and two non-transmissions while three individuals in
a case-control design give six informative alleles so that the letter provides 1.5 as much infor-
mation as the former (Morton et al., 1998)
Family-based transmission distortion was analyzed using the transmission disequilibrium
test as implemented in Haploview (Barret et al., 2005).
Not transmitted
1 2
Transmitted
1 n11 n12
2 n21 n22
Table 2-16 Two-by-two contingency table for the TDT.
χ2 n12 n21–( )
2
n12 n21+
----------------------------=
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The alleles (at different genes) received by an individual from one parent are called a haplo-
type (contraction of the phrase “haploid genotype“). In the context of this study, the word
haplotype refers to a set of SNPs found to be statistically associated on a single chromatid.
Focusing on haplotypes may be more relevant if there is a suspicion that the “additional” dis-
ease mutation occured on a specific ancestral haplotype.
In practice, genotypes but not haplotypes are observed. For a two-marker haplotype, eight
out of nine genotype combinations can be resolved into pairs of haplotypes. Phase uncer-
tainty exists for the ninth (either 1–1/2–2 or 1–2/2–1), see table 2-17:
To infer haplotypic phase from unphased genotype data, an algorithm can be formed by a
straightforward application of the estimation maximization algorithm (EM; Ott et al., 1977),
based on the assumption of Hardy-Weinberg equilibrium. Excoffier et al. (1995) were the first
to discuss the use of the EM algorithm in this context. In brief, the algorithm works as follows:
Assuming biallelic markers and a two-marker haplotype, only for individuals who are double
heterozygotes, the haplotype assignment is ambiguous. It is possible to assign haplotypes to
all other individuals because they are homozygous at one of the loci. The EM algorithm is
used to assign haplotypes to those people for which haplotype assignment is ambiguous, and
it does this by first calculating the frequency of the other haplotype assignments for those in-
dividuals whose phase can be resolved. It then makes a guess at the assignment of haplotypes
(which is essentially a random guess), and compares this guess to the likelihood based on the
observed haplotypes. The goodness of fit between the algorithm's guess and the most likely
assignment is then assessed (often through a likelihood function) and the guess adjusted on
this basis. This process is iterated until the change in likelihood used to assess the goodness
of fit is negligable.
Significance testing of haplotype frequency differences and haplotype estimations were per-
formed with COCAPHASE and TDTPHASE (Dudbridge et al., 2003), making use of the fact
that twice the log-likelihood ratio between two nested data models approximately follows a
χ2 distribution with k degrees of freedom, where k is the difference in parameter number be-
Locus A
Locus B
1/1 1/2 2/2
1/1 yes yes yes
1/2 yes no yes
2/2 yes yes yes
Table 2-17 Phase uncertainty, a problem of haplotype analyes.
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by -2 is called the log-likelihood statistic. A log-likelihood statistic is a relative measure of the
goodness-of-fit of a specific model and the difference between two log-likelihood statistics
produces a test-statistic with an approximate chi-square distribution (Selvin, 2004).
SNPs and haplotypes having a frequency below 1% in the examined population, were exclud-
ed from the analysis.
TDTPHASE, COCAPHASE, and Haploview take a standard linkage pedigree file as input. This
is a plain text file with lines of the following whitespace-delimited format:
pedigree ID, individual ID, father ID, mother ID, sex, Allele1a, Allele1b, Allele2a, Allele2b...
The pedigree name may be alphanumeric, all other fields must be numeric. Missing data is
coded as zero.
COCAPHASE v2.403 was used with the following command:
cocaphase input.pre -datafile input.dat -individual -EM -window 2
The given example is for a two-marker haplotype. The pre-file contains genotype data for sin-
gle cases and controls.
TDTPHASE v2.403 was executed from the command prompt as follows:
tdtphase input.pre -datafile input.dat -individual -window 2
With the above command a two-marker sliding window haplotype analysis will be started.
Genotypes for all triplets need to be provided by the input.pre file.
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A consequence of the lack of haplotype diversity in regions of strong LD, is that there is con-
siderable redundancy. Most polymorphisms and haplotypes in such a region can be predict-
ed from a smaller subset. Johnson et al. (2001) coined the term “haplotype tagging” SNPs, or
htSNPs for such a subset. Haplotype tagging SNPs are very valuable for investigating the ge-
netics behind common diseases as genotyping costs are significantly reduced.
Fig. 2-15 Tagging SNPs. (A) Single nucleotide polymorphisms(SNPs) are identified in DNA samples from multiple indivduals. (B) Adjacent
SNPs that are inherited together are compiled into "haplotypes." (c)"Tag" SNPs within haplotypes are identified that uniquely identify those
haplotypes. By genotyping the three tag SNPs shown in this figure, researchers can identify which of the four haplotypes shown here are
present in each individual. This significantly reduces genotyping costs and efforts. Illustration from http://www.hapmap.org.
Haplotype tagging SNPs for candidate genes were selected with Haploview, using the in-built
tagger, which is based on Paul de Bakker’s algorithm (Bakker et al., 2005). The following de-
fault settings were used: “pairwise tagging only” and an r2 threshold of 0.8. Genotype data
was obtained from the HapMap homepage, which currently provides scientists with geno-
types for more than three million non-redundant SNPs and four populations (CEU = U.S. res-
idents with northern and western European ancestry, YRI = Yoruba people of Ibadan,
Nigeria, CHB = Chinese from Beijing, JPT = Japanese from the Tokyo area; sum of 270 indi-
viduals).
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Logistic regression is part of a category of statistical models called generalized linear model-
sand it can be used for genetic data analyses, as the dependent variable is of dichotomous na-
ture (healthy or diseased). It is especially useful to determine the covariates that explain the
outcome best. In this study, logistic regression was utilized to determine whether a found
mutation is able to predict the disease outcome by itself or whether other surrounding SNPs
improve the model. This was done in parallel to a haplotype analysis which gives basicly the
same information. Furthermore, logistic regression was used to determine other factors that
have an influence on the association, such as sex, age, presence of other known risk factors,
et cetera.
Genotype-based logistic regression analysis was performed with R and SPSS 13.0, coding in-
dividual SNP genotypes as categorical variables and using forward likelihood ratio inclusion.
Analysis of the statistical interactions of risk genotypes, including Breslow-Day tests for odds
ratio homogeneity, was done by means of procedure FREQ of the SAS/STAT® software pack-
age.
2.9.7 Fisher’s exact test
If the number of observations obtained is small, e.g. very rare alleles, Karl Pearson’s χ2 test
may produce misleading results. A more appropriate form of analysis (when presented with
a 2 x 2 contingency table) is to use Ronald A. Fisher’s (1973) exact test (Sachs, 2003). The test
is exact because it uses the exact hypergeometric distribution rather than the approximate χ2
distribution to compute p-values. Fisher’s exact test was applied in the present study if the
allele count for one of the four cells was less than 5 or if the marginal was very uneven. It was
calculated by using the in-house programm rcexact.exe (written by Mehta) and by means
of the webinterface SISA. Fisher’s exact test was not used for regular 2 x 2 tables, as this would
have been an over-conservative test.
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Functional experiments were performed in collaboration with Dr. Philip Rosenstiel, Dr. An-
dreas Till, Dr. Robert Häsler, and Sven Künzel (all from the Institute of Clinical Molecular Bi-
ology, Kiel). In the following sections, only a brief overview of the used methods is given.
2.10.1 Gene expression experiments
To further investigate the pathways of ATG16L1 and NELL1, transcripts were quantified in
several stimulated cell lines using fluorogenic real-time PCR. 
2.10.1.1 Stimulation of cell lines
Four cell lines from different tissues were used for the subsequent stimulation experiments.
All cells were cultured at the cell biology laboratory of the ICMB using DMEM and RPMI cul-
ture medium (PAA Laboratories GmbH, Pasching, Austria):
❏ HT-29: Human epithelial colon adenocarcinoma cell line
❏ HeLa: HeLa cells are epithelial-like malignant cells derived from the cervix of Henrietta
Lacks (1920-1951).
❏ Caco-2: Human colonic, epithelial-like adenocarcinoma cell line
❏ THP-1: Human acute monocytic leukemia cell line; THP-1 cells have Fc and C3b recep-
tors and lack surface and cytoplasmic immunoglobulins. The cells were described to
produce lysozyme and to be phagocytotic. Futhermore, they can be primed to become
more macrophage-like and adherent. This induction was carried out by adding PMA
(phorbol 12-myristate 13-acetate; Sigma-Aldrich GmbH, Munich, Germany) to the cell
culture at a final concentration of 10 nM. Primed THP-1 cells were only used in the stim-
ulation experiment with Listeria monocytogenes since adherent leukocytes reflect the in
vivo response to bacterial invasion (Scorneaux et al., 1996).
The previously mentioned cell lines were incubated/stimulated with the following reagents:
Interferon-γ (IFN-γ)
The cytokine interferon-γ activates the JAK/STAT pathway (Shuai et al., 1992) and is secreted
by T-cells and natural killer lymphocyte. 5000 units of IFN-γ were added to the culture.
Lipopolysaccharide (LPS)
LPS is a large molecule that contains both lipid and a carbohydrate. They are a major supra-
structure of gram-negative bacteria. LPS contributes greatly to the structural integrity of the
bacteria, and protects them from host immune defenses. LPS was acquired from Prof. Zae-
hringer of the Forschungszentrum Borstel (Germany) and was added to the cell culture at a
final concentration of 1 µg/ml.
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Flagellin is the principal substituent of the bacterial flagellum, and is present in large
amounts on nearly all flagellated bacteria. It is, for example, recognized by Toll-like
receptor 5 (TLR-5), which is part of the innate immune system (Gewirtz et al., 2001). Flagel-
ling was added to the medium at a final concentration of 500 ng/ml.
Transforming growth factor β (TGF-β)
TGF-β plays crucial roles in tissue regeneration, cell differentiation, and embryonic develop-
ment, as it is involved in the TGF signal transduction pathways. A final concentration of 5
ng/ml was used.
Epidermal growth factor (EGF)
The protein EGF is involved in cell growth, proliferatoin, and differentiation. Human EGF is
a 6045 Da protein with 53 amino acid residues and three intramolecular disulfide bonds
(Carpenter et al., 1984). EGF was added to the medium at a final concentration of 1 µg/ml.
Tumor necrosis factor α (TNFα)
Tumor necrosis factor a is a cytokine with a wide range of pro-inflammatory activities (Beut-
ler et al., 1995) and it is produced primarily by monocytes/macrophages. TNFα has direct cy-
totoxic effects on the intestinal mucosa in CD and UC but also contributes to the systemic
manifestations seen in these diseases. Anti-TNFα antibodies have shown a clear anti-inflam-
matory effect in patients with Crohn's disease. A final concentration of 10 ng/ml was used.
Listeria monocytogenes
Listeria monocytogenes is a gram-positive bacterium which is motile by means of flagella. It
is easy to cultivate, non-spore-forming and ubiquitous. Bacteria were cultured overnight and
fresh cultures were inoculated and grown until a density of OD650 ~0.2 was reached. Approx-
imately 100 bacterias per cell were added to the medium. When the medium was changed
from “-/-” to “+/+” (10% FCS [fetal calf serum] -1% P/S [Penicillin/Streptomycin]) medium
after 1 hour of incubation, time was measured.
All cells were exposed to the stimuli for 0, 1, 2, and 8 hours and each experiment was per-
formed in duplicate. Afterwards, the RNA was extracted as described in the next section.
2.10.1.2 RNA extraction from cells
Cells were cultured in 2 ml medium and washed with PBS in 6-well plates (Nunc GmbH,
Wiesbaden). Afterwards, the cells were carefully scraped off and centrifuged for 5 min at 2000
rpm. RNA was extracted from the resuspensed pellet (1 ml RLT containing 10 µl/ml β-Mer-
captoethanol) by using the RNeasy-Kit of Qiagen (Hilden, Germany). All steps were carried
out according to the standard protocol. The protocol included a DNase I digestion step to de-
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bands are visible in intact RNA, smear indicates degradation) before they were used for cDNA
synthesis. Concentrations were measured using 1 µl of RNA and a NanoDrop® ND-1000
Spectrophotmeter (NanoDrop Technologies, Wilmington, DE, USA). Quality of RNA was fur-
ther checked by using an aliquot of RNA in a PCR with GAPDH primers. A band of 360 bp in-
dicated the isolation of intact RNA.
2.10.1.3 cDNA synthesis
For each sample, cDNA was reverse-transcribed from 1 µg of total RNA in a total volume of
100 µl using the SMART™ PCR cDNA Synthesis Kit from Clontech.
The success of the first strand cDNA synthesis was then checked by using 2.5 µl cDNA as a
template for PCR amplification of β-Actin:
95°C for 5 min; 35 cycles: 95°C for 30 sec, 58°C for 30 sec, 72°C for 45 sec; 72°C for 10 min
The amplification of the 518 bp β-Actin PCR product, indicated successful first stand synthe-
sis. The final theoretical concentration of cDNA, assuming 100% efficiency of reverse tran-
scription, was 10 ng of cDNA/µl.
2.10.1.4 Plate production
25 µl of cDNAs were diluted 1:5 with water to a final volume of 125 µl and a theoretical con-
centration of  2 ng/µl before being arrayed to 384-deep well plates. For relative quantitation
using a standard curve (according to Livak et al., 2001), several cDNAs were mixed and seri-
ally diluted (Undiluted, 1:1.5, 1:5, 1:10, 1:20, 1:40, 1:60, 1:80, 1:100, 1:200). A plate-layout,
showing the random distribution of the duplicates, is shown in fig 2-16, page 73.
Fig. 2-16 Plate layout for gene expression experiments. Each sample is arrayed once per quadrant, i.e. in duplicates per tested assay.
To circumvent artefacts arising by physical proximity, samples and their replicates are semi-randomly distributed. The precise llocalization
of each sample is given in the file APG16L_Realtime_Analysis.xls on the DVD.
For the real-time PCR reaction, 5 µl of the cDNA solution were pipetted from the deepwell
plates into 384 well PCR plates in quadruplicates: two wells for β-actin (“housekeeper”) and
two wells for “target” gene quantitation.
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The three commercially available TaqMan® Gene Expression assays for ATG16L1
(Hs00250530_m1), NELL1 (Hs00971083_m1), and β-Actin (Hs99999903_m1) were ordered
through Applied Biosystems (Foster City, CA, USA). All assay probes spanned an exon junc-
tion and did not detect genomic DNA (as indicated by the “_m” in the name). Probes for real-
time PCR were labelled with the fluorescent reporter dye 6-carboxyfluorescein (FAM) and
the quencher dye 6-carboxytetramethylrhodamine (TAMRA) at the 5' and 3' ends, respec-
tively.
Reaction mix was prepared according to table 2-18 and dispensed by multipipetting into a
384-well PCR plate containing 5 µl of cDNA. All reagents were kept on ice during the pipetting
procedure. Plates were sealed with an aluminum adhesive cover and stored at 4°C in the dark
if they were not immediately run.
Prior to running on an ABI 7900HT Sequence Detection System, plates were briefly centri-
fuged. The following thermocycling profile was used: 50°C for 2 min (AmpErase UNG activa-
tion); 95°C for 10 min (AmpliTaq Gold® activation); and 40 cycles of: 95°C for 15 s; 60°C for 1
min. Upon completion of the run, the data was analysed by the Sequence Detection System
2.1 (SDS) software using the following parameters:
1. The threshold line was set as low as possible such that the line intersects with the ampli-
fication curves in the exponential phase, thus reducing any amplification in the non-
template controls to a negligible levels
2. The baseline was set separately for housekeeper and target such that the baseline starts
at three cycles and ends just before the first amplification curves rise above the
threshold.
3. Extreme outliers in the standard curve were eliminated from the calculation of the stan-
dard curve.
Upon adjusting all of these parameters, the SDS software automatically calculated the rela-
tive quantities, which were then exported as a tab-delimited text file for further data process-
ing with MS Office Excel 2003.
Reagent Volume [µl] Final concentration
cDNA template (2 ng/µl) 5 1 ng/µl
20x Assay-on-Demand 0.5 1x
2x TaqMan® Universal PCR Master Mix 4.5 0.9x
Total 10
Table 2-18 Real-time PCR master mix. Volumes are given for a single reaction. For a 384-well MTP, 423 reactions were prepared
(384x + 10% excess volumen)
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ing relative quantities of the housekeeping gene, namely β-acting. Then, the fold-changes
were calculated by dividing each normalized value through the correspondinging normal-
ized reference (e.g. 0 hour stimulation sample or healthy control person). Finally, average
fold-changes and standard deviations were calculated. Fold-changes below zero indicated a
downregulation of the transcript and they were normalized to values greater than 1 by taking
the inverse 1/n.
2.10.2 Isolation of primary epithelial cells (IECs)
Epithelial cell preparation was carried out using a standard protocol as described (Rosenstiel
et al., 2003; Daig et al., 2000). In brief, mucosal biopsies were placed in 1.5 mM EDTA in
Hanks balanced salt solution without calcium and magnesium (HBSS) and tumbled for 10
minutes at 37°C. This supernatant containing debris and mainly villus cells was discarded.
The mucosa was incubated again with HBSS/EDTA for 10 minutes at 37°C. The supernatant
was collected into a 15 ml tube. The remaining mucosa was shortly vortexed in PBS and this
supernatant was also collected. It contained complete crypts, some single cells, and a small
amount of debris. To separate IECs (crypts) from contaminating non-epithelial cells, the sus-
pension was allowed to sediment for 15 minutes. The cells (mainly complete crypts) were
collected and washed twice with PBS. The number and viability of the cells were determined
by trypan blue exclusion. The purity of the epithelial cell preparation was checked by routine
hematoxylin-eosin staining, showing more than 90% of epithelial cells.
2.10.3 RT-PCR
Total RNA from primary intestinal epithelial cells was isolated using the RNeasy kit from
Qiagen. RNA yield was determined using a NanoDrop® ND-1000 spectrophotometer. 300 ng
of total RNA were reverse transcribed using the Advantage RT-for-PCR kit with oligo-dT-
primers according to the manufacturer’s protocol and Waetzig et al. (2005).
Resulting cDNA (5 µl of RT reaction) was amplified using GeneAmp PCR buffer and Ampli-
Taq DNA Polymerase in a 50 µl reaction volume containing primer pairs (0.2 µM/primer) and
0.2 mM dNTPs. Negative RT and PCR controls included reactions in the absence of RNA sam-
ple, reverse transcriptase, and cDNA, respectively.
For investigation of tissue specific expression patterns, a commercial tissue panel was ob-
tained from Clontech (Human Multiple Tissue cDNA Panel I and II). The concentration of
each cDNA was approx. 1 ng/µl. Primers used for amplification of ATG16L1 are listed in
table 8-3, page 163 (expected amplicon length: 231 bp). The following conditions were ap-
plied: Denaturation for 5 min at 95°C; 25 cycles of 30 s at 95°C, 20 s at 60°C, 45 s at 72°C; final
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tion, thus to allow a semi-quantitative analysis.
To confirm the use of equal amounts of RNA in each experiment all samples were checked in
parallel for β-actin mRNA expression. All amplified DNA fragments were analyzed on 1% aga-
rose gels and subsequently documented by a BioDoc Analyzer as described in 2.6 on page 33.
2.10.4 Western Blot
Biopsies from five healthy controls without any obvious intestinal pathology and five Crohn
patients with confirmed ileal and colonic inflammation were lysed and subjected to Western
blot analysis as described by Waetzig et al. (2005). 10 µg of total protein were separated by
SDS polyacrylamide gel electrophoresis and transferred to PVDF membrane by standard
techniques. ATG16L was detected using a polyclonal clonal anti-ATG16 antibody (anti-
ATG16L, ABGENT, San Diego, CA).
2.10.5 Immunohistochemistry
Paraformaldehyde-fixed paraffin-embedded biopsies from normal controls (n = 5) and from
patients with confirmed colonic CD (n = 5), which were obtained in parallel from the same
sites as the biopsies used for the expression analysis studies (2.10.3 on page 75), were analy-
sed. Two slides of each biopsy were stained with hematoxylin-eosin for routine histological
evaluation. The other slides were subjected to a citrate-based antigen retrieval procedure,
permeabilized by incubation with 0.1% Triton X-100 in 0.1 M phosphate-buffered saline
(PBS), washed three times in PBS and blocked with 0.75% bovine serum albumin in PBS for
20 minutes. Sections were subsequently incubated with the primary antibody (anti-ATG16L)
at a 1:200 dilution in 0.75% BSA for 1 h at room temperature. After washing in PBS, tissue
bound antibody was detected using biotinylated goat-anti rabbit followed by HRP-conjugat-
ed avidin, both diluted at 1:100 in PBS. Controls were included using irrelevant primary an-
tibodies as well as omitting the primary antibodies using only secondary antibodies and/or
HRP-conjugated avidin. Bound antibody was detected by standard chromogen technique
(Vector Laboratory) and visualized by an Axiophot microscope. Pictures were captured by a
digital camera system (Axiocam, Zeiss).
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Protein modeling of ATG16L1 was done in cooperation with the Max-Planck Institute for Bio-
informatics (Saarbrücken) in the following way:
Protein sequences were retrieved from the UniProt (Wu et al., 2006) and Ensembl (Birney et
al., 2006) databases and protein domain architectures were taken from the Pfam database
(Finn et al., 2006). 3D crystal structure coordinates were obtained from the Protein Data Bank
(Kouranov et al., 2006) and corresponding domain definitions from the SCOP database (An-
dreeva et al., 2004). Ensembl identifiers, UniProt accession numbers, and PDB codes are list-
ed in table 2-19 and table 2-20 for fig. 3-6 and fig. 9-5, respectively.
Using the alignment program MUSCLE (Edgar et al., 2004), multiple sequence alignments
(fig. 3-6 and fig. 9-5) of ATG16L1 homologs were computed, contained in the Ensembl family
ATG16L1 (identifier ENSF00000001431) and the Pfam family ATG16 (accession number
PF08614). To analyze the alignments further, the following evolutionarily related WD-repeat
proteins with known 3D structures were included: yeast cell division control protein 4
(CDC4; Orlicky et al., 2003), yeast SIR4-interacting protein 2 (SIR2; Cerna et al., 2005), yeast
glucose repression regulatory protein 1 (TUP1; Sprague et al., 2000), and human transducin-
like enhancer protein 1 (TLE1; Pickles et al., 2002). The alignments were manually refined
based on multiple sequence alignments of the WD40 Pfam family (accession number
PF00400), the published WD-repeat consensus sequence (Li et al. 2001; Smith et al. 1999),
and structure superpositions of WD-repeat proteins using FATCAT (Ye et al., 2004). The
alignment figures were prepared and illustrated using the editors GeneDoc (Nicholas et al.
1997), Jalview (Clamp et al., 2004), and SeaView (Galtier et al., 1996). 
The secondary structure assignment to PDB structures was obtained from the DSSP database
(Kabsch et al., 1983). To predict the secondary structure of ATG16L1 homologs in different
species, the prediction servers PSIPRED (McGuffin et al., 2000), YASPIN (Pyo et al., 2005),
PROFsec (Rost et al., 2004), and Porter (Pyo et al., 2005) were contacted. Consensus predic-
tions by majority voting (Albrecht et al., 2003) were also formed. All servers consistently pre-
dicted β-strands characteristic of eight WD repeats in ATG16L1, and a helical linker may
precede the eighth WD-repeat as it is the case for CDC4 (fig 9-6, page 184; Orlicky et al., 2003).
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vestigated the fold recognition results returned by the BioInfoBank online meta-server
(Bujnicki et al., 2001) and compared them to the very similar predictions by the web servers
FFAS03 (Jaroszewski et al., 2005) and Arby (von Öhsen et al., 2004). The BioInfoBank server
contacts a dozen other structure prediction servers and is coupled to a 3D-Jury system that
assesses the quality of the returned results based on a sophisticated scoring scheme (Ginalski
et al., 2003). FFAS03 and ARBY also provide statistically derived confidence scores for struc-
ture predictions.
In agreement with the WD40 Pfam family classification, all servers predicted at least seven
WD repeats at the C-terminus of ATG16L1 starting near residue P311. In addition, the sec-
ondary structure predictions for human ATG16L1 and its species homologs as well as the
conservation of amino acids characteristic of WD repeats (Li et al. 2001; Smith et al. 1999) in-
dicated an eighth non-canonical WD repeat in the 40-residue region P271-V310 (fig 9-5,
page 183 and fig 9-6, page 184). 
Since diverged WD repeats have already been observed with other WD-repeat proteins such
as CDC4, SIF2, and coronin-1 (Orlicky et al., 2003; Cerna et al., 2005; Appleton et al., 2006),
the eight-bladed β-propeller structure of the WD-repeat domain from the CDC4 subunit of
the yeast SCF ubiquitin ligase complex was chosen as structural template for ATG16L1. Be-
cause the WD-repeat domain of ATG16L1 is replaced by an actin domain in the ATG16L1 ho-
molog of Ustilago maydis (UniProt accession number Q4P303), one may speculate that the
WD-repeat domain of human ATG16L1 is involved in actin regulation like coronin proteins
with a domain architecture similar to ATG16L1 (Rybakin et al., 2005). To model the 3D pro-
tein structure of ATG16L1, pairwise sequence-structure alignment from the manually curat-
ed multiple alignment of ATG16L1 and WD-repeat domain homologs (fig 9-5, page 183) were
extracted and submitted to the WHAT IF server (Rodriguez et al., 1998). The image of the re-
sulting full-atom protein structure model (fig 3-7, page 112) was illustrated using Yasara and
POV-Ray.
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Homo sapiens ATG16L1_Ho_sa ENSP00000287735
Macaca mulatta ATG16L1_Ma_mu ENSMMUP00000030747
Pan troglodytes ATG16L1_Pa_tr ENSPTRP00000022319
Mus musculus ATG16L1_Mu_mu ENSMUSP00000027512
Rattus norwegicus ATG16L1_Ra_no ENSRNOP00000024445
Canis familiaris ATG16L1_Ca_fa ENSCAFP00000017340
Bos taurus ATG16L1_Bo_ta ENSBTAP00000005140
Gallus gallus ATG16L1_Ga_ga ENSGALP00000002472
Monodelphis domestica ATG16L1_Mo_do ENSMODP00000013062
Danio rerio ATG16L1_Da_re ENSDARP00000055987
Fugu rubripes ATG16L1_Fu_ru NEWSINFRUP00000138508
Tetraodon nigroviridis ATG16L1_Te_ni GSTENP00021121001
Xenopus tropicalis ATG16L1_Xe_tr ENSXETP00000030368
Table 2-19 Species and Ensembl identifiers for the homologous ATG16L1 sequences that were used to generate fig 3-6, page 111.
Protein Species Alignment UniProt/Ensembl PDB
ATG16L1 Homo sapiens ATG16L1-Ho-sa Q676U5 –
ATG16L1 Bos taurus ATG16L1-Bo-ta ENSBTAP00000005140 –
ATG16L1 Canis familiaris ATG16L1-Ca-fa ENSCAFP00000017340 –
ATG16L1 Gallus gallus ATG16L1-Ga-ga ENSGALP00000002472 –
ATG16L1 Mus musculus ATG16L1-Mu-mu Q8C0J2 –
ATG16L1 Rattus norwegicus ATG16L1-Ra-no ENSRNOP00000024445 –
ATG16L1 Tetraodon nigroviridis ATG16L1-Te-ni Q4SB59 –
CDC4 Saccharomyces cerevisiae CDC4-Sa-ce P07834 1nex, chain B
SIF2 Saccharomyces cerevisiae SIF2-Sa-ce P38262 1r5m, chain A
TUP1 Saccharomyces cerevisiae TUP1-Sa-ce P16649 1erj, chain A
TLE1 Homo sapiens TLE1-Ho-sa Q04724 1gxr,chain A
Table 2-20 Ensembl/UniProt identifiers for ATG16L1 homologs and related WD-repeat proteins shown in fig 9-5, page 183. PDB
codes are given for the WD-repeat domain structures CDC4, SIR2, TUP1, and TLE1.
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3.1 Genome-wide screenings (GWS)
With the objective to find new suceptibility regions and genes involved in the etiology of in-
flammatory bowel diseases, two (technically) independent and hypothesis-free genome-
wide screenings were carried out. In the first scan, approximately 20,000 protein-changing
SNPs were directly typed with SNPlex™. The second approach aimed to identify new IBD
loci by typing 116,161 evenly distributed SNPs across the genome, thereby relying on existing
linkage disequilibrium with the disease-causing variants. A summary of the used samples/
panels is given in table 2.2, page 25.
3.1.1 Direct approach: cSNP experiment
A total of 19,779 non-synonymous SNPs were genotyped in the samples of panel A (735 CD
patients and 368 controls from Northern Germany (table 2-1, page 26), using the SNPlex™
system as described in section 2.8.2 on page 44. The control plate XR01 and the two patient
plates XR02, and XR03 were used. Genotyping was successful for 16,360 assays, as defined by
a mean fluorescence reading greater 500 units on the ABI 3730xl sequencer. Of these SNPs,
some 7,159 occurred at a minor allele frequency greater 1% and were thus included in the
subsequent analyses with GENOMIZER. These markers were ranked and prioritized for fol-
low-up on the basis of the p-values obtained in the single-locus allele-based and genotype-
based test for disease association. A p-value of 0.01 in the allele-based test was used as a cut-
off for inclusion in a replication study, which resulted in 72 putative disease variants that
were evaluated in panel B (380 German CD trios, 878 single patiens and 1032 independent
controls, see also table 2-1, page 26). Initial results and outcomes of the replication for these
72 polymorphisms are given in table 3-1, page 81. For the replication studies, the following
plates were used:
❏ XN33, XGCON01, XGCON02 (controls)
❏ XG01, XG02, XG03, XG04 (trios)
❏ XG05, XG06 (single cases)
When p < 0.05 in both the TDT and the case-control comparison was held to indicate formal
replication, only three markers, rs2241880 in the ATG16L1 gene and the previously reported
variants, rs1050152 (Leu503Phe) in the OCTN1 gene (Peltekova et al., 2004), and the known
CARD15 SNP rs2066845 ("SNP12", Hugot et al., 2001), were found to match this criterion. The
newly found association of the “G” allele at rs2241880 with CD was significant with p = 1.6 x
10-05 in the allele-based case-control comparison and with p = 2.7 x 10-05 in the TDT. Thus,
all subsequent mapping and replication efforts of this GWS were confined to this variant.
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# gene celera ID dbSNP ID chr. position pCCA pCCG pCCA pCCG pTDT
1 DCP1B hCV2194128 rs12423058 12 1,934,927 5.8·10-14 3.6·10-13 0.92 0.54 0.07
2 TINAG hCV12027972 rs1058768 6 54,232,983 1.7·10-12 7.9·10-11 0.27 0.15 0.21
3 OR8H1 hCV25770775 rs17613241 11 55,839,523 2.2·10-09 2.8·10-09 0.27 0.41 0.15
4 TTN hCV25626488 rs10497517 2 179,646,084 3.4·10-07 2.7·10-06 0.17 0.37 0.70
5 OR10A4 hCV15895352 rs2595453 11 6,862,804 0.00005 0.0003 0.18 0.21 0.43
6 hCG1744077 hCV3111449 rs211716 1 75,529,932 0.0001 0.0006 0.05 0.16 0.14
7 hCG1744077 hCV928121 rs211715 1 75,530,066 0.0002 0.001 0.07 0.21 0.19
8 S100Z hCV8796177 rs1320308 5 76,255,325 0.0003 0.0010 0.05 0.11 0.40
9 IL7R hCV2025977 rs6897932 5 35,920,076 0.0004 0.0002 0.91 0.99 0.95
10 ATG16L hCV9095577 rs2241880 2 234,470,182 0.0004 0.002 0.00001 0.00007 0.00001
11 FLJ23577 hCV25770123 – 5 35,715,804 0.0004 0.004 0.21 0.41 0.81
12 U2 hCV25637975 rs6730351 2 223,793,960 0.0007 0.003 0.55 0.81 0.50
13 APBB2 hCV1558531 rs4861358 4 40,931,441 0.0009 0.004 0.04 0.06 0.57
14 SLC17A3 hCV1911085 rs1165165 6 25,970,445 0.0009 0.004 0.58 0.26 0.90
15 hCG1789632 hCV25929364 rs10948733 6 52,867,218 0.0009 0.004 0.05 0.04 0.50
16 NALP13 hCV2092168 rs303997 19 61,116,255 0.001 0.005 0.73 0.86 0.82
17 hCG1812162 hCV25994942 rs10483261 14 20,346,679 0.001 0.005 0.79 0.76 0.08
18 hCG1646471 hCV15965545 rs2291479 3 179,495,857 0.001 0.006 0.49 0.72 0.60
19 HS6ST3 hCV3118872 rs2282135 13 95,187,906 0.001 0.003 0.12 0.25 0.86
20 PKD1L2 hCV8443426 rs1869348 16 80,921,788 0.002 0.003 0.0004 0.002 0.52
21 VGF hCV25649609 – 7 100,378,082 0.002 0.006 0.27 0.17 0.13
22 TXNDC11 hCV1388401 rs3190321 16 11,740,094 0.002 0.002 0.09 0.04 0.74
23 PLSCR4 hCV25647383 rs3762685 3 147,259,528 0.002 0.005 0.71 0.77 0.30
24 OR5U1 hCV2519378 rs9257694 6 29,382,496 0.002 0.008 0.52 0.77 1.00
25 UBQLN4 hCV16187524 rs2297792 1 153,228,236 0.002 0.006 0.003 0.009 0.65
26 CARD15 hCV11717466 rs2066845 16 50,543,573 0.002 0.008 8.6·10-08 7.1·10-07 0.002
27 FUCA1 hCV12023629 rs11549094 1 23,650,437 0.002 0.008 0.48 0.54 0.69
28 hCG1999532 hCV2481084 rs3129096 6 29,291,365 0.002 0.008 0.45 0.67 0.83
29 OR2J2 hCV11194783 rs3116817 6 29,257,553 0.002 0.010 0.57 0.84 0.61
30 FLJ25660 hCV2537241 rs541169 19 40,410,860 0.003 0.01 0.77 0.39 0.32
31 KUB3 hCV25770320 rs3751325 12 56,621,893 0.003 0.001 0.46 0.75 0.25
32 SLC16A4 hCV15961275 rs2271885 1 110,220,442 0.003 0.01 0.31 0.09 0.10
33 U1 hCV2475291 rs2157453 1 170,103,324 0.003 0.0008 0.002 0.006 0.29
34 SLC22A4 hCV3170459 rs1050152 5 131,752,536 0.003 0.003 2.6·10-06 1.5·10-06 0.02
35 AQP9 hCV11669234 rs1867380 15 56,192,337 0.003 0.01 0.02 0.03 0.67
36 DHX34 hCV11507064 rs12984558 19 52,548,176 0.003 0.010 0.82 0.87 0.36
37 hCG26636 hCV2942610 rs1864147 16 64,719,751 0.003 0.01 0.06 0.16 0.29
38 DP58 hCV622249 rs32857 5 79,939,445 0.003 0.0008 0.93 0.36 0.15
39 PLSCR4 hCV9539784 rs1061409 3 147,238,670 0.003 0.01 0.93 0.99 0.29
40 hCG2038517 hCV1734658 rs3810071 18 2,508,697 0.003 0.006 0.26 0.24 0.02
41 ST5 hCV1506057 rs3812762 11 8,715,949 0.003 0.008 0.71 0.54 0.87
42 OAS2 hCV8920052 rs15895 12 111,860,241 0.004 0.01 0.60 0.74 0.91
43 FLJ46906 hCV8275411 rs1129180 6 138,998,702 0.004 0.006 0.72 0.91 0.51
44 C14orf125 hCV8601135 rs7157977 14 29,848,248 0.004 0.02 0.29 0.35 0.96
45 AKAP10 hCV926535 rs203462 17 19,974,570 0.004 0.004 0.55 0.79 0.01
Table 3-1 Lead SNPs of cSNP screening. Top 72 CD-associated SNPs, ranked with respect to the p-value obtained in an allele-based
case-control comparison (CCA) in panel A. Also included are the p-values for the genotype-based case-control comparison (CCG) and the
TDT. Nucleotide positions refer to NCBI build 34. The 17 markers with p < 0.05 in either the case-control or the TDT analysis of replication
panel B are highlighted in blue. SNPs with a significant result in both panel B tests are marked by grey shading. In addition to rs2241880,
only SNPs rs1050152 (Leu503Phe) in the OCTN1 gene, reported earlier (Peltekova et al., 2004) and the known CARD15 SNP
rs2066845 ("SNP12", Hugot et al., 2001) yielded consistent replication.
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SNP rs2241880, which replicated besides known CARD15 and 5q31 polymorphisms, is locat-
ed in the ATG16 autophagy related 16-like 1 (S. cerevisiae) gene. In the combined analysis of
all German individuals (panels A and B), the odds ratio was 1.45 (95% CI: 1.21 – 1.74) for het-
erozygous carriership of “G” and 1.77 (95% CI: 1.43 – 2.18) for homozygosity. The combined
p-values for the German samples were p = 4 x 10-08 for the allele-based and p = 2 x 10-07 for
the genotype-based test (see also 3.2.1 on page 89).
Genotyping results obtained with the SNPlex™ system were confirmed using a TaqMan® as-
say (C___9095577_20, 99.8% genotype concordance), thus excluding artefacts due to techno-
logical problems.
A summary of all results of the genome-wide scan is given in file cSNP_Results.xls on the
DVD.
46 CACNA1E hCV1432822 rs704326 1 178,999,038 0.004 0.01 0.32 0.61 0.17
47 KNSL7 hCV25924111 rs3804583 3 44,845,239 0.004 0.01 0.22 0.38 1.00
48 THRAP3 hCV25749777 rs6425977 1 36,180,095 0.004 0.01 0.36 0.47 0.01
49 SLC1A4 hCV2681351 rs759458 2 65,219,899 0.004 0.02 0.81 0.82 0.25
50 U15 hCV3215915 rs4774310 15 56,701,220 0.005 0.02 0.23 0.45 0.33
51 MYO10 hCV3132500 rs27431 5 16,723,356 0.005 0.01 0.70 0.83 0.55
52 IFI44L hCV11873694 rs3820093 1 78,518,119 0.005 0.007 0.35 0.63 0.92
53 CAPSL hCV8811801 rs1445898 5 35,956,030 0.005 0.01 0.35 0.53 0.75
54 FLJ31846 hCV25959811 rs3764147 13 42,255,925 0.005 0.009 0.05 0.11 0.77
55 hCG1794790 hCV37420 rs13092702 3 147,440,204 0.005 0.02 0.28 0.43 0.79
56 FLJ46320 hCV25973127 rs3829486 16 86,881,788 0.006 0.02 0.05 0.14 0.02
57 NUDCD1 hCV15883329 rs2980618 8 110,258,581 0.006 0.02 0.29 0.56 0.33
58 UBAP2 hCV8778477 rs1785506 9 34,007,106 0.006 0.02 0.10 0.21 0.96
59 A2BP1 hCV2973884 rs2191423 16 6,387,642 0.006 0.01 0.06 0.16 0.03
60 LRRK2 hCV3215842 rs3761863 12 39,044,919 0.007 0.02 0.60 0.80 0.06
61 MYO5A hCV25592080 – 15 50,351,450 0.007 0.006 0.14 0.27 0.04
62 hCG1994124 hCV2441812 rs2157650 8 17,715,645 0.007 0.0004 0.11 0.24 0.13
63 hCG2040272 hCV25988773 rs10427252 2 215,765,119 0.007 0.02 0.09 0.14 0.90
64 BCAR1 hCV25764619 – 16 75,048,530 0.008 0.02 0.04 0.04 0.74
65 C14orf8 hCV2434490 rs9624 14 19,490,249 0.008 0.010 0.35 0.64 0.21
66 U10 hCV12017135 rs1826619 10 31,005,500 0.008 0.02 0.21 0.41 0.37
67 FLJ23577 hCV25742805 rs7710284 5 35,738,276 0.008 0.03 0.80 0.53 0.42
68 NALP8 hCV8110157 rs306481 19 61,179,415 0.008 0.04 0.97 0.93 0.96
69 U1 hCV27080230 rs4534436 1 119,108,418 0.008 0.02 0.21 0.16 0.31
70 IGHMBP2 hCV25474530 rs17612126 11 68,481,034 0.009 0.01 0.98 0.92 0.27
71 USP16 hCV2870492 rs2274802 21 29,330,540 0.009 0.04 0.52 0.18 0.11
72 CLEC2D hCV25992569 rs3764022 12 9,724,791 0.009 0.007 0.82 0.80 0.14
Screening (panel A) Replication (panel B)
# gene celera ID dbSNP ID chr. position pCCA pCCG pCCA pCCG pTDT
Table 3-1 Lead SNPs of cSNP screening. Top 72 CD-associated SNPs, ranked with respect to the p-value obtained in an allele-based
case-control comparison (CCA) in panel A. Also included are the p-values for the genotype-based case-control comparison (CCG) and the
TDT. Nucleotide positions refer to NCBI build 34. The 17 markers with p < 0.05 in either the case-control or the TDT analysis of replication
panel B are highlighted in blue. SNPs with a significant result in both panel B tests are marked by grey shading. In addition to rs2241880,
only SNPs rs1050152 (Leu503Phe) in the OCTN1 gene, reported earlier (Peltekova et al., 2004) and the known CARD15 SNP
rs2066845 ("SNP12", Hugot et al., 2001) yielded consistent replication.
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116,161 SNPs were successfully genotyped in 399 controls and 393 cases (Panel C) using the
Affymetrix 100k GeneChip® as described in section 2.8.5 on page 49. SNPs of which the posi-
tion was annotated as “unknown” and SNPs that were located on the Y-chromosome, were
not included in the analysis. Thus, a subset of 115,571 SNPs was analyzed, of which 92,631
(80.2%) were of good quality, i.e. they were non-monomorphic, had a call rate above 90%,
and a HWE p-value greater than 0.01. Since Affymetrix did include repetitive regions in their
chip design, much more SNPs were out of HWE than expected. According to Affymetrix, this
inclusion was done for the following reasons:
❏ to provide users with an uniform genomic coverage
❏ SNPs in repeats might be used for the analysis of copy number variations (CNVs)
❏ technical restrictions of the method
With respect to the p-value obtained in a case-control comparison for genotypes (CCG), the
top 150 SNPs were chosen for replication in panel D. The same SNPlex™ plates were used for
follow-up as for the cSNP experiment (3.1.1 on page 80). Hit SNPs were defined as being
“replicated”, if the p-value was lower than 0.05 in the family-based test (TDT) and in the case-
control comparison. A total of ten SNPs matched this criteria, from which five are located in
yet unknown regions. In addition to rs2631372, rs272867 and rs2631370, which all localize to
the 5q31 haploype, reported earlier by Peltekova et al. (2004), CARD15 (Hugot et al., 2001)
yielded consistent replication (SNPs rs2076756 and rs10521209). SNP rs2076756, which had
the lowest p-value (<10-12) in this GWS, is located between exon 8 and 9 of CARD15, the latter
exons coding for the LRR domain. Since both variants are in close proximity with the three
important disease-causing variants (SNP 8, 12, and 13), the results of the GWS are likely to be
consistent.
dbSNP ID Position [bp] Distance to next SNP [kb] Comment
rs2066844 49,303,427 9,783 SNP 8, Arg702Trp
rs10521209 49,313,210 831 Hit #120
rs2066845 49,314,041 341 SNP 12, Gly908Arg
rs2076756 49,314,382 6,898 Hit #1
rs2066847 49,321,280 – SNP 13, Leu1007fs
Table 3-2 Distance between known mutations and typed SNPs in the CARD15 gene region. Results are based on HapMap data and
positions refer to NCBI build 35.
Chapter 3: Results 84Screening (panel C) Replication (panel D)
# locus dbSNP ID chr. position pCCA pCCG pCCA pCCG pTDT
1 CARD15, intron rs2076756 16 50,534,914 1.9·10-13 2.0·10-12 - - -
2 BCL11B, downstream rs200354 14 97,365,362 0.003 2.2·10-06 0.59 0.39 1.00
3 CARD8, intron rs2009530 19 53,411,500 0.002 4.9·10-06 0.73 0.83 0.52
4 FLJ40089, intron rs10507063 12 94,769,766 0.08 1.2·10-05 0.13 0.06 0.70
5 MRPS22, intron rs10513059 3 140,313,327 2.1·10-06 1.6·10-05 0.15 0.14 0.93
6 ZNF452, upstream rs10484543 6 28,899,189 9.4·10-06 3.6·10-05 0.16 0.11 0.07
7 BC036877, intron rs6659639 1 14,802,853 0.002 5.2·10-05 0.68 0.86 0.05
8 ATRNL1, intron rs1590734 10 117,023,506 0.003 5.6·10-05 0.30 0.11 0.84
9 FBXL13, intron rs10487283 7 102,031,744 0.16 8.6·10-05 0.37 0.09 0.42
10 HPSE2, intron rs483952 10 100,048,586 0.005 8.7·10-05 0.59 0.71 0.79
11 C18orf1, intron rs1559865 18 13,493,887 0.001 0.0001 0.05 0.15 0.30
12 PRPF18, intron rs2478126 10 13,663,744 2.7·10-05 0.0001 0.30 0.29 0.83
13 BC050321, intron rs10517460 4 37,864,263 0.01 0.0001 0.60 0.85 0.26
14 RAD23B, upstream rs4978664 9 105,199,766 1.7·10-05 0.0001 0.57 0.33 0.66
15
SLC7A11,
downstream
rs7674505 4 134,995,809 2.6·10-05 0.0001 0.56 0.38 0.13
16
SLC7A11,
downstream
rs2724261 4 135,030,348 4.0·10-05 0.0002 0.41 0.15 0.06
17
CDO1,
downstream
rs249721 5 115,098,473 0.006 0.0003 0.07 0.20 0.19
18 DZIP1, intron rs7324781 13 93,932,754 4.4·10-05 0.0003 0.46 0.75 0.25
19 NLGN1, downstream rs10490876 3 176,472,702 0.0004 0.0003 0.17 0.32 0.39
20 LTF, upstream rs867619 3 46,498,342 0.04 0.0003 0.27 0.21 0.16
21 BCL9, intron rs10494251 1 144,530,971 9.8·10-05 0.0004 0.32 0.23 0.59
22 BC036403, intron rs6074780 20 14,701,879 7.1·10-05 0.0004 0.05 0.08 0.64
23 QPCT, intron rs7582749 2 37,573,872 0.17 0.0004 0.91 0.97 0.80
24 ZFP37, downstream rs747066 9 111,078,184 0.0002 0.0004 0.97 0.08 0.86
25 SYT5, downstream rs3859540 19 60,373,858 6.2·10-05 0.0004 0.04 0.12 0.27
26
KHDRBS3,
downstream
rs10505673 8 138,349,577 0.0007 0.0004 0.98 0.69 0.90
27 GJA5, upstream rs1342705 1 144,761,333 0.0003 0.0004 0.12 0.28 0.73
28 MYST4, intron rs7092435 10 76,014,914 0.0002 0.0004 0.79 0.22 0.56
29 KIAA1912, intron rs10490395 2 56,422,800 0.004 0.0005 0.70 0.63 0.76
30 GPC6, intron rs1333261 13 92,604,104 0.0002 0.0005 0.22 0.46 0.11
31 HS3ST4, downstream rs10492804 16 26,420,874 0.002 0.0006 0.72 0.43 0.67
32
BC035912,
downstream
rs1488927 7 153,794,409 0.002 0.0006 0.86 0.68 0.50
33
NM_178506,
upstream
rs10514013 18 67,303,699 0.0008 0.0006 0.75 0.72 0.82
34 CTSO, upstream rs10517634 4 157,722,979 0.0006 0.0007 0.44 0.72 0.21
35 PXMP3, upstream rs723510 8 78,550,027 0.0006 0.0007 0.04 0.09 0.07
36 SULF2, upstream rs6122682 20 47,749,305 0.29 0.0007 0.69 0.66 0.80
37 BMPER, downstream rs1419790 7 34,517,746 0.54 0.0007 0.71 0.49 0.25
38 CHORDC1, upstream rs10501720 11 89,950,836 0.0002 0.0008 0.82 0.69 0.43
39 GRM5, intron rs549700 11 88,326,335 0.0009 0.0008 0.82 0.97 0.73
40
MAP3K7,
downstream
rs4707614 6 91,077,734 0.16 0.0008 0.96 1.00 0.55
41 BCL9, downstream rs10494248 1 144,615,337 0.0009 0.0008 0.67 0.65 0.34
Table 3-3 Lead SNPs of 100k genome-wide scan (GWS). The top 150 SNPs are ranked according to the p-value obtained in genotype-
based case-control comparison (CCG) in panel C. Also included are the p-values for the allele-based case-control comparison. Nucleotide
positions refer to NCBI build 34. Markers with p < 0.05 in either the case-control or the TDT analysis in replication panel D are highlighted
in blue. SNPs with a significant result in both panel D tests are additionally marked by grey shading. The five SNPs from the two known
disease loci CARD15 and 5q31 are highlighted in red.
Chapter 3: Results 8542 API5, upstream rs10501292 11 42,960,696 0.01 0.0008 0.67 0.52 0.01
43 GJA5, upstream rs10494257 1 144,761,646 0.0005 0.0008 0.16 0.35 0.84
44 CRYBA4, downstream rs569626 22 26,071,824 0.002 0.0008 0.13 0.32 0.33
45
SLC7A11,
downstream
rs10518641 4 134,981,546 0.0003 0.0008 0.38 0.38 0.06
46 JAG1, upstream rs973542 20 10,687,559 0.0003 0.0008 0.57 0.21 0.61
47 C10orf97, intron rs10508494 10 15,825,784 0.004 0.0008 0.28 0.33 0.70
48 JAG1, upstream rs6077888 20 10,687,989 0.0003 0.0008 0.57 0.21 0.61
49 GNG2, intron rs10498440 14 50,403,611 0.0002 0.0008 0.12 0.19 0.50
50 RAB6B, intron rs7644124 3 134,896,774 0.0003 0.0008 0.28 0.18 0.02
51 PPP2R2B, intron rs3096085 5 146,074,928 0.001 0.0008 0.44 0.75 0.64
52 NDN, upstream rs10519449 15 21,597,566 0.22 0.0009 0.79 0.64 0.38
53
LOC339047,
downstream
rs1994893 16 17,879,139 0.007 0.0009 0.62 0.23 0.33
54 SLC1A2, intron rs3847621 11 35,328,744 0.77 0.0009 0.60 0.75 0.82
55 DSCAM, intron rs2837758 21 40,939,405 0.06 0.0009 0.61 0.83 0.55
56 KIAA1463, upstream rs10506296 12 49,374,124 0.001 0.001 0.10 0.18 0.85
57 LOC151963, intron rs2367129 3 193,916,220 0.0002 0.001 0.96 0.91 0.76
58
FLJ11175,
downstream
rs10520778 15 93,657,496 0.003 0.001 0.63 0.18 0.34
59 CYLC2, upstream rs4743487 9 99,916,141 0.0002 0.001 0.01 0.05 0.80
60 C21orf7, downstream rs2832238 21 29,469,808 0.0008 0.001 0.83 0.63 1.00
61 NR3C2, upstream rs853727 4 150,412,639 0.0002 0.001 0.68 0.85 0.58
62
NM_030903,
downstream
rs9257453 6 29,076,919 0.0003 0.001 0.38 0.29 0.03
63 POU3F1, upstream rs10493084 1 38,577,447 0.0001 0.001 0.90 0.38 0.88
64
SLC7A11,
downstream
rs2660693 4 135,078,432 0.0002 0.001 0.87 0.98 0.48
65 NEBL, intron rs10508629 10 20,881,787 0.001 0.001 0.23 0.34 0.04
66
DKFZP564O0823, 
downstream
rs7681167 4 76,619,617 0.0003 0.001 0.89 0.72 0.35
67
PDCD6IP,
downstream
rs7428001 3 35,500,582 0.0004 0.001 0.84 0.97 0.01
68 CLUL1, intron rs10502288 18 621,435 0.0003 0.001 0.69 0.66 0.08
69 MAML2, intron rs10501843 11 95,528,273 0.0002 0.001 0.48 0.55 0.73
70
SLC22A4,
downstream
rs2631372 5 131,779,794 0.26 0.001 – – –
71 FGL1, downstream rs396462 8 17,680,469 0.0007 0.001 0.46 0.46 0.03
72 ITGB6, upstream rs2925757 2 161,303,713 0.0002 0.001 0.004 0.02 1.00
73 CYLC2, upstream rs1930551 9 100,720,179 0.002 0.001 0.36 0.49 0.50
74 SNX7, upstream rs770918 1 98,391,860 0.0009 0.001 0.74 0.54 0.44
75 MYST4, intron rs951308 10 75,962,082 0.0007 0.002 0.62 0.56 0.85
76 BC036403, intron rs10485515 20 14,844,853 0.0008 0.002 0.33 0.53 0.85
77 CSMD1, intron rs10503282 8 4,626,114 0.0003 0.002 0.98 0.86 0.84
78 PAK1, upstream rs1793483 11 76,701,775 0.0005 0.002 0.41 0.71 0.87
79 SCG2, downstream rs9283536 2 224,133,045 0.0007 0.002 0.24 0.42 0.005
80 B3GALT2, upstream rs1160521 1 191,026,538 0.003 0.002 0.65 0.57 0.21
81 SLCO1B3, intron rs3764007 12 20,905,430 0.0005 0.002 0.73 0.91 0.34
82 OR5V1, downstream rs10484545 6 29,342,503 0.0005 0.002 0.0003 2.8·10-07 0.16
Screening (panel C) Replication (panel D)
# locus dbSNP ID chr. position pCCA pCCG pCCA pCCG pTDT
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Chapter 3: Results 8683 LOC253827, intron rs10506523 12 64,122,774 0.002 0.002 0.36 0.36 0.65
84 MAP3K7, upstream rs1546210 6 92,572,189 0.0004 0.002 0.86 0.58 0.19
85 FHIT, downstream rs812965 3 59,693,634 0.0005 0.002 0.30 0.59 0.30
86 PTGER4, upstream rs1992662 5 40,439,353 0.0005 0.002 7.6·10-05 0.0002 0.001
87 TSN, downstream rs10496586 2 123,281,730 0.0004 0.002 0.27 0.52 0.32
88 SPOCK, intron rs1859346 5 136,523,790 0.0007 0.002 0.55 0.69 0.25
89
SLC22A4,
downstream
rs272867 5 131,757,273 0.15 0.002 – – –
90 CD36, intron rs3211830 7 79,891,769 0.0003 0.002 0.34 0.58 0.59
91 C1D, downstream rs2902041 2 68,089,432 0.002 0.002 0.19 0.40 0.20
92 CDH10, upstream rs2928266 5 25,827,114 0.0003 0.002 0.23 0.37 0.39
93 NELL1, intron rs1793004 11 20,663,238 0.0005 0.002 0.03 0.06 0.03
94 SLC14A2, upstream rs10502861 18 41,052,135 0.0005 0.002 0.32 0.22 0.86
95 PTGER4, upstream rs1992660 5 40,460,568 0.0005 0.002 4.5·10-05 0.0002 0.0005
96 BC030984, intron rs10483112 22 21,051,522 0.0004 0.002 0.03 0.02 0.37
97 LPHN2, intron rs3790889 1 81,835,193 0.43 0.002 0.86 0.99 0.74
98 PTGER4, upstream rs1553575 5 40,548,433 0.0005 0.002 1.7·10-06 6.4·10-06 0.03
99 TMEM16A, intron rs3781661 11 69,725,941 0.002 0.002 0.26 0.53 0.21
100 AK091523, intron rs4327488 4 103,117,607 0.0005 0.002 0.09 0.04 0.93
101
NM_018461,
upstream
rs3922590 10 132,706,022 0.0005 0.002 0.55 0.75 0.19
102 BCHE, upstream rs1440657 3 167,262,663 0.003 0.002 0.88 0.90 0.09
103 GRM8, downstream rs6947579 7 125,087,495 0.0005 0.002 0.006 0.01 1.00
104
SLC7A11,
downstream
rs1493517 4 134,930,683 0.0005 0.002 0.23 0.48 0.11
105 GLI3, downstream rs10486725 7 41,613,489 0.0007 0.002 0.72 0.26 0.93
106 BCL9, downstream rs1953977 1 144,615,549 0.003 0.002 0.91 0.91 0.34
107 AK095544, upstream rs10489924 1 98,921,897 0.0007 0.002 0.65 0.57 0.03
108 PPP3R2, intron rs4743484 9 99,859,318 0.0008 0.003 0.002 0.007 0.90
109 UBAP2, intron rs1785512 9 34,016,538 0.002 0.003 0.003 0.004 1.00
110 CHORDC1, upstream rs562085 11 89,840,073 0.006 0.003 0.59 0.05 0.23
111 PDE8A, intron rs289386 15 83,311,157 0.0006 0.003 0.87 0.61 0.91
112 PDE1C, downstream rs7795363 7 31,529,121 0.0007 0.003 0.34 0.03 0.71
113 NELL1, intron rs951199 11 20,665,084 0.0008 0.003 0.03 0.06 0.27
114
SLC7A11,
downstream
rs1559781 4 138,684,038 0.0004 0.003 0.65 0.90 0.65
115
ADAMTS20,
downstream
rs2134066 12 42,000,804 0.0008 0.003 0.24 0.30 0.07
116 KCND2, upstream rs10500069 7 118,069,959 0.0008 0.003 0.54 0.81 0.90
117
LOC137886,
upstream
rs10504252 8 59,267,687 0.0007 0.003 0.85 0.97 0.07
118 PAH, downstream rs1463446 12 101,488,216 0.0005 0.003 0.32 0.60 0.74
119 NPAS3, intron rs8005131 14 31,581,144 0.0004 0.003 0.44 0.35 0.57
120 CARD15, intron rs10521209 16 50,533,742 0.001 0.003 – – –
121 GRIA1, intron rs778999 5 152,936,197 0.001 0.003 0.02 0.04 0.14
122 TEK, intron rs1413829 9 27,191,968 0.0006 0.003 0.27 0.45 0.43
123 IMMP2L, intron rs1528039 7 110,003,303 0.0009 0.003 0.75 0.12 0.30
124 SIAT8B, upstream rs10520704 15 90,450,368 0.0008 0.003 0.02 0.04 0.08
125 CHI3L2, downstream rs4323713 1 111,121,947 0.0005 0.003 0.60 0.87 0.43
Screening (panel C) Replication (panel D)
# locus dbSNP ID chr. position pCCA pCCG pCCA pCCG pTDT
Table 3-3 Lead SNPs of 100k genome-wide scan (GWS). The top 150 SNPs are ranked according to the p-value obtained in genotype-
based case-control comparison (CCG) in panel C. Also included are the p-values for the allele-based case-control comparison. Nucleotide
positions refer to NCBI build 34. Markers with p < 0.05 in either the case-control or the TDT analysis in replication panel D are highlighted
in blue. SNPs with a significant result in both panel D tests are additionally marked by grey shading. The five SNPs from the two known
disease loci CARD15 and 5q31 are highlighted in red.
Chapter 3: Results 87The five replicated SNPs, that are not restricted to either the CARD15 or the 5q31 region, are
located in NELL1, and in the gene-free regions on chromosome 5p13.1 and 7q31.1. The latter
was not subjected to further experiments due to borderline replication (p = 0.04). The signal
at the NELL1 locus is supported by 2 SNPs (#93 and #113) among the top 150, from which one
is only significant in the case-control analysis (#113, rs951199) and not in the TDT. With three
replicated SNPs (#86, #95, #98) and one semi-replicated SNP (#150, only significant in case-
control sample) among the top 150, the 5p13.1 region is standing out.
A summary of all results is given in file 100k_Results.xls on the DVD.
126 FLJ11588, intron rs3118223 1 48,833,718 0.0008 0.003 0.03 0.08 0.47
127
AY320401,
downstream
rs6673693 1 206,802,809 0.0006 0.003 0.39 0.42 0.73
128 NOVA1, downstream rs9323605 14 23,606,664 0.0008 0.003 0.21 0.38 0.62
129 A2BP1, upstream rs7200548 16 5,890,864 0.001 0.003 0.78 0.96 0.30
130 CYLC2, upstream rs10512301 9 100,701,999 0.001 0.003 0.46 0.60 1.00
131 MIPEP, intron rs1536299 13 22,116,963 0.0006 0.004 0.06 0.13 0.15
132 ITGB6, intron rs10497212 2 161,167,244 0.0008 0.004 0.41 0.46 0.64
133 GRIA1, intron rs6580022 5 152,962,446 0.008 0.004 0.01 0.02 0.31
134 TUSC3, upstream rs10503536 8 15,023,600 0.001 0.004 0.47 0.72 0.90
135 LARGE, upstream rs130461 22 32,734,453 0.001 0.004 0.76 0.94 0.23
136 DGKB, upstream rs10255000 7 14,785,866 0.0009 0.004 0.02 0.09 0.32
137 SYT1, upstream rs3911786 12 77,767,173 0.0005 0.004 0.65 0.62 0.06
138
SLC22A4,
downstream
rs2631370 5 131,779,992 0.14 0.004 – – –
139 DNAH11, intron rs6461599 7 21,544,775 0.0007 0.004 0.90 0.67 0.02
140 OXTR, upstream rs2241330 3 8,832,963 0.001 0.004 0.12 0.17 0.79
141 VRK1, downstream rs8011773 14 95,847,773 0.0005 0.004 0.06 0.08 0.37
142 KUB3, downstream rs951901 12 56,684,632 0.001 0.004 0.41 0.46 0.17
143
TMEM16F,
downstream
rs10492248 12 44,329,880 0.001 0.004 0.11 0.22 0.23
144
BC036480,
downstream
rs977669 5 87,946,906 0.004 0.004 0.28 0.28 0.78
145 RNF111, intron rs1446240 15 57,012,547 0.001 0.004 0.12 0.31 0.51
146
AY134745,
downstream
rs9304344 18 43,010,652 0.001 0.004 0.98 0.05 0.74
147 PDE4D, intron rs1027747 5 59,108,797 0.002 0.004 0.67 0.85 0.45
148 PPP1R3A, upstream rs10500037 7 113,262,290 0.0009 0.005 0.01 0.04 0.04
149 NEBL, downstream rs10508621 10 20,650,445 0.0008 0.005 0.91 0.99 0.03
150 PTGER4, upstream rs7725523 5 40,417,724 0.0007 0.005 0.14 0.32 0.01
Screening (panel C) Replication (panel D)
# locus dbSNP ID chr. position pCCA pCCG pCCA pCCG pTDT
Table 3-3 Lead SNPs of 100k genome-wide scan (GWS). The top 150 SNPs are ranked according to the p-value obtained in genotype-
based case-control comparison (CCG) in panel C. Also included are the p-values for the allele-based case-control comparison. Nucleotide
positions refer to NCBI build 34. Markers with p < 0.05 in either the case-control or the TDT analysis in replication panel D are highlighted
in blue. SNPs with a significant result in both panel D tests are additionally marked by grey shading. The five SNPs from the two known
disease loci CARD15 and 5q31 are highlighted in red.
Chapter 3: Results 883.1.2.1 Randomization of the 100k dataset
An estimate of the rate of false-positive association findings was obtained from GENOMIZER
by generating replicates of the entire study under the null hypothesis of no association. To
this end, the affection status of cases and controls was randomly shuffled over the entire
study population. The same analyses were performed as for the non-randomized dataset and
results compared.
Because neither the position, nor the penetrance of the potential new disease variants un-
derlying association signals is known, the single-point analyses results for CCA and CCG
were linked with a logical "OR". A given marker was considered a potential "lead" marker if a
nominal p-value < 0.001 was reached in either analysis. If multiple such "signals" were iden-
tified adjacent to each other, markers were merged into "associated regions" if the distance
was below 50 kilobases.
Using these criteria, a total of 272 markers, corresponding to 245 associated regions were
identified at the p < 0.001 level. Analysis of the randomized dataset at p < 0.001 yielded 112
markers corresponding to 94 regions, suggesting the presence of "real" disease driven asso-
ciation signals. This means in other words that approximately 59% of the hits should corre-
spond to "real" hits.
Chapter 3: Results 893.2 Replication of leads
SNPs from the GWSs that replicated in two independent German sample collections (trios
and case-controls), were tested in other ethnical panels.
3.2.1 Replication of the ATG16L1 nsSNP in a UK panel
The association of rs2242880 was replicated in a UK-derived CD sample (table 2-1, page 26,
panel F: ncases = 509, ncontrols = 656), using an independent TaqMan
® assay. The British data
yielded p = 0.0004 in the allele-based comparison (OR: 1.35; 95% CI: 1.15 – 1.59) and
p = 0.0001 in the genotype-based test (OR for homozygous carriership of “G”: 1.71; 95%
CI: 1.23 – 2.39). This finding strongly supports a consistent association between rs2241880
and CD. Table 3-4 summarizes the results for all panels.
The analyses point out that CD patients have a 7% higher frequency of the risk allele “G”.
There is even a 9% increase of the risk genotype “GG” in the patients panel. Furthermore, no
significant increase was seen in the IBD subphenotype UC.
Panel MAFco MAFca ORHOM pCCA pCCG
A - German screening panel 0.48 0.40 1.92 [95% CI (1.33 – 2.79)] 0.0004 0.002
B - German replication panel 0.47 0.40 1.74 [95% CI (1.34 – 2.25)] 0.00001 0.00007
A + B Combined German 0.47 0.40 1.77 [95% CI (1.43 – 2.18)] 4 x 10-08 2 x 10-07
E - German UC panel 0.47 0.46 1.11 [95% CI (0.85 – 1.44)] 0.40 0.59
F - UK replication panel 0.48 0.41 1.71 [95% CI (1.23 – 2.39)] 0.0004 0.0002
Table 3-4 Summary of association results for rs2241880. MAF is the minor allele frequency (A allele) in controls (co) or cases (ca). It is
apparent that CD patients have a 7% higher frequency of the mutant “G” allele while the nsSNP is not associated with UC.
Panel fAAco fAAca fAGco fAGca fGGco fGGca
A - German screening panel 0.22 0.15 0.52 0.49 0.26 0.36
B - German replication panel 0.22 0.16 0.51 0.48 0.27 0.36
A + B combined German 0.22 0.16 0.51 0.48 0.27 0.36
E - German UC panel 0.22 0.22 0.51 0.49 0.27 0.29
F - UK replication panel 0.22 0.19 0.53 0.44 0.25 0.37
Table 3-5 Summary of genotype frequencies for rs2241880. CD patients have a 9% increased frequency of the risk genotype “GG”,
while there is no difference in the UC panel.
Chapter 3: Results 903.2.2 Replication of the NELL1 and 5p13.1 lead SNPs in independent panels
In analogy to ATG16L1, the replicated SNPs of the Affymetrix scan were typed in the same UK
CD sample (panel F). To this end, two SNPs of the 5p13.1 and one from the NELL1 region, all
replicating in the case-control and family-based panel, were selected for genotyping. In ad-
dition, the NELL1 SNP rs951199 was genotyped, which was only significant in the case-con-
trol panel. TaqMan® was used as an independent technology (assays rs951199,
C____392093_10, C__11472026_10, C__11472042_10) and the results are shown in the follow-
ing table:
While SNPs rs1992660 and rs1992662 of the 5p13.1 region were replicated in the British pop-
ulation, SNPs rs951199 and rs1793004 failed to show a significant association. Allele and gen-
otype frequencies of the four variants are listed in the following table:
Although the single-point statistics for rs1793004 gave no significant results, there are 3.0%
more homozygous cases for the common allele. The same effect is seen in the German case
sample (panel D), where 4.6% more homozygous cases exist for rs1793004.
SNP rs1793004, located in the NELL1 gene, was also replicated in a French-Canadian trio
sample. The TDT test gave a significant p-value of p = 0.02. More detailed results are given in
table 9-4, page 185.
Region/gene # in GWS dbSNP ID Celera ID MAF HWE CD pCCA CD pCCG
NELL1 113 rs951199 hCV8886311 0.26 0.32 0.62 0.63
NELL1 93 rs1793004 hCV392093 0.26 0.51 0.35 0.63
5p13.1 95 rs1992660 hCV11472026 0.40 0.55 0.04 0.09
5p13.1 86 rs1992662 hCV11472042 0.30 0.56 0.001 0.0004
Table 3-6 Replication of NELL1 and 5p13.1 lead SNPs in a UK CD panel. Minor allele frequencies (MAF) and Hardy-Weinberg p-val-
ues (HWE) plus single-point p-values for an allelic (CCA) and a genotypic (CCG) test are shown.
controls cases controls cases
dbSNP ID f11 f12 f22 f11 f12 f22 f1 f2 f1 f2
rs951199 0.541 0.400 0.059 0.566 0.370 0.064 0.741 0.259 0.751 0.249
rs1793004 0.542 0.396 0.062 0.572 0.374 0.055 0.740 0.260 0.759 0.241
rs1992660 0.368 0.467 0.165 0.415 0.466 0.119 0.601 0.399 0.648 0.352
rs1992662 0.489 0.413 0.098 0.437 0.377 0.185 0.696 0.304 0.626 0.374
Table 3-7 Genotype and allele frequencies of the NELL1 and 5p13.1 lead SNPs. Frequencies are listed for genotypes and alleles in
both controls and cases. Significant differences >5% are highlighted in blue.
Chapter 3: Results 913.3 Mutation detection and fine mapping of candidate genes and regions
Promoters and all exons plus flanking intronic sequences of NELL1 and ATG16L1 were rese-
quenced in 47 CD patients (plate MD6) as described in section 2.7 on page 34. This was done
to verify the previously found mutations and to find new ones, especially SNPs with a puta-
tive functional effect. Since the number of sequenced individuals allowed only the detection
of rather common mutations, private mutations, which are usually found only in a single
family or a small population, were not accessible by this approach,
Power calculations (according to Glatt et al., 2001)
The probability of detecting a variant with allele frequency f in a sample of n individuals (2n
chromosomes) was calculated as 1-(1-f)2n (for seeing it once) or 1-(1-f)2n-2nf(1-f)2n-1 (for
seeing it at least twice). Therefore, the probability to detect a variant with f = 0.05 and n = 47
was 99% to detect it once and 95% to detect it twice in our experiment. This high power is not
achieved for rare SNPs, e.g. for f = 0.01 the probability is only 1%.
3.3.1 ATG16L1 fine mapping
For a more comprehensive assessment of the CD risk conferred by changes in the ATG16L1
gene, a systematic search for mutations was carried out by resequencing all exons, splice
sites and the promoter regions of 47 CD patients and by fine mapping the gene region. 
3.3.1.1 Resequencing of ATG16L1
Sequences were retrieved from the UCSC Golden Path (contig NT_005120) and used for
primer design as described in section 2.7.1 on page 34. ATG16L1 comprises 18 exons which
give rise to a coding sequence of 1821 base pair length (607 aa).
Sequencing was successful for all exons and the promoter of ATG16L1. Twenty-two SNPs
were found in the analysis of the traces, from which 12 were yet unknown variants. Detailed
results are listed in table 3-8, page 92. The common variant rs2241880 was detected as well in
several traces (37% GG, 43% GA, 20% AA), thus verifying the existence of this biallelic poly-
morphism. Besides rs2241880 in exon 9, no other non-synonymous SNP was found in
ATG16L1. Only the synonymous coding SNP rs13011156 was verified in exon 3.
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position 
(build 35)
SNP type sequence
1 ATG16L1_01 233,941,476 Promoter
AGAAACAAGAAAGAAACACGAAAAGCAGC
TTAACAATCAAAGACAGGTTTATTTTG-
GAGAATAAACCTGAGAGGGGCTTCT-
TGTCGATTTTGGTCAGGAG
[C/T]
GTTTTCTCTTACACACTAAGGGTGTTTAA
GGGTTTACGAAGCGGTGAGCTTATTG-
CAGGTTCGTAATGTTTCTGTATGAGG-
GAAAGTTTATTGCAGGGTT
2 ATG16L1_02 233,941,591 Promoter
ACTAAGGGTGTTTAAGGGTTTACGAAGCG
GTGAGCTTATTGCAGGTTCGTAAT-
GTTTCTGTATGAGGGAAAGTTTATTG-
CAGGGTTGGAAAGTCTCTGGC
[C/T]
GGAGGGGAGGCTATCTCTGGGTTGGCAT-
GTTTCTGGTTGGAAGTGGGTTTATCTTAG
GGTTGGAATGTTTCTGGTTATGCTGA-
CATTAGCCATTAGGCTG
3 rs1816753 233,941,609 Promoter –
4 rs12476635 233,941,685 Promoter –
5 ATG16L1_03 233,941,758 Promoter
GTTTCTGGTTATGCTGACATTAGCCATT-
AGGCTGATGTTTTTGGGTTGGATTTAGGC
AGTTTCTTAATCAAGGGGAACTTAAAATG-
GTGGCAGTTGTCCA
[A/T]
GATGGCAATGCTCCTGCTGTCAGGGTAG-
GCCTTGGGAAGACACCAGGTGTCTTTGTA
AACTTAGGTTTCCCCTGTACCAAGCA-
CAGTGCTGACTGCATTA
6 ATG16L1_04 233,946,704 intronic
TCTTGCAGGTGATTCTGTAGGTTACTGTG
GCTGAGGAATGTATGTTCCTGTATTG-
CATCCTTCAATACATGACAAGGTAGGTAC-
CTAGCAAGTGTACATA
[C/T]
GTTGTAATAAATAACTTAGTTTCTGACTTT
TTTATTTTAATAGATAACAAATTGCTG-
GAAAAGTCAGATCTTCATTCAGTGTTG-
GCCCAGAAACTACAGG
7 rs13011156 233,953,812 synonymous –
8 rs12994997 233,955,503 intronic –
9 rs2289476 233,963,556 intronic –
10 rs2289475 233,963,593 intronic –
11 rs2289472 233,964,240 intronic –
12 rs2241880 233,965,368
non-synonymous
T→A
–
13 rs2241879 233,965,468 intronic –
Table 3-8 Results of mutation detection of ATG16L1. 12 hitherto unknown polymorphisms were found and 10 annotated SNPs were
verified. The latter includes the nsSNP rs2241880. Primer sequences are listed in table table 8-2, page 162.
Chapter 3: Results 9314 ATG16L1_05 233,980,474 intronic
GTTCCTGGCCGGATCTCAGGGTGGTCT-
GACACTCTGACTCTGGAGGTAAGGATGCT
GTGGATACTTTGCCAGCATAGGCAGGGC-
CTGGCGCCCTGAGGCT
[C/T]
ACCCTGGCTGTGTTCTCTCTCCTAGCACA
CACTCACGGGACACAGTGGGAAAGTGCT-
GTCTGCTAAGTTCCTGCTGGACAAT-
GCGCGGATTGTCTCAGGA
15 ATG16L1_06 233,980,852 intronic
CTGAGGATAGTGATAGTTTTTCTTGTTTA
AAGCTTCATTTAAGTGAGTAACTCTGA-
CAAGTCAGTGGTTAGAGGGTGGCAGCAT-
TATGTAAACAGCCACG
[T/A]
TGGTGCCTCTGCTTGATTAATGATGTTTG
CATTTCTTTCAGGCATAAAGACAGT-
GTTTGCAGGATCCAGTTGCAATGATAT-
TGTCTGCACAGAGCAATGT
16 ATG16L1_07 233,981,059 intronic
AGTGGACATTTTGACAAGAAAATTCGTTT
CTGGGACATTCGGTATGATAC-
CCAAGCTCCTGACTGGAGGCACATAA-
GAGTCTCCACAGTAATGGTTCTGT
[A/G]
CATGGGTTGTGCTTTTAAGATCTCAGGA-
CATGGCAGAAATGAGTTTCGGTACACGTA
TAGTGTTAGCTTATTAACACTTGGCTGT-
TCTTTCCCATGAAGT
17 ATG16L1_08 233,982,979 intronic
AAAAGTTATTGATCTCCGAACAAATGCTA
TCAAGCAGACATTCAGGTAACTGAAGAT-
GTGCTGGTTGCATGAAGACCAGAGGC-
CCAGCCCTGCTCTCTTA
[A/–]
CGTGCTGCGTGGCCTGAGCNCCCTCAGT
GACAGTGCCCTGTTGTTTGTTTCAGTG-
CACCTGGGTTCAAGTGCGGCTCTGACTG-
GACCAGAGTTGTCTTCA
18 ATG16L1_09 233,982,999 intronic
CAAATGCTATCAAGCAGACATTCAGGTAA
CTGAAGATGTGCTGGTTGCATGAAGAC-
CAGAGGCCCAGCCCTGCTCTCTTANCGT-
GCTGCGTGGCCTGAGC[
T/A]
CCCTCAGTGACAGTGCCCTGTTGTTTGTT
TCAGTGCACCTGGGTTCAAGTGCG-
GCTCTGACTGGACCAGAGTTGTCTTCAG-
GTTAGTAGTGACCCACCCC
19 ATG16L1_10 233,983,767 intronic
ACTTGGAGCCCCAAGAAGCAATGTGATGC
CACTGTTCATTAGCCGGACGGGGCT-
GAAATACTGGGGAAAAGCAGATTTG-
GCTGGAAGGGCCATGACTAGC
[A/G]
CACATTCTGAGGTCTGGGTACACAGGAGT
GGTCATCAGTGAAGAACAAACATTCCT-
TCTTGGGAAAAAGGCCACAGAGATGCT-
GAATTGGGGGTGGGGAA
# SNP ID
position 
(build 35)
SNP type sequence
Table 3-8 Results of mutation detection of ATG16L1. 12 hitherto unknown polymorphisms were found and 10 annotated SNPs were
verified. The latter includes the nsSNP rs2241880. Primer sequences are listed in table table 8-2, page 162.
Chapter 3: Results 9420 ATG16L1_11 233,984,036 intronic
GAGGGCTCTCTGTATATCTGGAGTGTGCT
CACAGGGAAAGTGGAAAAGGT-
TCTTTCAAAGCAGCACAGGTAAGAT-
GAACCCTGTCTCAGCCCCCCGTTGC
[G/A]
TTGTGAGCAAGGCCTTTGACTTCATCTCA
GGGGTCATCCGGTTTAGACCTCAGTCG-
GCGCTGTGAGGGCACTGTCCGCCCACCT-
GCTCGGCTGGCTGAGC
21 rs6748547 233,984,766 intronic –
22 ATG16L1_12 233,985,029 3’ UTR
CGCCCTCTGGCTCGCACGTTGTCAGTGT
GGACAAAGGATGCAAAGCTGTGCT-
GTGGGCACAGTACTGACGGGGCTCT-
CAGGGCTGGGAGGACCCCAGTGC
[C/T]
CTCCTCAGAAGAAGCACATGGGCTCCTG-
CAGCCCTGTCCTGGCAGGTGATGTGCTG
GGTATAGCATGGACCTCCCAGAGAAGCT-
CAAGCTATGTGGCACT
# SNP ID
position 
(build 35)
SNP type sequence
Table 3-8 Results of mutation detection of ATG16L1. 12 hitherto unknown polymorphisms were found and 10 annotated SNPs were
verified. The latter includes the nsSNP rs2241880. Primer sequences are listed in table table 8-2, page 162.
Chapter 3: Results 953.3.1.2 ATG16L1 linkage disequilibrium analysis
The CD risk associated with ATG16L1 variation was then also analysed at the haplotype level
using 28 tagging SNPs selected from the Caucasian HapMap data on the basis of r2 > 0.8 and
a minor allele frequency >1% (see also 2.8.3 on page 48). The location of the respective SNPs
and their linkage disequilibrium structure is shown in fig. 3-1.
Fig. 3-1 Overview of the physical and genetic structure of the ATG16L1 gene region. Along the y-axis negative logs10 of correspond-
ing p-values are plotted in the upper panel. For detailed results see table 3-9, page 96. Physical positions of the SNPs investigated and a
schematic chart of the gene structure are shown in the middle panel. The only coding SNP is marked in red. The coordinates refer to the
genome assembly build 35. The lower panel gives an overview of the LD structure of the locus (D') as generated by Haploview (Barrett et
al., 2005) from the Caucasian HapMap data. Fields are color-coded according to LD strength (white, D’=0.0; red, D’=1). The SNPs used
in the haplotype analysis (table 3-10, page 97) are marked with asterisks.
Chapter 3: Results 96When the tagging SNPs were genotyped in panel B (results are shown in table 3-9), the in-
tronic SNP rs2289472 was found to have the same minor allele frequency (0.47) as the coding
SNP rs2241880, and to yield a slightly more significant disease association (p = 1.4 x 10-05).
This variant is located 1082 bases upstream of exon 9 and is not located in any recognizable
regulatory motif. Synonymous SNP rs13011156, on the other hand, was not significantly as-
sociated with CD.
In a logistic regression model, none of the tagging SNPs significantly improved the model fit
in the presence of rs2241880 (all p > 0.05). Together with results of a subsequent haplotype
analysis (table 3-10, page 97), these findings imply that the CD risk at ATG16L1 gene variation
is indeed mainly due to carriership of susceptibility allele “G” at rs2241880.
The association of ATG16L1 with CD is strongly supported by these results, as 11 out of the
28 typed SNPs are significant in the TDT and the CC analysis.
# SNP ID Position [bp] MAFco MAFca HWEco pCCG pCCA pTDT
1 rs6757418 233,909,321 0.16 0.16 0.13 0.56 0.95 0.42
2 rs11674242 233,916,795 0.12 0.14 0.59 0.47 0.23 0.88
3 rs2341565 233,917,138 0.15 0.16 0.33 0.57 0.29 0.58
4 rs12471808 233,920,324 0.46 0.46 0.10 0.68 0.81 0.46
5 rs12472651 233,920,522 0.41 0.39 0.24 0.67 0.36 0.03
6 rs10211468 233,921,467 0.43 0.43 0.02 0.24 0.80 0.13
7 rs11675235 233,922,554 0.13 0.14 0.12 0.69 0.43 0.76
8 rs4663340 233,924,691 0.08 0.05 0.66 0.02 0.004 0.25
9 rs7563345 233,925,244 0.34 0.31 0.88 0.04 0.02 0.002
10 rs2083575 233,927,080 0.07 0.05 0.36 0.07 0.03 0.04
11 rs13412102 233,927,971 0.41 0.36 0.96 0.004 0.001 0.006
12 rs12471449 233,928,958 0.14 0.10 0.16 0.0005 0.0001 0.02
13 rs11685932 233,948,322 0.33 0.30 0.94 0.11 0.04 0.008
14 rs6431660 233,949,234 0.47 0.40 0.79 0.0001 0.00002 0.0001
15 rs1441090 233,950,042 0.07 0.05 0.99 0.002 0.001 0.13
16 rs13011156 233,953,812 0.05 0.06 0.99 0.77 0.61 0.83
17 rs12105443 233,961,028 0.01 0.01 0.84 0.63 0.63 0.74
18 rs3792110 233,962,638 0.28 0.25 0.63 0.23 0.09 0.006
19 rs2289476 233,963,556 0.06 0.05 0.89 0.88 0.64 0.80
20 rs2289472 233,964,240 0.47 0.41 0.69 0.00007 0.00001 0.00002
21 rs2241880 233,965,368 0.47 0.40 0.59 0.00008 0.00002 0.00003
22 rs2241879 233,965,468 0.47 0.40 0.82 0.0001 0.00002 0.00003
23 rs7600743 233,971,359 0.06 0.05 0.18 0.21 0.16 0.61
24 rs3792106 233,972,740 0.41 0.35 0.54 0.0003 0.00008 0.00005
25 rs4663396 233,974,251 0.20 0.15 0.74 0.0006 0.0001 0.02
26 rs7587051 233,976,755 0.34 0.31 0.48 0.09 0.04 0.008
27 rs6748547 233,984,766 0.05 0.05 0.36 0.69 0.73 1.00
28 rs6759896 233,992,972 0.41 0.38 0.39 0.06 0.02 0.007
Table 3-9 Fine mapping of the CD association signal at the ATG16L1 locus. The p-values obtained in panel B in allele-based (CCA)
and genotype-based (CCG) association analyses of the tagging and coding SNPs are shown. In addition, the p-value for the TDT test in a
family-based sample is shown.The only non-synonymous SNP in ATG16L1 (rs2241880) is highlighted in blue. MAF: minor allele frequency.
Positions are according to NCBI build 35. The region comprises 84 kb and the average SNP density is 3.1 kb.
Chapter 3: Results 973.3.1.3 ATG16L1 haplotype analysis
A nine-marker haplotype analysis was carried out for panel B as described in 2.9.5 on
page 67. The results of COCA- and TDTPHASE are listed in table 3-9, page 96.
Obviously, the sole risk haplotype (ACACAGGCG) is fully tagged by rs2241880 allele “G”,
while all other haplotypes carry allele A. This haplotype pattern strongly suggests that
rs2241880 is indeed the major risk variant at the ATG16L1 locus. Rare haplotypes that had a
frequency <1% were excluded from the analysis.
SNPs #20 (2289472) and #22 (rs2241879), which are adjacent to the nsSNP rs2441880, were
also strongly associated with CD. This is obvious as linkage disequilibrium among these
three variants is very high (r2 > 0.80), even when using the conservative measure r2:
Fig. 3-2 Linkage disequilibrium between significant SNPs of the ATG16L1 gene. Using the measure r2, pairwise LD between the five
SNPs with p-values <0.001 in the case-control and TDT analysis (see table 3-9, page 96) is shown.
Haplotype fcases fcon-
trols
ORcase-
control
p-value
COCAPHASE
ftransmitted fnon-trans-
mitted
ORTDT p-value
TDTPHASE
ACACAGGCG 0.603 0.532 1.34 0.00002 0.535 0.285 2.87 0.0001
ACGCTAACG 0.254 0.283 0.86 0.0502 0.262 0.396 0.54 0.0164
AGATAAATG 0.047 0.069 0.67 0.0045 0.077 0.092 0.82 0.5462
GGACAAATG 0.052 0.069 0.74 0.0420 0.081 0.139 0.55 0.0608
ACGCAAGTA 0.044 0.048 0.91 0.5685 0.035 0.073 0.46 0.0728
ACACAAGTG <0.01 <0.01 n.d. n.d. 0.012 0.015 0.80 0.7050
Table 3-10 Results of a haplotype analysis of 9 SNPs at the ATG16L1 locus. SNPs included in the haplotype analysis are marked by
asterisks in fig. 4-1, thereby allowing to discern their block assignment. All analyses were carried out using either COCAPHASE or TDT-
PHASE (Dudbridge et al., 2003). Non-synonymous SNP rs2241880 is highlighted in bold and the risk allele is underlined.
Chapter 3: Results 983.3.2 NELL1 fine-mapping
The best and only replicated candidate gene out of the LD-based 100k scan was NELL1 (nel-
like 1). The gene is located on the plus strand of chromosome 11p15.1 and comprises 20 ex-
ons that stretch over an immense genomic region of 906 kb. The coding sequence of NELL1
is 2430 bp long (810 aa). NELL1 contains epidermal growth factor (EGF)-like repeats and the
encoded heterotrimeric protein may be involved in cell growth regulation and differentia-
tion.
3.3.2.1 Resequencing of NELL1
Using the same 47 CD patient DNAs as described for ATG16L1 (3.3.1.1 on page 91), mutation
detection was carried out for NELL1. This was done to detect potentially existing non-synon-
ymous SNPs. The results are listed in the following table:
# SNP ID
position 
(build 35)
SNP type sequence
1 rs1715283 20,646,687 Promoter –
2 rs3808993 20,646,953 Promoter –
3 NELL1_01 20,647,024 Promoter
CTGCCCTGCAGAATGAGAAGGTTTGCAAA
TAGACTTCCCAAACCCCAACCA-
CAGCTCGCTCCGCCTCGAGGAC-
CCCTTTTCTGCACCCCCACCTCAGCGC
[C/A]
CTCTTCCTGCACCCACAAAGAGAGTACT-
CAGTCATAGGGGTTCAACAGGAGAGAG-
GAGACAGAAGGTACAGGCGGTGAGCAGG
GACTCAGCCATCATCCC
4 rs1793003 20,655,970 intronic –
5 rs2280362 20,761,694 intronic –
6 rs8176785 20,761,862
non-synonymous
R→Q
–
7 rs2280363 20,761,911 synonymous –
8 NELL1_02 20,825,777
non-synonymous 
R→S
AAACAAATGTTTGTTCCTTTACATACAGC-
TATTTTGAACTGGAGAGCAGTGGCCTGAG
GGATGAGATTCGGTATCACTACATACA-
CAATGGGAAGCCAAG
[G/C]
ACAGAGGCACTTCCTTACCGCATGGCAGA
TGGACAATGGCACAAGGTTGCACTGT-
CAGTTAGCGCCTCTCATCTCCTGCTC-
CATGTCGACTGTAACAGGT
Table 3-11 Results of mutation detection of NELL1. Corresponding primer sequences are shown in table table 8-5, page 163.
Chapter 3: Results 99Three new polymorphisms, including two non-synonymous SNPs, were found and 24 anno-
tated SNPs were verified. In total, 4 non-synonymous and 4 synonymous SNPs were detected
in coding regions but no SNPs were found in splice sites. 
9 NELL1_03 20,825,826
non-synonymous
A→T
TGGCCTGAGGGATGAGATTCGGTATCAC-
TACATACACAATGGGAAGCCAAGGACAGA
GGCACTTCCTTACCGCATGGCAGATGGA-
CAATGGCACAAGGTT
[G/A]
CACTGTCAGTTAGCGCCTCTCATCTCCTG
CTCCATGTCGACTGTAACAGG-
TATTTCTTTGTCTTTGAGTGTTGCTGAT-
TCTGCCCTTGAAATCAAGCAAT
10 rs3740874 20,896,231 intronic –
11 rs1429785 20,897,351 intronic –
12 rs2293241 20,905,691 intronic –
13 rs1880088 20,915,761 Intronic –
14 rs8176786 20,915,970
non-synonymous
R→W
–
15 rs1880087 20,916,005 Intronic –
16 rs8176791 20,916,041 intronic –
17 rs1880086 20,916,058 intronic –
18 rs8176796 20,925,428 intronic –
19 rs2280584 20,938,470 intronic –
20 rs3758810 21,091,662 intronic –
21 rs8176792 21,349,039 synonymous –
22 rs4151056 21,349,063 synonymous –
23 rs7119475 21,538,241 intronic –
24 rs8176789 21,538,381 synonymous –
25 rs8176790 21,538,573 intronic –
26 rs4922847 21,548,804 intronic –
27 rs8176793 21,549,083 intronic –
# SNP ID
position 
(build 35)
SNP type sequence
Table 3-11 Results of mutation detection of NELL1. Corresponding primer sequences are shown in table table 8-5, page 163.
Chapter 3: Results 1003.3.2.2 Linkage disequilibrium and association statistics for NELL1
118 tagging SNPs were selected from the Caucasian HapMap data and genotyped in the Ger-
man replication panel D. A different set of 93 tagging SNPs was genotyped by a collaborator
(Genizon BioSciences) in French-Canadian CD trios (panel H). The results for this experi-
ment are listed in table 9-4, page 185 and they are included in plot fig 3-3, page 103 as well.
Genotyping 118 SNPs across the genomic region of 963 kb, gave an average SNP density of
8.2 kb. For the French-Canadian sample, an average of 10.5 kb was achieved. Although the
extent of LD varies greatly across the genome, this high density will extract most of the infor-
mation in this region.
# SNP ID position (build 35) MAF pCCG pCCA pTDT pHAP3
1 rs7942430 20,594,635 0.69 0.61 0.75 0.53 0.75
2 rs3740872 20,605,132 0.63 0.42 0.55 0.87 0.26
3 rs7122910 20,636,147 0.70 0.32 0.60 0.69 0.42
4 rs1792969 20,646,062 0.89 0.11 0.05 0.87 0.09
5 NELL01 20,647,024 0.99 0.57 0.56 0.03 0.21
6 rs1793005 20,655,334 0.73 0.03 0.06 0.50 0.10
7 rs1793004 20,655,505 0.72 0.03 0.06 0.03 0.22
8 rs1793003 20,655,970 0.73 0.05 0.10 0.50 0.07
9 rs951199 20,657,351 0.73 0.03 0.07 0.33 0.02
10 rs870194 20,663,881 0.79 0.28 0.25 0.05 0.03
11 rs1607616 20,674,469 0.65 0.005 0.01 0.001 0.03
12 rs1792983 20,674,751 0.79 0.24 0.23 0.02 0.15
13 rs11025705 20,688,454 0.86 0.95 0.99 0.20 0.43
14 rs7952174 20,695,492 0.85 0.30 0.54 0.54 0.06
15 rs908940 20,708,141 0.97 0.44 0.15 0.25 0.90
16 rs7116986 20,711,993 0.86 0.93 0.99 0.35 0.83
17 rs1996623 20,715,992 0.85 0.65 0.74 0.27 0.46
18 rs1519727 20,721,594 0.65 0.83 0.49 0.73 0.98
19 rs1554368 20,732,334 0.82 0.82 0.45 0.13 0.17
20 rs17232778 20,735,857 0.92 0.62 0.82 0.28 0.09
21 rs1429796 20,739,579 0.98 0.007 0.006 0.37 0.10
22 rs4922623 20,741,119 0.69 0.97 0.98 0.06 0.51
23 rs327025 20,746,233 0.85 0.62 0.40 0.03 0.57
24 rs16906777 20,748,858 0.66 0.42 0.73 0.19 0.45
25 rs327028 20,748,995 0.92 0.78 0.84 0.41 0.50
26 rs1949523 20,750,221 0.73 0.10 0.08 0.75 0.43
27 rs8176785 20,761,862 0.73 0.12 0.04 0.39 0.44
28 rs2280363 20,761,911 0.73 0.12 0.08 0.42 0.30
29 rs7129413 20,769,224 0.87 0.70 0.76 0.48 0.36
30 rs1158547 20,771,723 0.67 0.34 0.37 0.02 0.18
31 rs11601634 20,791,637 0.78 0.35 0.38 0.55 0.18
32 rs1519735 20,791,833 0.65 0.03 0.06 0.05 0.28
33 rs7109624 20,792,580 0.95 0.54 0.11 0.80 0.61
Table 3-12 Results of NELL1 fine mapping. The p-values obtained for the tagging and coding SNPs that were typed in panel D are
shown. SNPs that are significant in either one of the case-control analyses (CCA: allele-based comparison; CCG: genotype-based com-
parison) or the TDT are highlighted in blue. Lead SNPs from the initial screening are highlighted by a grey shading. Non-synonymous SNPs
are marked in red and significant nsSNPs are highlighted in bold italics. MAF: minor allele frequency in unrelated control individuals. pHAP3:
p-value obtained by a sliding three-marker window haplotype analysis by means of COCAPHASE.
Chapter 3: Results 10134 rs7130897 20,796,450 0.84 0.75 0.88 0.42 0.47
35 rs435001 20,800,510 0.88 0.25 0.50 0.75 0.10
36 rs17298565 20,806,806 0.96 0.14 0.16 0.80 0.44
37 rs1914984 20,807,913 0.92 0.91 0.56 1.00 0.90
38 rs2680989 20,809,773 0.88 0.62 0.49 0.22 0.54
39 rs919473 20,822,486 0.82 0.71 0.44 0.26 0.67
40 rs7114248 20,824,095 0.78 0.79 0.89 0.22 0.99
41 rs1429799 20,824,886 0.79 0.78 0.80 0.30 0.99
42 rs1346690 20,827,819 0.81 0.80 0.72 0.19 0.87
43 rs1367002 20,828,374 0.89 0.45 0.32 0.93 0.76
44 rs11025788 20,829,897 0.79 0.62 0.70 0.24 0.02
45 rs7121400 20,831,014 0.90 0.93 0.53 0.13 0.02
46 rs12293297 20,832,922 0.98 0.0009 0.006 0.87 0.04
47 rs1429794 20,838,013 0.82 0.55 0.69 0.29 0.51
48 rs6483735 20,844,275 0.79 0.10 0.19 0.12 0.26
49 rs10766733 20,844,335 0.76 0.33 0.25 0.07 0.10
50 rs919476 20,845,201 0.93 0.19 0.19 0.04 0.30
51 rs10766735 20,846,648 0.83 0.07 0.16 0.50 0.31
52 rs4923128 20,848,373 0.71 0.18 0.34 0.05 0.81
53 rs7109004 20,849,339 0.71 0.21 0.43 0.07 0.75
54 rs1549717 20,867,190 0.86 0.80 0.96 0.10 0.49
55 rs2082080 20,891,024 0.75 0.85 0.55 0.14 0.42
56 rs1880088 20,915,761 0.75 0.14 0.03 0.49 0.54
57 rs8176786 20,915,970 0.95 0.63 0.27 0.34 0.44
58 rs1880084 20,927,365 0.73 0.71 0.63 0.07 0.04
59 rs10833417 20,945,048 0.74 0.02 0.04 0.49 0.008
60 rs10500884 20,955,364 0.88 0.94 0.99 0.74 0.005
61 rs1400373 20,956,134 0.88 0.98 0.94 0.68 0.06
62 rs10500885 20,971,636 0.90 0.05 0.02 0.87 0.05
63 rs2896623 20,973,973 0.84 0.33 0.19 0.36 0.50
64 rs10500886 20,976,742 0.76 0.11 0.29 0.44 0.63
65 rs11025878 20,998,335 0.76 0.31 0.61 0.80 0.21
66 rs4922728 21,009,790 0.81 0.74 0.63 0.55 0.79
67 rs7937542 21,017,772 0.56 0.78 0.25 0.71 0.81
68 rs10833444 21,029,035 0.76 0.49 0.79 0.80 0.70
69 rs9666195 21,038,467 0.65 0.56 0.78 0.56 0.71
70 rs1543153 21,047,961 0.77 0.82 0.96 0.80 0.68
71 rs7932820 21,056,960 0.58 0.94 0.86 0.96 0.10
72 rs12417046 21,066,312 0.81 0.17 0.17 0.84 0.29
73 rs2403652 21,076,903 0.53 0.80 0.29 0.83 0.54
74 rs7933049 21,087,224 0.79 0.58 0.25 0.95 0.99
75 rs4922753 21,096,666 0.71 0.91 0.98 0.51 0.81
76 rs10766767 21,108,451 0.70 0.91 0.99 0.56 0.95
77 rs6483748 21,137,843 0.70 0.71 0.37 0.44 0.48
78 rs4475918 21,147,706 0.60 0.35 0.39 0.60 0.31
79 rs1453983 21,166,668 0.75 0.95 0.81 0.53 0.22
80 rs1454003 21,175,735 0.83 0.21 0.46 0.32 0.66
81 rs1823843 21,185,111 0.97 0.85 0.36 0.78 0.90
# SNP ID position (build 35) MAF pCCG pCCA pTDT pHAP3
Table 3-12 Results of NELL1 fine mapping. The p-values obtained for the tagging and coding SNPs that were typed in panel D are
shown. SNPs that are significant in either one of the case-control analyses (CCA: allele-based comparison; CCG: genotype-based com-
parison) or the TDT are highlighted in blue. Lead SNPs from the initial screening are highlighted by a grey shading. Non-synonymous SNPs
are marked in red and significant nsSNPs are highlighted in bold italics. MAF: minor allele frequency in unrelated control individuals. pHAP3:
p-value obtained by a sliding three-marker window haplotype analysis by means of COCAPHASE.
Chapter 3: Results 102Of the 118 typed SNPs, the three SNPs rs1793004, rs1607616, and rs1519735 were significant
in the TDT and the CC analysis, while 17 were significant in either analysis (7x TDT/10x CC).
Out of the 20 significant SNPs and with a genotypic p-value of 0.005 and a TDT p-value of
0.001, rs1607616 showed the strongest association. A strong peak showed up in the 5’ region
of NELL1, while (fig 3-3, page 103) the neighbouring gene SLC6A5 can be excluded. Using
Pearson’s χ2 (Ott et al., 1985), no significant or borderline association was seen for the two
82 rs1945327 21,190,821 0.90 0.61 0.83 0.80 0.52
83 rs1453988 21,201,279 0.69 0.47 0.75 0.32 0.62
84 rs1670638 21,207,776 0.68 0.69 0.88 0.34 0.98
85 rs1670640 21,218,026 0.54 0.74 0.15 0.64 0.87
86 rs1454008 21,230,114 0.59 0.53 0.74 0.57 0.93
87 rs1791822 21,240,131 0.54 0.65 0.12 0.87 0.86
88 rs10500901 21,240,719 0.97 0.84 0.98 0.66 0.45
89 rs1453990 21,249,027 0.53 0.57 0.48 0.91 0.21
90 rs716577 21,262,140 0.63 0.46 0.62 0.42 0.22
91 rs6483756 21,267,196 0.62 0.24 0.46 0.41 0.07
92 rs10833498 21,277,881 0.68 0.32 0.60 0.02 0.28
93 rs4335544 21,286,758 0.59 0.83 0.86 0.52 0.25
94 rs1349818 21,292,747 0.51 0.28 0.37 0.74 0.76
95 rs4399327 21,302,941 0.52 0.52 0.09 1.00 0.94
96 rs2187522 21,313,688 0.51 0.91 0.73 0.25 0.61
97 rs11026036 21,323,317 0.64 0.44 0.73 0.87 0.59
98 rs7126959 21,333,727 0.71 0.32 0.59 0.95 0.23
99 rs1945404 21,343,840 0.63 0.81 0.13 1.00 0.24
100 rs4151056 21,349,063 0.95 0.07 0.18 0.41 0.56
101 rs10833520 21,352,936 0.80 0.79 0.47 0.18 0.93
102 rs1945443 21,365,895 0.66 0.58 0.25 0.61 0.80
103 rs4539321 21,375,322 0.54 0.45 0.03 0.66 0.23
104 rs11026072 21,385,901 0.67 0.47 0.58 0.07 0.02
105 rs7943922 21,394,268 0.50 0.09 0.22 0.20 0.68
106 rs11026079 21,406,963 0.75 0.59 0.50 1.00 0.68
107 rs7110569 21,418,064 0.83 0.88 0.97 0.56 0.91
108 rs1945408 21,428,394 0.86 0.88 0.62 0.36 1.00
109 rs7945802 21,438,700 0.57 0.66 0.48 0.83 0.52
110 rs10766821 21,458,271 0.62 0.72 0.91 0.54 0.09
111 rs7116826 21,472,159 0.85 0.44 0.60 0.39 0.86
112 rs10219188 21,479,105 0.53 0.48 0.74 0.87 0.91
113 rs6483774 21,491,019 0.51 0.55 0.81 0.96 0.76
114 rs10766829 21,499,146 0.59 0.45 0.41 0.91 0.49
115 rs7926887 21,523,755 0.61 0.53 0.54 0.96 0.30
116 rs4319515 21,534,943 0.51 0.14 0.34 0.96 0.28
117 rs8176789 21,538,381 0.83 0.86 0.50 0.94 –
118 rs4922850 21,557,214 0.93 0.30 0.10 0.58 –
# SNP ID position (build 35) MAF pCCG pCCA pTDT pHAP3
Table 3-12 Results of NELL1 fine mapping. The p-values obtained for the tagging and coding SNPs that were typed in panel D are
shown. SNPs that are significant in either one of the case-control analyses (CCA: allele-based comparison; CCG: genotype-based com-
parison) or the TDT are highlighted in blue. Lead SNPs from the initial screening are highlighted by a grey shading. Non-synonymous SNPs
are marked in red and significant nsSNPs are highlighted in bold italics. MAF: minor allele frequency in unrelated control individuals. pHAP3:
p-value obtained by a sliding three-marker window haplotype analysis by means of COCAPHASE.
Chapter 3: Results 103non-synonymous SNP rs8176785 and rs8176786, respectively. More detailed results for all
four nsSNPs are given in table 3-13, page 104.
Fig. 3-3 Fine mapping results and LD structure for NELL1. The vertical axis shows the negative log10 of corresponding p-values and
plotted along the horizontal axis are chromosomal positions according to NCBI build 35. The region shown here comprises 0.96 Mb. (A)
SNP density and initial analysis results of the genome-wide scan in panel C; (B) Results of replication and fine mapping in panel D and (C)
panel H. The red dotted line depicts the significance threshold of p = 0.05. (D) Linkage disequilibrium across the NELL1 locus based on
HapMap data (1298 SNPs) using the measure D’. LD blocks are shown in red color. The legend next to (A) gives an explanation of the
symbols used for the different analyses (CCA = allele-based case-control comparison, CCG = genotype-based case-control comparison,
and TDT = transmission disequilibriumg test).
Chapter 3: Results 104Analyses of the French-Canadian genotype data revealed that the peak, which was observed
in German CD patients, co-localizes with the results of the TDT test (fig 3-3, page 103, C).
This finding in an independent population strengthens the detected association of NELL1
and CD.
Since the strongest associated SNP rs1607616, which is located between exon 3 and 4 of
NELL1, fails to provide a direct explanation for a harmful change on the NELL1 protein level,
a closer look was taken at the four non-synonymous SNPs. Results are listed in the following
table. The characteristics described for rs1607616 concerns all associated SNPs in non-cod-
ing regions of NELL1 as well.
Two additional nsSNPs are listed in NCBI’s dbSNP for NELL1: rs11820003 und rs8176788.
Both were not chosen for genotyping because the first is annotated as monomorphic in Cau-
casians and the latter is not validated.
Fisher’s exact test (as described in 2.9.7 on page 70) was calculated for the low-frequency
nsSNPs NELL1_02 and rs8176786, since both contingency tables contained values smaller
five. The results were not significant: p = 0.225 for NELL1_02 and p = 0.128 for rs8176786. In-
terestingly, there are 6% more heterozygotes for rs8176785 in the control population than in
the CD sample but fewer homozygotes for both alleles. This finding could not be replicated
in a British CD sample (panel F). Besides rs8176785, five percent more homozygous cases for
the common allele exist for rs1793004 and rs951199. No significant differences in genotype
or allele frequencies are seen for rs8176786. Therefore, other causative SNPs might exist that
contribute to the risk associated with this loci. Using the same R script and logistic regression
as done for rs2241880, no statistical interaction was observed between rs8176785, rs8176786,
and the three CARD15 mutations “SNP 8”, “SNP 12”, and “SNP 13”.
Finally, SNPlex™ results for the two nsSNPs rs8176785 and rs8176786 were validated with
TaqMan®, an independent genotyping method. The genotype concordance was 99.78% for
rs8176785 and 99.94% for rs8176785 (n = 3231 and 3247 genotypes compared, respectively).
controls cases controls cases
dbSNP ID Exon f11 f12 f22 f11 f12 f22 f1 f2 f1 f2
rs8176785 4 0.515 0.427 0.058 0.570 0.365 0.065 0.729 0.271 0.752 0.248
NELL1_02 5 1.000 0.000 0.000 0.998 0.002 0.000 1.000 0.000 0.999 0.001
NELL1_03 5 0.991 0.009 0.000 0.992 0.009 0.000 0.996 0.004 0.996 0.004
rs8176786 11 0.907 0.092 0.001 0.905 0.088 0.006 0.953 0.047 0.949 0.051
Table 3-13 NELL1 non-synonymous SNPs. Frequencies are listed for genotypes and alleles in both controls and cases. Significant differ-
ences are highlighted in blue.
Chapter 3: Results 1053.3.3 Fine mapping of the new susceptibility region on 5p13.1
The region on chromosome 5p was identified in the genome-wide scan using Affymetrix ar-
rays. Three SNPs in this region replicated in an independent German sample of single pa-
tients and nuclear families. In the inital screening, besides a high and wide peak with a
maximum at rs1992662, a small narrow peak at rs2122564 was detected. The same peaks
showed up in the replication study, when 28 SNPs were typed across a region of 777.5 kb at
an average SNP density of 28.8 kb. For the replication in panel H, a sample of French-Cana-
dian CD trios, 72 tagging SNPs were typed across 1058.1 kb by the collaborator (average den-
sity: 14.9 kb). 13 SNPs had a significant p-value (<0.05) in the TDT and the same peaks were
seen as in the outbred German population. Detailed results of this analysis can be found at
the end of this thesis: 9.6 on page 187.
# SNP ID position (build 35) MAF pCCG pCCA pTDT pHAP3
1 rs189814 40,292,083 0.49 0.25 0.21 0.04 0.0002
2 rs1445011 40,315,959 0.28 0.05 0.08 0.01 5.62·10-05
3 rs1445002 40,355,634 0.14 3.94·10-05 0.0002 0.04 0.0001
4 rs443583 40,368,840 0.21 0.06 0.16 0.02 0.13
5 rs12518245 40,381,478 0.06 0.50 0.70 0.91 0.0001
6 rs7725523 40,407,980 0.25 0.14 0.32 0.01 4.14·10-06
7 rs1992662 40,429,609 0.32 7.59·10-05 0.0002 0.001 0.0007
8 rs1992660 40,450,824 0.38 4.53·10-05 0.0002 0.0005 0.0001
9 rs4957300 40,499,496 0.33 0.003 0.006 0.0002 4.89·10-05
10 rs4422570 40,518,098 0.10 0.83 0.75 0.03 2.77·10-05
11 rs7725052 40,523,027 0.44 3.24·10-06 1.95·10-05 0.002 9.20·10-06
12 rs1553575 40,538,689 0.35 1.68·10-06 6.37·10-06 0.03 1.05·10-06
13 rs7718309 40,564,656 0.19 0.02 0.01 0.08 7.60·10-09
14 rs7713972 40,588,231 0.16 0.26 0.15 0.14 1.80·10-08
15 rs6451525 40,590,026 0.30 1.64·10-05 4.49·10-05 0.04 1.02·10-07
16 rs6864749 40,604,350 0.19 0.03 0.01 0.12 0.04
17 rs6451529 40,611,106 0.08 0.66 0.68 0.27 0.02
18 rs4409138 40,639,362 0.12 0.05 0.14 0.35 0.12
19 rs924967 40,650,879 0.12 0.06 0.16 0.40 0.23
20 rs6877753 40,677,032 0.11 0.50 0.56 0.52 0.43
21 rs4546432 40,718,307 0.38 0.43 0.20 0.37 0.22
22 rs6451535 40,723,788 0.32 0.98 0.27 0.22 0.13
23 rs10053664 40,821,568 0.43 0.43 0.48 0.46 0.007
24 rs10512747 40,877,498 0.12 0.08 0.23 0.06 0.11
25 rs16870407 40,888,804 0.11 0.05 0.13 0.92 0.23
26 rs2122564 41,023,131 0.44 0.69 0.53 0.13 0.03
27 rs896118 41,054,986 0.49 0.99 0.84 0.15 –
28 rs325832 41,069,536 0.16 0.007 0.02 0.36 –
Table 3-14 Association results for the 5p13.1 locus. The p-values obtained in the German patient panel D in allele-based (CCA) and
genotype-based (CCG) association analyses of the tagging and coding SNPs are shown. Lead SNPs from the initial screening (table 3-3,
page 84) are highlighted by grey shading, coding SNPs in CARD6 in red. Polymorphisms that are significant in either the TDT or the case-
control analysis, are highlighted in bold italics. Those that are significant in both are highlighted in blue. pTDT is the p-value for the TDT and
pHAP3 is the p-value for a three-marker haplotype analysis performed with COCAPHASE.
Chapter 3: Results 106Fig. 3-4 Fine mapping and LD analysis of 5p13.1. The y-axis shows the negative log10 of corresponding p-values and plotted along the
x-axis are chromosomal positions according to NCBI build 35.The entire region spans 1.30 Mb. (A) SNP density and initial analysis results
of the genome-wide scan in panel C; (B) Results of replication and fine mapping in panel D and (C) panel H. The red dotted line depicts
the significance threshold of p = 0.05. (D) Linkage disequilibrium across 5p13.1 based on HapMap data (1476 SNPs) using the measure
D’. LD blocks are shown in red color. Known genes are drawn above the LD-plot. The legend next to (A) gives an explanation of the symbols
used for the different analyses (CCA = allele-based case-control comparison, CCG = genotype-based case-control comparison, and TDT
= transmission disequilibriumg test).
Chapter 3: Results 107The consistent peak on 5p13.1 localizes to the gene-free region upstream of prostaglandin E
receptor 4 (PTGER4, see figure above). A closer look at the data of the UCSC genome browser
in this region revealed no convincing gene prediction (chr5: 40,315,959–40,604,350, NCBI
build 35), although a single mRNA fragment (BC041051, 752 bp, poly-A tail) and four spliced
ESTs exist (BG182136, BG188413, BG201263, BG184600). A tblastx search for the poly-ade-
nylated mRNA BC041051 at the NCBI homepage showed that it is likely to be a repetitive se-
quence. More than 100 hits were found on different chromosomes with E values below
2 x 10 -73.
It should be noted here that PTGER4 contains a bi-directional promoter and a first-exon pre-
diction, thus another upstream-located gene could be transcribed theoretically. No signifi-
cant association was seen in the LD block comprising the promising candidate genes
PTGER4 and CARD6.
The SNPlex™ results for the two lead SNPs rs1992660 and rs1992662 were validated with
TaqMan®. The genotype concordance was 99.51% for rs1992660 and 99.36% for rs1992662
(n = 2,638 and 2,650 genotypes compared, respectively).
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As mentioned above, CD and UC are both inflammatory bowel diseases, and though they
represent different disorders, they share some characteristics. Furthermore, many diagnoses
change during the course of the disease from one type of IBD to the other. Hence, it is rea-
sonable to test the previously found polymorphisms for association with UC as well. This was
carried out in large UC patient collections of German and British descent.
3.4.1 Evaluation of rs2241880 in ulcerative colitis
SNP rs2241880, found to be significantly associated with CD, was also evaluated in a sample
of German patients with UC (panel E, table 2-1, page 26). Allele frequencies of allele “G“ in
cases (0.46) and controls (0.47) were virtually identical, and evidence for association was thus
neither obtained from the case-control comparison (p > 0.4 in both the allele- and genotype-
based  test), nor from the the TDT (p > 0.9).
3.4.2 Testing of 5p13.1 association with ulcerative colitis
Similarly to rs2241880, the two lead SNPs of 5p13.1 (rs1992662, rs1992660) were tested in a
UC sample. The sample (panel E) comprised 439 trios, 1227 single cases, and 1032 healthy
normals. No evidence of association was detected between rs1992662 and UC:
pCCA = 0.2391, pCCG = 0.4719, and pTDT = 0.5940, MAFcontrols = 32% vs. MAFcases = 30%
SNP rs rs1992660 was not significant either:
pCCA = 0.1784, pCCG = 0.3999, and pTDT = 0.4434, MAFcontrols = 37% vs. MAFcases = 35%
With p-values > 0.4 in the allelic and genotypic χ2 test, both lead SNPs of the 5p13.1 region
were not associated with UC in UK patients (panel G). Therefore, polymorphisms in the
5p13.1 regions seem to play a role only in the etiology of CD but not UC.
Chapter 3: Results 1093.4.3 NELL1 and its association with ulcerative colitis
Replicated NELL1 lead SNPs of the 100k scan, rs951199 and rs1793004, were tested for asso-
ciation with UC in the German panel E and the UK panel G. As both SNPs were signficant in
the case-control analysis of the German sample, the two non-synonymous SNPs rs8176785
and rs8176786 were tested in these panels as well. Detailed results are given in the following
table.
Single-point analyses in the German UC panel show a significant association of the NELL1
gene with the disease, interestingly, associations are even stronger with UC than with CD
(see 3.3.2.2 on page 100). Substantial differences in genotype frequencies are seen for all
SNPs in the German and the British population, except for the nsSNP rs8176786. Although
the TDT results are insignificant for all four SNPs, which could be a result of transmission ra-
tio distortion, the massive lack or excess of heterozygotes in the case sample provides further
evidence for an association of the NELL1 gene with UC. For example, there are 7% fewer het-
erozygous cases for rs8176785 in the German panel compared to healthy normals. In the Brit-
ish UC sample, there are 4% more heterozygous cases than in the controls for rs1793004.
Associations with UC and CD lead to the conclusion that NELL1 is a true IBD susceptibility
gene, though further experiments and analyses are necessary to determine the more compli-
cated genetic background. It is possible that other functional variants exist that contribute to
the risk at this locus and that are in linkage disequilibrium with the above three associated
SNPs. This could also explain the inconsistent results that were obtained for the tested mu-
tations.
dbSNP ID Panel pCCA pCCG pTDT 11co 11ca 12co 12ca 22co 22ca
rs1793004
GER (E) 0.002 0.003 0.54 0.514 0.598 0.414 0.343 0.071 0.059
UK (G) 0.24 0.38 – 0.542 0.496 0.396 0.438 0.062 0.066
rs951199
GER (E) 0.001 0.0008 0.19 0.497 0.601 0.431 0.334 0.072 0.065
UK (G) 0.58 0.81 – 0.541 0.528 0.400 0.404 0.059 0.068
rs8176785
GER (E) 0.06 0.006 0.68 0.517 0.580 0.425 0.352 0.058 0.068
UK (G) 0.77 0.95 - 0.594 0.604 0.337 0.329 0.069 0.067
rs8176786
GER (E) 0.35 0.64 0.77 0.906 0.893 0.092 0.105 0.002 0.003
UK (G) 0.43 0.049 - 0.901 0.876 0.92 0.124 0.008 0.000
Table 3-15 Evidence of association between NELL1 and UC. Significant differences >5% are highlighted in blue. Single-point p-values
are listed for an allelic (pCCA) and genotypic (pCCG) test as well as for the TDT (pTDT) test.
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3.5.1 Epistasis between ATG16L1 and CARD15
The ATG16L1 gene encodes a protein in the autophagosome pathway that processes intrac-
ellular bacteria. Since both the ATG16L1 and the NOD2 proteins are involved in the innate
defence against bacterial pathogens, the disease-associated variants in the two genes were
investigated for a possible statistical interaction with respect to CD risk. To this end, individ-
uals in the German fine mapping and replication sample (panel B) were classified as either
homozygous wild-type (dd), heterozygous carrier (dD) or homozygous carrier (DD, which in-
cluded compound heterozygotes) for the three main causative CARD15 SNPs rs2066844
(R702W, “SNP 8”), rs2066845 (G908R, “SNP 12”) and rs2066847 (1007InsC, “SNP 13”). Appro-
priateness of this classification is supported by the published haplotype structure of the
CARD15 gene (Croucher et al., 2003). The frequency and odds ratio for individual CARD15
risk genotypes, stratified by rs2241880 genotype, are shown in table 3-16.
The odds ratio difference was significant for rs2241880 genotype “GG” (2.03 versus 1.04;
Breslow-Day χ2 = 4.267, 1 d.f., p = 0.039), and not for “AG”. Thus, the ATG16L1 variant
rs2241880 is a risk factor even in the absence of CARD15 mutations. On the background of
CARD15 high-risk genotype “DD”, the risk conferred by carriership of the rs2241880 allele
“G” appeared to be higher than in the presence of “dd” or “dD”, but the confidence intervals
of the respective odds ratios were still wide owing to the small number of “DD” controls
(table 3-16). Nevertheless, when rs2241880 genotypes “GG” and “AG” were combined, the
joint OR of 5.89 (95% CI: 1.23 – 29.21) was found to be statistically significantly larger than
unity (Fisher's exact two-sided p = 0.016), thereby confirming that rs2241880 allele “G” is a
risk factor on a high-risk CARD15 genotype background as well.
CARD15
affection status ATG16L1 dd dD DD
control
GG 219 62 2
AG 435 87 2
AA 185 35 5
CD
GG 175 92 42
AG 232 136 57
AA 73 50 21
odds ratios
GG 2.03 (1.43 – 2.88) 1.04 (0.59 – 1.84) 5.00 (0.76 – 41.05)
AG 1.35 (0.98 – 1.87) 1.09 (0.64 – 1.88) 6.79 (1.04 – 55.16)
AA 1.00 1.00 1.00
Table 3-16 Analysis of the statistical interaction between SNP rs2241880 and CARD15 genotype. See description above.
Chapter 3: Results 1113.5.2 Location of T300A in ATG16L1 (protein model)
ATG16L1 homologues are present in a wide range of eukaryotes in the same domain archi-
tecture, except for yeast ATG16 (fig. 3-5).
Fig. 3-5 Domain architecture of human ATG16L1 and yeast ATG16. The position of the variant amino acid T300A in the WD repeat
domain is marked. The annotated ATG16 Pfam domain consists of coiled-coils. The C-terminal residue K150 of yeast ATG16 corresponds
to S213 of human ATG16L1 according to a pairwise sequence alignment.
The threonine residue at position 300, which is substituted to alanine by rs2241880, is con-
served across many species including mouse and rat (fig. 3-6), suggesting an important role
of this amino acid. Human ATG16L1 is organized into an N-terminal ATG16 domain consist-
ing of coiled-coils and eight C-terminal WD repeats.
Fig. 3-6 Multiple sequence alignment of conserved region surrounding variant T300A in ATG16L1 homologs. Physicochemically
similar amino acids are highlighted with identical colors. Homo sapiens (human), Macaca mulatta (rhesus monkey), Pan troglodytes (chim-
panzee), Mus musculus (mouse), Rattus norvegicus (rat), Canis familiaris (dog), Bos taurus (domesticated cow), Gallus gallus (domesticated
chicken), Monodelphis domestica (opossum), Danio rerio (zebrafish), Fugu rubripes (Japanese pufferfish), Tetraodon nigroviridis (Spotted
green pufferfish), Xenopus tropicalis (pipid frog). Further details of used sequences are given in table 2-19, page 79.
Chapter 3: Results 112The 3D structure of ATG16L1 was modelled (see 2.11 on page 77) using the eight-bladed  β-
propeller crystal structure of the evolutionarily related WD-repeat domain in yeast CDC4
(Orlicky et al., 2003). The location of the T300A variant in human ATG16L1 corresponds to
T397 of CDC4, where it lies at the N-terminus of the WD-repeat domain in the  β3 strand of
the first propeller blade (fig. 3-7 and fig 9-5, page 183). Therefore, the Thr to Ala amino acid
change might have a detrimental effect on the structural stability of the affected blade and on
potential binding sites nearby.
Fig. 3-7 3D structure model of the WD-repeat domain of human ATG16L1. The 32 β-strands forming an 8-bladed  β-propeller are
numbered as in fig 9-5, page 183. The location of the variant amino acid T300A in strand β3 is marked in yellow.
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Since the frequency of the more common “G” allele is significantly higher in CD patients than
in healthy normals (53% in controls, 60% in cases), we determined whether “G” is also the ac-
tual mutant allele. Judging by the frequency itself, one would expect the rarer “A” allele to be
the mutant and “G” to be the ancestral allele. The latter is the sequence that is found in the
last common ancestor between humans and chimpanzees (Hacia et al., 1999).
A multi-species comparison on the nucleotide level of exon nine revealed that the conserved
“A” variant is the ancestral allele (fig 3-8, page 113). This supports our finding that “G” is the
mutant allele that predisposes to CD.
Fig. 3-8 Exon 9 multi-species alignment - Which is the ancestral allele? Exon nine sequences from six different species (human, chim-
panzee, rhesus macaque, mouse, chicken) were retrieved from UCSC Golden Path and aligned with MultAlin. The conserved “A” allele of
rs2241880 is shown in green color. Other mutations that occured during the evolutionary history are highlighted in blue.
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Previous investigations showed that IBD associated mutations are more prevalent in certain
disease subgroups. Hampe et al. (2002), for example, found that CD patients with inflamma-
tion in the ileum are more often carriers of the CARD15 risk allele of “SNP 13”. Therefore, sev-
eral subgroups of a retrospective CD sample (panel B) were examined for significant
differences in carriership of the risk genotype “GG“. Results are summarized in the following
table:
No significant differences were observed concerning allele frequencies among the different
clinical subgroups, thus classifying rs2241880 allele “G“ as a rather general risk factor for CD.
Furthermore, the median age of disease onset is very similar for risk- and non-risk carriers.
Although sample numbers are low (n = 245), significantly more men are carriers of the risk
genotype “GG” compared to female patients.
Clinical phenotype n fGG fGA fAA fG fA
Controls 1032 0.27 0.51 0.22 0.53 0.47
All cases 929 0.36 0.48 0.17 0.60 0.40
Only males 245 0.40 0.40 0.20 0.60 0.40
Only females 684 0.34 0.50 0.15 0.59 0.41
Stenoses 507 0.37 0.48 0.15 0.61 0.39
Fistulae 488 0.36 0.49 0.15 0.61 0.39
Family history 88 0.35 0.43 0.22 0.57 0.43
Ileal 718 0.36 0.47 0.17 0.60 0.40
Colonic 594 0.35 0.49 0.16 0.59 0.41
Extra intestinal manifestations 665 0.35 0.50 0.15 0.60 0.40
Median age of disease onset 929 37 years 37 years 36 years – –
Table 3-17 Results of subphenotype analysis for retrospective panel B. The case panel was divided into several subgroups represent-
ing distinct clinical presentations. Frequencies (f) are given for each genotypic or allelic subgroup. More than one family member had to
be affected by IBD in case of “Family history”.
Chapter 3: Results 1153.5.5 Validation of genotyping methods
Several quality control experiments were necessary to generate consistent high-throughput
genotyping data. This included the comparison of genomic DNA with WGA-DNA and the
comparison between the different used genotyping methods.
3.5.5.1 Performance of genomic DNA and amplified DNA in genotyping
To compare amplified DNA with genomic DNA, 360 samples (plate XKN34) of each type were
genotyped with control pool A. Thirty-seven ng of fragmented gDNA, undiluted WGA prod-
uct (~1 µg), and 1:10 diluted WGA product (~100 ng) were used. This experiment resulted in
17,280 genotypes for each experiment, which were analyzed for concordance by means of
MS Excel. Failed assays and null alleles were excluded from the analysis (max. 2,200 gt). Only
3 disconcordant genotypes were found between WGA-DNA and gDNA, which gives a concor-
dance rate of more than 99.98% (15,077/15,080). Genotype clusters were even tighter in the
polar plot and low-performing assays worked significantly better with WGA-DNA compared
to gDNA. No important difference was seen between diluted and undiluted WGA-DNA.
Another experiment was carried out to validate different WGA kits that were being used
throughout these studies: GenomiPhi version 1, version 2, and high yield (HY). Amplification
products of v1 and v2 were diluted 1:10, while the HY product was diluted 1:40 with 1x TE-
buffer. For this test, WGA was performed for the same 92 DNA samples according to the pro-
tocols. Control pool A, containing 48 distinct assays, was used for genotyping. No difference
was seen in the concordance analyses for all comparisons.
Given the results of these experiments, WGA-DNA was used in SNPlex™ and TaqMan®
genotyping experiments throughout this study. The latter was done to spare DNA resources
and to meet the demands of the large-scale studies.
Chapter 3: Results 1163.5.5.2 Genotype concordance between Affymetrix arrays and SNPlex™
Concordance rates were tested between SNPlex™ and array-based hybridization. To this
end, genotypes of 210 SNPs that were typed with the Affymetrix 100k GeneChip®, and which
were genotyped in a subset of 140 single cases by means of SNPlex™, were compared. 28,186
comparisons were possible and 222 discrepancies were detected. With 99.21%, the concor-
dance rate was convincingly high among the overlapping sample. Excluding three DNA sam-
ples with conspiciously high error rates (52/64/24 errors), yielded only 82 remaining errors,
increasing genotype concordance to 99.71%. The result is consistent with the genotype con-
cordance of 99.78%, mentioned by Affymetrix. In this experiment, almost 2 million array-
based genotypes were compared with the HapMap Release 8.
Only assays that passed the following quality criteria were used for this comparison:
CR > 95%, pHWE > 0.05, MAF >5%. Therefore, this approach is biased towards common and
high-quality SNPs as they were used in the actual analysis of the screening.
Except for the lead SNPs of the three susceptibility regions (rs2241880, rs951199, rs1793004,
rs1992660, rs1992662), no further investigations were carried out with regard to concordance
rates between SNPlex™ and TaqMan®. This was extensively studied by De La Vega and col-
leagues (2005). By comparing 3,901 genotypes (47 assays, 83 DNAs), they found a genotype
concordance of 99.7% between the two systems.
Given the results of these experiments, false positive or false negative findings due to geno-
typing errors can be neglected.
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Genetic findings need functional validation to support and elucidate the etiology of corre-
sponding suceptibility genes. The previously found ATG16L1 gene was further characterized,
given the clear genetic replication.
3.6.1 Detection of differentially spliced transcripts
Recently, the existence of multiple splice variants of ATG16L1 was reported (Zheng et al.,
2004) and many such variants are annotated in the Golden Path assembly. In all annotated
and reported splice variants, exon 9 (containing susceptibility variant rs2241880) is con-
tained in the same frame orientation, thus consistently leading to a Thr to Ala amino acid
substitution. The results of Zheng and colleagues were verified by cloning and subsequent
sequence analysis of 233 clones. Inserts were amplified from colon, small intestine spleen,
and inflamed bowel tissue by using the ATG16L_ex1-9 primers listed in table 8-4, page 163.
42% of the ATG16L1 transcriptome is represented by the splice variant α, namely the RefSeq
AY398617.
3.6.2 Expression in various tissues
Expression of the ATG16L1 gene was investigated by RT-PCR in a panel of different tissues,
confirming expression in the tissues of interest: colon, small bowel, intestinal epithelial cells,
and immune-tissues like spleen and leukocytes (fig. 3-9). Strong expression was seen in co-
lon, kidney, prostata, and thymus tissue. Primers covered the constitutively expressed exons
10, 11, and 12 to avoid amplification from genomic DNA. Sequences of the primers are listed
in table 8-3, page 163.
Fig. 3-9 RT-PCR in multiple tissue panel for ATG16L1. Expression of ATG16L1 in a set of different tissues as detected by RT-PCR. The
corresponding β-Actin control (518 bp amplicon size) is given below. IEC: intestinal epithelial cells.
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It is not fully clear yet, which pathways ATG16L1 is involved in. Therefore, it was evaluated
whether ATG16L1 expression is regulated in response to different stimuli. As ATG16L1 is in-
volved in autophagy and thus might play a key role in bacterial defense, cells were mainly
stimulated with bacterial antigens, such as flagellin, LPS, and Listeria monocytogenes. In ad-
dition, substances, which are involved in inflammatory cascades, e.g. TNF-α and IFNγ, were
used for stimulations
Stimulation of different cell lines and real-time PCR was carried out as described in 2.10.1 on
page 71. Fold-changes and standard deviations were computed and the results are plotted in
the diagram on the next page.
Overall, most significant changes in ATG16L1 gene expression were seen after 2 hours. Inter-
estingly, different cell lines respond differently to the same stimulus.
A 2.0-fold downregulation is seen in THP-1 cells after 1 hour, when challenged with Listeria
monocytogenes. Downregulation increases with time and peaks at 2 hours after stimulation
(3.5-fold change). This is supported by a small deviation from the mean of two independent
stimulation experiments and is specific for THP-1 cells, as no significant changes are ob-
served for Caco-2, HeLa, and HT-29 cell lines. TNF-α has a similar effect on ATG16l1 gene ex-
pression as Listeria, but the the downregulation is not as strong with a 2.3-fold change after
2 hours of incubation. The third stimulation experiment that exceeded a threshold of 1.5-
fold, was the stimulation of HT-29 cells with EGF. After 2 hours, an almost 2 times higher ex-
pression level is seen than in the 0 hour control experiment.
In summary, no clear pattern is observed and only three of the twenty-three examined com-
binations provide a small insight into the ATG16L1 pathway. Further studies are required to
replicate these findings and to improve the understanding of the autophagy pathway.
Chapter 3: Results 119Fig. 3-10 Fold-changes of ATG16L1 gene expression after different stimuli. Fold-changes are shown on the y-axis and different stimu-
lation experiments are listed along the x-axis with related stimulations framed. A yellow line is shown to indicate the fold-change threshold
of 1.3. Green bars highlight an upregulation, while red bars indicate downregulation. Standard deviations are plotted with each bar.
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In a Western Blot from colon tissue (fig. 3-11), a dominant 68.2 kD protein band was identi-
fied corresponding to the annotated coding sequence AY398617, the predominant splice
variant alpha. The derived protein sequence was therefore used for the modelling of the
ATG16L1 protein (see fig. 3-7).
Fig. 3-11 Western blot analysis of ATG16L1 in colonic mucosa. Proteins (15 µg) from rectal mucosal biopsies of CD patients and nor-
mal controls (N) were separated by denaturing SDS-PAGE, transferred onto PVDF membranes and probed for presence of ATG16L1 using
a specific primary antibody and horseradish-peroxidase-coupled secondary antibody. ATG16L1 is present in the mucosa of CD patients
and healthy controls at the same level.
Presence of ATG16L1 in the intestinal epithelium was shown by immunohistochemistry
staining (fig. 3-12). No significant difference in expression level and protein distribution was
detected between normal and patient tissue.
Fig. 3-12 Expression and localization of the ATG16L1 protein in colonic tissue. (A) CD patient, (B) normal control, (C) control staining
without the primary antibody in a CD sample. Intestinal epithelial cells are marked with arrows, mononuclear cells are highlighted with
arrowheads.
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Recently, an association between IBD and variants in the CARD4 gene, which encodes the
protein NOD1, has been shown in the British population (McGovern et al., 2005). In that
study, McGovern and colleagues identified the common deletion allele of the marker
ND1+32656 as a risk factor for IBD. Conversely, the minor ND1+32656 allele, in haplotype
combination with its adjacent marker rs2907748, exhibited a protective effect.
CARD4 is located on the minus strand of chromosome 7p15.1 between 30,430,675 and
30,484,790 bp (NCBI build 35). Fourteen exons code for the 953 aa large protein NOD1, that
is a structural homologue of NOD2. As CARD15 replicated in both genome wide screenings
and CARD4 appeared not among the top significant hits, its association with IBD in the Ger-
man population was evaluated in more detail. SNP genotyping was undertaken on a case-
control and an independent family-based panel:
❏ 1015 IBD patients (676 CD, 344 UC, 886 unrelated controls)
❏ 775 trios (328 CD, 447 UC)
Given these sample sizes, the study provided >96% power to detect an OR of 2.0, assuming a
risk allele frequency of 79% and 1% type I error. However, no significant association was de-
tected in the German population between IBD and the previously reported variants.
Genotyping was performed with TaqMan® and in addition to ND1+32656, the adjacent sin-
gle nucleotide polymorphisms ND1+27606 (rs2075822) and ND1+45343 (rs2907748) were in-
cluded for haplotype analyses. ND1+233 and ND1+21984, which were only weakly associated
with IBD in the study of McGovern et al., were not examined here.
Phenotype Variant MAFcontrols MAFcases
CCA CCG TDT
P-value P-value P-value
CD
rs2075822 0.81 0.80 0.569 0.308 1.000
ND1+32656 0.79 0.79 0.847 0.977 0.091
rs2907748 0.79 0.77 0.420 0.578 0.306
UC
rs2075822 0.81 0.78 0.152 0.357 0.480
ND1+32656 0.79 0.76 0.124 0.295 0.951
rs2907748 0.79 0.75 0.073 0.195 0.956
IBD
rs2075822 0.81 0.79 0.263 0.327 0.580
ND1+32656 0.79 0.78 0.510 0.804 0.248
rs2907748 0.79 0.77 0.132 0.279 0.547
Table 3-18 Summary of single-marker association statistics for CARD4. All three assays had a call rate >95% and showed no signifi-
cant deviations from Hardy-Weinberg equilibrium. P-values for alleles (CCA), genotypes (CCG), and the TDT are listed. 
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the patient sample was stratified for patients with early-onset IBD (n = 449 <25 years) and pa-
tients with fistulae and stenoses (n = 491). Analyses of both subgroups showed no significant
association (data not shown).
In conclusion, there is no evidence for an association of the IBD phenotype with the previ-
ously reported CARD4 susceptibility variants in the German population (Franke et al., 2006)
suggesting ethnic differences as seen for other disease-associated SNPs previously (Mori et
al., 2005). This finding is consistent with the results of the two genome-wide screenings. Sev-
en SNPs in the CARD4 region were located on the Affymetrix 100k gene chip and only one
(rs563092) proved to be borderline significant with a p-value of 0.02 in the allelic case-control
comparison.
Variations Haplotype fcontrols fcases
CC
P-value
fT fNT
TDT
P-value
D'
rs2075822
+
ND1+32656
1 – 1 0.771 0.762
0.846
0.455 0.486
0.094 0.91
1 – 2 0.042 0.040 0.140 0.101
2 – 1 0.013 0.015 0.026 0.057
2 – 2 0.174 0.184 0.380 0.357
ND1+32656
+
rs2907748
1 – 1 0.784 0.775
0.727
0.473 0.519
0.719 0.98
1 – 2 0.002 0.002 0.011 0.011
 2 – 1 0.006 0.004 0.014 0.008
2 – 2 0.208 0.220 0.503 0.462
Table 3-19 Two-marker haplotype frequencies, transmission, and association statistics for CARD4 in IBD. Allele 1 is defined as the
major allele. P-values resemble global significances after 10,000 permutations with COCAPHASE or TDTPHASE. Estimated frequencies for
cases and controls, as well as transmitted and non-transmitted haplotype frequencies are shown. D’ was calculated for unrelated controls.
Highlighted in blue is the protective haplotype identified by McGovern et al. (2005).
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The two performed genome-wide association screenings of this thesis have led to the identi-
fication of two replicable disease susceptibility genes and one region. As the initial screen-
ings identified hundreds of significant SNPs, among which only a few replicated in the
follow-up studies, possible influencing and disturbing factors require detailed consider-
ation. Furthermore, the potential roles of ATG16L1 and NELL1 in disease-associated path-
ways, and how this adds to the understanding of inflammatory bowel diseases, need to be
discussed.
4.1 Potential methodological pitfalls
4.1.1 Multiple testing and false positive results
Statisical testing of thousands of SNPs in a genome-wide association study, as done in this
thesis, is the most likely reason for a large number of false positve results that simply arise by
chance. Besides the real association between a disease and a causative marker, or a marker
in LD with the latter, false positive association signals can result by several reasons. False
positive findings or type I errors describe the scenario that the Null hypothesis of “no associ-
ation” is incorrectly rejected, leading to a “false alarm”. On the α = 0.05 significance level, 5%
of the results are likely to be false-positives. Since α has to be greater than 0, as for α = 0 the
null hypothesis will always be accepted, a type I error will always exist.
It is generally agreed that α must be defined before the actual testing. Therefore, the p-value
is used as an a posteriori measure of significance, i.e. it is is the probability to err if the null
hypothesis is rejected. A p-value smaller or equal to 5% is generally considered significant. If
thousands of alleles are tested, then a nominal α equal 0.05 is unacceptable, as far too many
results will simply arise by chance statistical fluctuation, which has economical consequenc-
es in terms of minimizing costs per true positive. Decreasing α will only result in a loss of pow-
er (see 4.1.3 on page 128) and therefore, different methods exist to estimate the rate of false
positives by interpretation of the p-value.
Reality
Result of test H0 is true (NO association) H0 is false (association)
H0 is accepted correct decision with 1-α type II error with β
H0 is rejected type I error with α correct decision with power 1-β
(see 4.1.3 on page 128)
Table 4-1 Test results and reality. According to Sachs (2003).
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sesses the probability of a hypothesis being correct by incorporating the prior probability of
the hypothesis and the experimental data supporting the hypothesis.
Individual p-values are corrected for multiple-hypothesis testing by multiplying the p-value
with the number of tests “n” (Plenge et al., 2006; Bland et al., 1995):
Pcorrected = n x Puncorrected
This would mean a corrected value of p = 0.05 for a p-value of 5 x 10-7 in a genome-wide
screen of 100,000 SNPs. As this is overly conservative, if an allele has a very high probability
of being a true-positive result, replication studies were used throughout this thesis to filter
out false positive results rather than Bonferroni correction. Only marker rs2076756 in the
CARD15 gene had a p-value below 5 x 10-7 in the 100k scan and would have been considered
a truly significant association finding. In April 2005, a broad consensus emerged at a work-
shop for genome-wide association studies (Thomas et al., 2005) that multi-staged designs are
the most reasonable way to conduct whole-genome scans. The different levels of replication
allow to correct for type I error rates, besides reducing genotyping costs without any loss of
power. Sobell et al. (1993) first suggested a two-stage design for association studies, which
has recently been extended to a genome-wide scale by Satagopan and colleagues (2002; 2003;
2004), Lowe et al. (2004), and van den Oord et al. (2003).
Another effect that can cause false positive or false negative results are ethnic differences or
admixture among the group being studied, so-called population stratification (discussed in
section 4.1.4 on page 130). Misclassifications of patients and selection bias are also con-
founding factors, that researchers need to be aware of. Selection bias arises when the case
and control groups are not truly comparable and a difference exists between what is actually
estimated and the true effect of interest. It is mainly due to effects on personality leading to
“volunteer bias”, which might affect a limited number of loci, and more general effects that
are due to differences in population substructure between cases and controls. A “healthy vol-
unteer bias” could be an issue of the used control group in the replication study as it partially
consists of blood donors. The latter are considered to be exceptionally healthy persons that
are self-selected on the basis of better lifestyles (Vineis et al., 1998).
Although not really affecting the results of this study, publication bias (Colhoun et al., 2003)
is also a pitfall in association studies. This so-called “Winner’s Curse” phenomenon de-
scribes the fact that the original study often overestimates the true magnitude of the genetic
effect, since larger sample collections are used in following replication studies. Furthermore,
mostly positive results are submitted for publication, let alone accepted.
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LD-based whole-genome scans strongly rely on a good genomic coverage of markers. This
means that the used SNP set must capture as much of the total genomic variation as possible.
It must also be mentioned that genome copy number variations (CNVs) are far more fre-
quent than originally expected (Aitman et al., 2006; Sebat et al., 2004), and several genetic dis-
orders are the result of CNVs. However, methods to evaluate CNVs are just beginning to
evolve and it should be kept in mind that the performed SNP screenings are not suitable to
detect CNVs and their contribution to disease susceptibility. It has been shown just recently
that a lower human beta-defensin 2 (HBD-2) gene copy number in the beta-defensin locus
predisposes to colonic CD (Fellermann et al., 2006). The ultimate strategy to identify genetic
variations that influence disease is complete resequencing in clinical samples, thereby com-
prehensively testing all variants across the genome. Resequencing thousands of genomes is
not yet feasible because of economic and technical constraints, although the 1000$ genome
is within reach (Bennett et al., 2005). Therefore, genomic coverage of the used SNP sets of this
thesis, which need to represent the entire genomic variation, must be carefully evaluated.
Barrett et al. (2006) have calculated coverage rates for the currently available technologies for
GWS. They determined a coverage rate of 31% for the Affymetrix 100k GeneChip®. This low
coverage and efficiency is mainly due to the underlying LD “agnostic“ marker set, i.e. SNPs
were randomly selected instead of using tagSNPs. Therefore, it can be assumed that many
gaps exist, where no information about any association can be derived. Nicolae et al. (2006)
observed that SNPs in the 100k set are undersampled from coding regions and oversampled
(57.5% vs. 59.6%) from regions outside genes relative to the distribution of SNPs in the Hap-
Map. Adding to the problem of low coverage, marker numbers for a real whole-genome scan
are calculated to be 500,000 and even a lot more, when randomly distributed SNPs are used.
Therefore, the screening described in this thesis is more a “genome-wide” scan than a
“whole-genome” study and certainly, a lot more susceptibility loci could be identified with
another technology. However, random SNP sets offer a protective redundancy against the
failure of any given SNP and their disadvantage in coverage compared to population-specific
tagSNP sets is reduces, when other populations are used that have a different LD pattern. Fi-
nally, when this study started, the Affymetrix 100k GeneChip® was the first and only publicly
available technology that made it possible to conduct genome-wide association mapping.
Since non-synonymous SNP sets are designed to test functional variants directly, coverage
rates are not of major concern for these SNP sets. However, to conduct a genuine whole-ge-
nome nsSNP study, all known and validated nsSNPs should be typed and as many as possible
of the 28,000 existing genes and more should be “covered” (Roest Crollius et al., 2000; Ewing
et al., 2000). In the current study, 19,779 non-synonymous SNPs were genotyped, of which
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genome-wide experiment is more appropriate in this context.
As existence of linkage disequilibrium between the genotyped SNPs and potentially disease-
causing variants is assumed, LD-disturbing factors can lead to false-negative or fale-positive
outcomes. Ideally, LD decays with time since the alleles evolved and distance between the lo-
ci, but empirical studies have shown that the pattern of LD is very complex and poorly un-
derstood. Sometimes LD can be detected between distant markers, while there may be little
or no LD between very closely located markers. It has been estimated that physical distance
can explain about half of the variation in LD (Abecasis et al., 2001). There are a number of dif-
ferent factors that contribute to the extent of LD in a population, like recombination and mu-
tation rates, gene conversion, selection, genetic drift, growth rate, migration and population
structure (Ardlie et al., 2002; Pritchard et al., 2001). Below, these factors are discussed in
somewhat more detail.
Recombination
Regional variability of recombination rates has been observed in the human genome. Since
LD is highly dependent upon the recombination rate, the pattern of LD will vary between re-
gions of high recombination activity (expected low LD) and regions of less recombination
(higher LD is expected). Furthermore, recombination, even within shorter regions, may not
be randomly distributed, but instead be restricted to shorter regions of high recombination,
so-called recombination hotspots, surrounded by more conserved regions with little or no
recombination (Daly et al., 2001; Jeffreys et al., 2001). This has been convincingly shown to
be the case in the HLA class II region and in the mouse MHC (Jeffreys et al., 2001; Yauk et al.,
2003; Cullen et al., 2002; Kauppi et al., 2003). It appears that at least some hotspots are found
across populations and haplotypes (global hotspots; Kauppi et al., 2003), while evidence
from the HLA seems to support that hotspot activity can be specified for certain haplotype
constellations, i.e. certain haplotypes might be more prone to recombination than others
(Kauppi et al., 2003).
Mutation
The mutation rate may vary between different genetic sequences. Recurrent mutations are
probably very rare with some exceptions: microsatellites and variable number of tandem re-
peats for example, are more prone to mutations than SNPs (Brinkmann et al., 1998). Such dif-
ferences may affect the decline of LD. 
Gene conversion
When a short stretch of DNA on one chromosome is transferred/copied to the other chromo-
some during meiosis, this is termed gene conversion. The event appears to be more common
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LD decay, since gene conversion is able to break down LD between very tightly linked mark-
ers without affecting long-range LD between markers located outside of the converted seg-
ment (Ardlie et al., 2001; Frisse et al., 2001).
Selection
If there is strong selection for or against a certain variant at a locus, the surrounding haplo-
type may considerably increase or decrease its population frequency. If the rise in allele fre-
quency occurs over such short time that recombination is unable to break down the
haplotype carrying the selected mutation, LD can become very strong for this allele. It has
been suggested that as a response to pathogens, selection has been an important factor in
maintaining high levels of LD in the HLA-complex (Hedrick et al., 1991; Huttley et al., 1999).
Random genetic drift
Random genetic drift is the stochastic process which describes the change in allele and hap-
lotype frequencies between generations in a finite sample. For example, in a very small pop-
ulation there is a chance that the allele frequency of a specific allele will change somewhat in
the next generation, just by the chance transmission of a few more, or less, alleles of one kind.
Such changes are unlikely to have an impact on large populations but they can have drastic
effects in very small populations where these chance effects will occur until one of the alleles
gets extinct, and the other alllele becomes fixed in the population. Genetic drift can also oc-
cur through accidents, or so-called “bottle-necks” that leave only a few individual survivors
with a limited gene pool. An extreme bottle-neck refers to the founder effect, the latter occurs
if only a few founders form a new population. Then the genetic make-up in the new popula-
tion may be very different from the original population within which the founders lived.
Population growth rate
Rapid growing populations reduce genetic drift, hence there is a decrease in LD.
Population structure and migration
Population substructure (see also 4.1.4 on page 130) can produce significant LD even if no
linkage exists.
The extent of LD in the human genome has been highly debated and estimates range be-
tween 3 kb and several 100 kb (Abecasis et al., 2001; Ardlie et al., 2002; Pritchard et al., 2001;
Reich et al., 2002; Kruglyak et al., 1999; Reich et al., 2001). However, as several authors point-
ed out, knowledge of the average extent of LD between random markers may not be a very
useful tool for designing association studies, since there is such great variance of LD in dif-
ferent regions (Nordborg et al., 2002).
Chapter 4: Discussion 1284.1.3 Power
In contrast to false positive results that are of minor importance in the described multi-tiered
scans, overlooking true association signals poses a greater threat. While the type I error rate
α is the probability that a true null hypothesis is incorrectly rejected, the type II error β de-
scribes the failure to detect a false null hypothesis (“a chance is missed”). Power is the prob-
ability to reject H0, if HA is correct and it is calculated as 1-β. All three measures are correlated
as with decreasing error probability α, type II error β increases to result in decreasing power.
A summary of this relationship is given in the following diagram:
Fig. 4-1 Threshold of test statistic in dependence of α and β. With decreasing α, power (1-β) decreases.
To circumvent the problem of being “underpowered”, thus missing true association signals,
sample sizes must be increased. Given the sample sizes of the initial screenings, power can
be calculated to detect SNPs of different allele frequencies and different effect sizes:
Fig. 4-2 Power estimation. Graphical representation of a power estimation in the sample size at a significance level of α = 0.05 for a
two-sided test over an odds ratio range of 1 to 2. The graph was generated using PS-power (Dupont et al., 1997) and shows the test
power as a function of the odds ratio (x-axis). (A) Shows the power calculation for the cSNP and (B) of the LD-based scan. Different minor
allele frequencies (MAF) were used.
As depicted in fig. 4-2, both screenings provided sufficient power of 80% to detect SNPs with
a minor allele frequency of 20% and an odds ratio of 1.6. Of course, it would be desirable to
have sufficient power to detect even low frequency SNPs with moderate to low effects. Many
investigators argue that complex diseases are caused by numerous loci with small effects and
few genetic loci with large effects. The potential for a large number of variants with small in-
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lelic variation frequently affects gene expression and exon splicing (Pagani et al., 2004;
Hoogendoorn et al., 2003; Lo et al., 2003; Mira et al., 2004), which is likely to have smaller ef-
fects than polymorphisms that affect the coding sequence. A genome-wide association study
that could detect rare variants (MAF = 0.05) with small effects (OR = 1.3) would need large
sample numbers of 4,282 cases and 4,282 controls to provide a descent power of 80%
(α = 0.05). Although this is theoretically and technical feasible, few laboratories possess this
large sample collections for a certain disease, which is in some cases also rare in the popula-
tion. In addition, genotyping of 8,000 samples and more can only be afforded by large re-
search centers with sufficient funding. The Institute of Clinical Molecular Biology in Kiel has
for example a CD patient panel of app. 3,000 samples, which is close to the required number
of 4,282 samples. According to Wang et al. (2005) unrealistically large sample sizes of even
more than 10,000 cases and 10,000 controls would be required to achieve convincing statis-
tical support for a disease association if effect sizes are less than 1.3 and allele frequencies be-
low 10%. Therefore, the two screenings described in this thesis are a compromise between
sufficient power, genotyping costs, limited sample size, and it is likely that rare (MAF < 20%)
associated SNPs with an OR below 1.6 were missed. Using larger numbers of patients and
controls for the replication experiments, minimizes the chance of missing associations that
were found in the previous scan. Replication panel B consists of 878 cases and 1032 healthy
controls and has 80% power to detect an odds ratio of 1.36 (MAF = 0.2; α = 0.05). For the
equivalent conditions, the 380 used trios have sufficient power to detect an effect size of OR
= 1.51.
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As even a small extent of population admixture could undermine the association studies of
this thesis and lead to false positive results, it has to be discussed whether the two screenings
could have been affected by this confounding factor. The term population stratification de-
scribes the confounding effect that a population under study consists of a mixture of two or
more subpopulations that have different allele frequencies and disease risks. An example is
given in the following figure:
Fig. 4-3 Effects of population structure at a SNP locus. If the study population consists of subpopulations that differ genetically, and if
disease prevalence also differs across these subpopulations, then the proportions of cases and controls sampled from each subpopulation
will tend to differ, as will allele or genotype frequencies between cases and controls at any locus at which the subpopulations differ.
Illustration from Marchini et al. (2004).
The extent to which population stratification poses problems to association studies has been
widely debated (Wacholder et al., 2000 and 2002; Thomas et al., 2002; Cardon et al., 2003;
Freedman et al., 2004). Population substructure can lead to three distinct problems: con-
founding, cryptic relatedness (resulting in overdispersion of the test statistic), and selection
bias. Unlike some other biases, these problems do not become smaller with increasing sam-
ple size, on the contrary, type I error rate even increases.
For these case-control experiments of this thesis, control individuals were mainly drawn
from the POPGEN biobank (Krawczak et al., 2006), thus having a Northern German back-
ground. Since the sampling area is restricted to Kiel and surrounding cities that are “en-
closed” by the canal in the south, the Danish border in the north, and the sea to the west and
east, this area is thought to consist of a very homogenous population. Although samples from
Northern German patients were preferentially selected to match the control population, a
large proportion of samples was used from patients that live in different parts of Germany.
Further concern of an inflated type I error rate due to population stratification is driven by
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ification can be obtained by genomic control experiments (GC; Devlin et al., 1999 and 2001),
structured association (Pritchard et al., 2000), and simple logistic regression (Tang et al.,
2004). For the the still ongoing German genomic control study (Lamina et al., 2005), 720 in-
dividuals were randomly drawn from the POPGEN (Kiel, Northern Germany; Krawczak et al.,
2006), KORA (Augsburg, Southern Germany; Holle et al., 2005), and SHIP (Greifswald, East-
ern Germany) sample and genotyped for 210 SNPs. Of the latter, 140 were chosen from non-
functional region of the genome (“genomic desert”), since these loci are presumably not un-
der selective pressure and thus, are only subject to neutral processes of drift and migration
in demographic history. The other 70 SNPs were chosen from intragenic regions. First results
show very low and non-significant FST values of less than 0.001 for the three sample collec-
tions under study (Caliebe and Krawczak, personal communications). Therefore, no signifi-
cant population stratification seems to exist in Germany compared to, for example,
populations from the Caucasus that have FST values of 0.113 (Nasidze et al., 2001). Interest-
ingly, the European population in total is genetically homogenous (FST = 0.017), in contrast
to the African (FST = 0.086) or American (FST = 0.038) population (Stoneking et al., 1997;
Nasidze et al., 2001). Since no significant population substructure seems to exist in Germany
and therefore is likely to be absent in the used case-control panels, plus the fact that the fam-
ily-based TDT test was employed, which is robust against such substructure, type I errors
have arisen rather by multiple testing, i.e. chance, or other selection biases.
Clinical heterogeneity is also of importance in a genetic study, if a genetic variant influences
a disease subset. This confounding becomes even more complex, if the screening group dif-
fers significantly in its clinical presentation from the replication sample. Because inflamma-
tory bowel diseases present a variety of distinct clinical phenotypes, it is important to
investigate the extent to which this heterogeneity impacts variability in the risk of developing
common diseases. This was done for the ATG16L1 mutation rs2241880, by testing its associ-
ation in different CD subphenotypes, but no differences were seen for different clinical out-
comes. It could be considered to analyze associations with subphenotypes on the genome-
wide level, but as this significantly reduces the already small sample size of the patient group
by 30% and more, power would drastically drop, thus running into problems of overlooking
true association signals. Furthermore, since the number of possible subgroup analyses that
can be undertaken is large, significant results obtained in such analyses should be treated
with even more scepticism than tests for the average genetic effect across all subgroups com-
bined. The selection of “genetically enriched” cases on the basis of severity, as done for most
cases of the 100k scan, could also have the counterproductive effect of enriching environ-
mental as well as genetic factors.
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In the present study, more association signals, which were significant in the case-control
replication panel, could not be replicated in the family-based study group composed of trios
than vice versa. For the cSNP scan eleven SNPs replicated in the case-control analysis and
not in the TDT, while six were only significant in the TDT. The corresponding numbers were
17 and 12 for the 100k scan, thus less SNPs are replicated in the TDT analysis. Either popula-
tion stratification among cases and/or controls or transmission distortion could be a result
of this imbalance. Several known biological processes lead to skewed transmission probabil-
ities among surviving offspring and departure from Mendelian expectation has been ob-
served by several groups (Zöllner et al., 2004; Friedrichs et al., 2006; Warburton et al., 1983).
Processes that result in transmission distortion are (according to Pardo-Manuel del Villena
et al., 2000 and 2001):
❏ Meiotic drive - biased segregation during meiosis
❏ Gametic selection - differential success of gametes in achieving fertilization
❏ Postzygotic viability (embryonic mortality) selection for or against particular genotypes,
so-called in utero selection
It is known that a large fraction of conceptions, perhaps as many as 75%, end with early em-
bryonic loss (Edmonds et al., 1982; Regan et al., 2000; Macklon et al., 2002). Some fractions of
these losses are presumably due to genetic factors, including genetic incompatibility be-
tween the mother and fetus or inviability of the fetus’s genotype. These forms of selection
would skew the observed transmission probabilities among those offspring that do survive
to term, with fitter genotypes being transmitted more frequently. Interestingly, an increased
activity of CD in the beginning of pregnancy causes high rates of prematurity, spontaneous
abortions, and stillbirths (Briese et al., 1993). Friedrichs et al. (2006) also observed gender-
specific transmission distortion of the R30Q risk allele, a variant that is present in the gene
DLG5 and is associated with CD. This male-specific association might also explain, why none
of the 4 SNPs in the DLG5 gene were not significant in the 100k genome-wide scan.
Transmission ratio distortion might also explain why the TDT test was not significant for the
NELL1 mutation rs8176785, which was highly significant in the case-control analysis. NELL1
knock-out mice embryos can only be rescued by caesarian delivery and die a few hours after
birth (Desai et al., 2006). This finding is further discussed in 4.3.2 on page 139.
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In recent years it has become obvious that for common diseases there may be more complex
interactions among genes with and without strong independent main effects. The presence
of epistasis is a particular cause of concern, if the effect of one locus is altered or masked by
effects at another locus. These effects are more difficult to detect using traditional method-
ologies and the number of studies documenting epistasis is small (Ritchie et al., 2005). The
difficulty in detecting epistasis stems from the “curse of dimensionality” (Bellman et al.,
1961). Stated simply, as the number of parameters increases, the number of interaction
terms grows exponentially and most parametric statistical methods are limited to deal with
interaction data involving many simultaneous factors. Although recent publications show
that it is computationally feasible to detect multiple loci that influence complex diseases on
a genome-wide level (Marchini et al., 2005), Krawczak and colleagues (personal communica-
tions) have calculated that it takes 3 days, 264 years, and 7 x 106 years to evaluate 2, 3, and 4
SNP-interactions, respectively, in a genome-wide screening of 100,000 SNPs using a
Pentium 4 PC with a 2 GHz processor (4 GFLOPS). Even on the grid project GIMPS with
17,000 GFLOPS it would last 2,000 years to calculate all four-wise SNP interaction terms. Nev-
ertheless, the question of true biological interaction remains of paramount interest, but may
ultimately be better answered via molecular, rather than statistical, investigation. A good re-
view of statistical methods for epistasis is given by Cordell (2002).
In summary, genetic association studies become complicated and computationally inten-
sive when the simple correspondence between genotype and phenotype breaks down due to
effects of chance, environmental factors, incomplete penetrance of mutations with moder-
ate effects, interaction phenomena, or genetic heterogeneity.
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It is still discussed whether one should intend to search for common polymorphisms having
main effects on disease risk or those having modifying effects on other genes or environmen-
tal factors, as well as prior beliefs about the “common disease/common variant” (CD/CV;
Cargill et al., 2000; Reich et al., 2001; Lohmueller et al., 2003) versus “multiple rare variant”
(Pritchard et al., 2001; Pritchard et al., 2002; Wang et al., 2003; Fearnhead et al., 2004) hypoth-
eses. The most prominent example for the “multiple rare-variant“ theorem is CARD15, where
the risk alleles are rare among the general population (1.3-4.7%; see table 1-4, page 13). The
allelic spectra of most common diseases probably fall between these two extremes (Wang et
al., 2005). Since in this study a common variant associated with CD was found, the “common
disease/common variant“ hypothesis is strongly supported. 27% of controls (vs. 36% in cas-
es) carry the risk genotype “GG“ of the non-synonymous SNP rs2241880 in the ATG16L1
gene. Adding evidence comes also from a study by Valentonyte et al. (2005), who found a
truncating splice site mutation (rs2076530) in BTNL2, which is associated with sarcoidosis
and has a minor allele frequency of 42% in unaffected individuals. Other examples are SNP
R30Q associated with CD (Stoll et al., 2004) with a MAF of 10% in healthy normals and SNP
rs7566605 that is associated with obesity and has a MAF of 37% (Herbert et al., 2006). Finally,
the identification of rather common genetic risk factors in complex diseases partially ex-
plains the steep increase in prevalence of barrier diseases since the beginning of the 20th
century, i.e. actual genetic predisposition develops in response to the drastic environmental
changes (“yesterday’s neutral SNP, today’s risk factor”). Rare and highly penetrant risk alleles
that exert their effect “agnostic“ to environmental influences are subject of negative selec-
tion as they significantly reduce the reproductive fitness of an individual. These kind of mu-
tations are rather known from rare Mendelian diseases, e.g. cystic fibrosis, than for common
complex traits.
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4.3.1 ATG16L1 is involved in autophagosome formation
In this thesis, a new susceptibility variant for CD in ATG16L1 was identified and disease as-
sociation was replicated in independent German and UK samples. The mutation rs2241880,
which leads to an amino acid substitution, yielded a highly significant result both in a case-
control comparison (overall p = 4.0 x 10-8) and by the TDT (p = 2.7 x 10-5). The failure to detect
any other disease-associated coding or regulatory variants in the ATG16L1 gene in a system-
atic mutation search, and in regression and haplotype analyses, suggests that the CD risk at
the ATG16L1 locus is conferred mainly by rs2241880 alone, and that additional variants do
not contribute significantly to the observed association. The disease-associated “G” allele is
frequent (0.53 in Germans) and shows odds ratios of 1.45 for carriership and 1.77 for homozy-
gosity. It therefore represents an example of the "common disease - common variant"
paradigm (Reich et al., 2001). A statistical interaction between rs2241880 and the established
CARD15 disease mutations was noted (table 3-16, page 110). 
The disease-associated variant rs2241880 leads to an amino acid exchange (Thr to Ala) at po-
sition 300 of the N-terminus of the WD-repeat domain (see fig 3-7, page 112) in ATG16L1
(other aliases: APG16L, WDR30). The interaction partner of the WD domain in ATG16L1 has
not yet been identified experimentally, but during their studies of mouse ATG16L1, Mizush-
ima et al. (2003) found a p144 protein that remains a good candidate. It is clear, however, that
in yeast the ATG12-ATG5 conjugate, which is required for autophagy, assembles in a multi-
meric complex via the coiled-coil region of ATG16 (Mizushima et al., 2003; Kuma et al., 2002).
ATG16 interacts with the conjugate through ATG5, and ATG16 homo-oligomers formed by
the coiled-coils connect multiple ATG12-ATG5 conjugates. Furthermore, it has been shown
that the ~350 kDa large ATG12-ATG5·ATG16 complex is necessary for autophagosome for-
mation and localizes to the so-called preautophagosomal structure (Mizushima et al., 2003).
In metazoans, this conjugate is contained in a ~800 kDa protein complex and yeast ATG16 is
known as ATG16-like protein 1 (ATG16L1) because it contains an additional WD-repeat do-
main of as yet unidentified function at the C-terminus (see fig 3-5, page 111; Zheng et al.,
2004; Mizushima et al., 2003). In most WD-repeat proteins, seven or eight copies of the WD-
repeat form a β-propeller domain structure with blades consisting of four-stranded anti-par-
allel β-sheets (Li et al., 2001). Due to the circular arrangement of the propeller blades, the N-
terminal strand β1 is included in the C-terminal blade, and this stable β-propeller structure
provides an extensive surface for molecular interactions. These interactions may be im-
paired by the conformational change resulting from the T300A substitution.
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other ATG gene. ATG5-deficient mice die within 1 day of delivery due to energy depletion.
Therefore, the degradation of “self” proteins seems to be essential during the early neonatal
starvation process.
Fig. 4-4 The ATG12-ATG5·ATG16L ubiquitin-like system. (A) In Saccharomyces cerevisiae, a chain of reactions that are similar to ubiq-
uitinylation are necessary to form the ATG-complex, which subsequently locates to the preautophagosomal membrane. This complex then
promotes autophagosome formation. Tetramer-formation is facilitated through the ATG16 protein, which forms homo-oligomers. Illustration
from Marino et al. (2004). (B) Model of autophagosome formation in mammalian cells. The ATG12-ATG5·ATG16L conjugate localizes
to the preautophagosomal isolation membrane througout its elongation process. LC3, which is homologous to yeast ATG8, is recruited to
the membrane in the ATG5-dependent manner. ATG12-ATG5 and ATG16L dissociate from the membrane upon completion of the autoph-
agosome formation, while LC3 remains on the membrane. Therefore, LC3 is commonly used as a marker for autophagosomes. Illustration
from Mizushima et al. (2002).
The single columnar epithelial lining of the small intestine is the primary barrier restricting
transgression by luminal bacteria, endotoxin, bile, digestive enzymes, and antigens while
also serving as the principal site for selective transport of electrolytes and nutrients. Bacteria
that are able to invade the cytoplasm of host cells are recognized by the innate immune sys-
tem. Proteins from the NLR (NACHT/LRR or NOD-like receptors) family recognize patho-
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innate immune defense, mainly in phagocytes and epithelial cells (Girardin et al., 2003; Ino-
hara et al., 1999; Chamaillard et al., 2003). In particular, NOD2, the protein encoded by
CARD15, plays a pivotal role in the detection of cytosolic muramyl-dipeptide (MurNAc-L-
Ala-D-isoGln; MDP), a fragment of the bacterial cell wall. Autophagy (Greek word for self-di-
gestion) is a fundamental molecular machinery of eukaryotes for bulk protein degradation.
It has been implicated in diverse physiological processes such as organelle turnover, starva-
tion response, cell death and defence against invading bacteria, a process referred to as xe-
nophagy (Codogno et al., 2005; Mizushima et al., 2005; Deretic et al., 2005; Swanson et al.,
2005). Three differenct mechanisms of autophagy are known: chaperone-mediated autoph-
agy, microautophagy, and macroautophagy (Schmid et al., 2006). The latter mechanism is
known to play a major role in several diseases, such as cancer (tumor cells can survive in nu-
trient-poor environment), muscular disorders (accumulation of autophagosomes), and neu-
rodegeneration (accumulation of aggregated proteins) [Shintani et al., 2004].
Fig. 4-5 Xenophagy. Cellular defense against invading extracellular pathogens, Group A Streptococcus (GAS), in a non-phagocytic cell
and an intracellular pathogen, M. tuberculosis, in a phagocytotic cell. Illustration from Levine et al., 2005.
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pathogens (Nakagawa et al., 2004) and true intracellular bacterial pathogens (Gutierrez et al.,
2004; Ogawa et al., 2005). Pathogens trapped by the autophagic membrane are ultimately tar-
geted to the autophagolysosome compartment (Kirkegaard et al., 2004; Ogawa et al., 2005), a
pathway of which the ATG16L1 protein is part of. This fusion with a lysosyme (inner pH < 5.0)
leads eventually to the degredation of the content by several hydrolytic enzymes (see
fig. 4-5).
A genetic interaction between rs2241880 and risk variants in CARD15 may reflect a connec-
tion between the two encoded proteins at the functional level. Both proteins are part of mo-
lecular defence pathways and could be additively involved in the interaction with
intracellular bacteria.  Hence, variants in the encoded proteins could result in an incapacita-
tion of phagocytic cells. Since the risk variants in both CARD15 and ATG16L1 are only asso-
ciated with CD but not with UC, one can hypothesize that an additive functional defect
caused by both variant genes could be a disease specific characteristic leading to the pathol-
ogy found in CD. 
While only the risk conferred by SNP rs2241880 in the ATG16L1 gene could be replicated in
other samples, some of the remaining, apparently significant, variants listed in table 3-9,
page 96 may still represent important candidates for disease susceptibility. The requirement
of a significant replication (p < 0.05) in both the TDT and the case-control comparison may
lead to the exclusion of relevant variants due to a lack of power. These variants should there-
fore be evaluated in further, independent large patient samples. While the present study still
falls short of comprehensively assessing all putative functional variation in the human ge-
nome, it is the largest cSNP study hitherto performed, both in terms of the number of SNPs
included and of the size of the database from which they were selected. Our results, together
with those of other recent studies, demonstrate that the direct association analysis using
cSNPs is a meaningful complement to genome-wide LD-based association studies as the one
that has been reported for CD previously (Yamazaki et al., 2005) and the one that was per-
formed in this study.
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The NELL1 gene was identified as a susceptibility gene for CD in the 100k association screen-
ing of this thesis. Further genotyping efforts in other IBD patient panels replicated the initial
finding and showed an association with UC as well. Of the four discovered non-synonymous
SNPs in the present study, the mutation Arg82Gln (rs8176785) showed the strongest associ-
ation.
The neural epidermal growth-factor-like (nel) gene was first isolated from an embryonic
chicken cDNA library and so named because it was found to be predominantly expressed in
neural tissues (Matsuhashi et al., 1995 and 1996). The NELL1 gene encodes a polypeptide
(810 aa) that is glycosylated and processed in the cytoplasm and then secreted as a 400 kDa
homotrimer. The protein contains thrombospondin-like, laminin G, von Willebrand factor-
like repeats, and epidermal growth-factor (EGF)-like domains (Kuroda et al., 1999; see also
fig. 4-6). EGF-like domains are composed of 40-50 amino acid residues, including six con-
served cysteine residues. It has been revealed that these domains participate in the Ca2+-de-
pendent protein-protein interactions. The protein binds to and is phosphorylated by PKC-β1
via the EGF-like domains, suggesting that NELL1 represents a novel class of cell-signaling
ligand molecules critical for growth and development. Furthermore, the NELL proteins pos-
sess heparin-binding activity (Kuroda et al., 1999), which implies an interaction of the NELL1
protein with the heparan sulfate proteoglycan on the cell surface.
Fig. 4-6 NELL1 protein domain structure. Highlighted in red is the hydrophobic N-terminal secretion signal sequence and in green the
coiled-coil region. TSPN: Thrombospondin N-terminal-like domain; VWC: von Willebrand factor type C domain; EGF-like: epidermall
growth-factor like domain; EGF CA: Calcium-binding EGF-like domain. SMART accession number Q92832.
Has NELL1 previously be considered a neuronal-restricted gene, Luce and colleagues (1999)
found that NELL1 mRNA is transcribed during a narrow window of pre-B cell development.
Sequence identities between NELL1 and its homologue NELL2 are rather low (40% on pro-
tein level), suggesting that these proteins have diverged in an early stage of molecular evolu-
tion (Kuroda et al., 1999). NELL1 shares many protein motifs with thrombospondin-1 (TSP-
1), which could mean they also have similar molecular functions. TSP1 interacts with various
receptors, cytokines, proteases, and extracellular molecules, and exhibits versatile cell-spe-
cific effects on adhesion, migration, and proliferation (Bornstein et al., 1995). Mouse models
have significantly contributed to the understanding of the NELL1 function, for example,
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CS is a significant medical condition that is caused by the premature closure of the cranial
suture, which can severely constrain the growth of the brain. This premature closure is
caused by an increase in osteoblast differentiation, apoptosis, and mineralization (Zhang et
al., 2003). NELL1’s importance for osteoblast differentiation was recently supported by
NELL1-deficient mice, which manifest skeletal defects in the vertebral column and ribcage,
and an altered cranial morphology (Desai et al., 2006). Interestingly, these knock-out mice
showed a significantly reduced expression of extracellular matrix (ECM) proteins critical for
chondrogenesis and osteogenesis, e.g. tenascin (Tnxb), collagen 5 alpha 3 subunit (Col5a3),
and thrombospondin 3 (Thbs3). Furthermore, the prostaglandin E receptor 4 (PTGER4),
which is an interesting candidate of the 5p13.1 region (see 4.3.3 on page 141), is 1.23-fold
downregulated in NELL1-deficient mice. Desai and colleagues (2006) reported further that
NELL1-knockout mice develop to late gestation (E19 days) but do not survive the physical
trauma of birth. Mutant neonates were alive after recovery by caesarean section, but quickly
succumbed, because they were unable to breathe. However, heterozygote mice survive to
adulthood and breed normally, with no readily visible phenotypic differences when com-
pared with wild-type mice.
Given the variety of known NELL1 functions, but missing a connection to the pathogenesis
of IBD, it is difficult to speculate about a potential role of this susceptibility gene. Neverthe-
less, it is intriguing that NELL1 is involved in bone formation (Cowan et al., 2006) and that a
higher than average prevalence of osteoporosis exists among IBD patients (Abitbol et al.,
1995; Roux et al., 1995; Compston et al., 1987). Furthermore, the protein tenascin, mentioned
before to be significantly downregulated in NELL1-deficient mice, is thought to be involved
in stricture formation in CD patients (Geboes et al., 2001).
Before functional or clinical studies are carried out to further clarify the role of NELL1 in IBD,
more efforts are necessary to identify (or verify) the underlying causative mutation(s). Insig-
nificant TDT results for the non-synonymous mutations could be due to transmission ratio
distortion (TRD; see 4.1.5 on page 132). Negative selective pressure that might result in TRD
is possible, since NELL1 is a crucial protein for the organism as shown by NELL1-knockout
mice that die during birth.
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A broad CD-specific association signal of more than 160 kb was identified on chromosome
5p13.1. Unfortunately, none of the 28 typed SNPs indicated an association of the genes near-
by. The signal clearly localizes 125 kb upstream of the next gene PTGER4, the latter coding for
the prostaglandin E receptor 4 (suptype EP4). Enhancer or silencer elements for PTGER4
could reside in the peak region, as it is known from some examples that regulatory elements
can be very distant from the gene of which transcription is influenced (Hardison et al., 2000).
The ligand of the EP4 seven-transmembrane domain, G-protein-coupled receptor is known
to be prostaglandin E2 (PGE2). In the prostaglandin (PG) pathway, the PG endoperoxide in-
termediate PGH2 is synthesized from arachidonic acid by the enzyme cyclooxygenase (COX;
also known as PTGS2). Several PGE synthases exist that convert PGH2 into PGE2, which is
known to have a relatively short half-life and to act over short distances in an autocrine or
paracrine manner (Hull et al., 2005). EP4 receptor signaling generates increased intracellular
cyclic AMP (cAMP) levels via coupling to Gs proteins. Interestingly, the EP4 receptor is highly
expressed in the intestinal epithelium (see GeneCards® entry). Potential physiologic roles for
EP receptors in vivo can also be hypothesized from in vitro data. For example, the EP4 recep-
tor mediates mucus production and protects against apoptosis in colonic and gastric epithe-
lial cells (Sheng et al., 1998; Belley et al., 1999 ; Hoshino et al., 2003). Therefore, impaired
function of the EP4 receptor could promote mucosal injury in vivo (Hatazawa et al., 2006)
and increase susceptibility to IBD. Not surprisingly, drugs for IBD treatment are evaluated
that alter the PG pathway, e.g. inhibitors of the enzyme COX-2 (McCartney et al., 1999). Pros-
taglandins are thought to be essential in the process of wound healing in the gastrointestinal
tract (Wallace et al., 2001) and use of non-steroidal anti-inflammatory drugs (NSAIDs), which
inhibit both the transcription and activity of COX-2, exacerbates the symptoms in UC (Eber-
hart et al., 1995) and may even activate quiescent IBD (Kaufmann et al., 1987). Thus, the ex-
pression of COX-2 in the inflamed intestine might be a protective response within the
woundhealing process (Singer et al., 1998). Two polymorphisms in the COX-2 gene have
been associated with IBD by Cox et al. (2005), but this finding needs support from further
replication studies.
Just recently, Kurz and colleagues (2006) fine mapped a previously known linkage region on
chromosome 5p13 that was associated with asthma. Strikingly, besides five other candidate
genes, they identified variation in PTGER4 as a susceptibility factor for asthma. Since pros-
taglandins have important roles in inflammation and immediate hypersensitivity, the EP4
receptor can be involved in the pathogenesis of asthma and IBD. It has long been known that
PGE2 is produced abundantly in skin upon exposure to antigens (Ruzicka et al., 1982; Eber-
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this immune response by stimulating Langerhans cell mobilization, migration, and matura-
tion.
In summary, PTGER4 seems to be the perfect candidate gene in the 5p13 susceptibility re-
gion and PTGER4 regulatory elements might be altered in CD patients. However, it cannot be
ruled out that a potentially existing regulatory element could also influence the expression of
a more distant candidate gene, such as CARD8. As long as this hypothesis has not been prov-
en, it is also likely that a yet unknown gene exists in the peak region, but evidence in form of
spliced ESTs is scarce.
4.4 Concluding remarks and future studies
The genetic findings of the novel IBD susceptibility loci ATG16L1, NELL1, and 5p13.1 in this
study require further investigations, especially on the functional level. Since the non-synon-
ymous SNP rs2241880, which is strongly associated with CD, is the most consistent and un-
ambigous finding of the two screenings, next experiments should focus on the altered
function of the ATG16L1 protein.
The first reasonable experiment, which is already ongoing, is to look for a different cellular
localization of the mutant protein compared to the wildtype protein. This can be achieved by
examining the two different protein variants, which must be GFP-labelled, using a fluores-
cence microscope. To this end, the point mutation must be introduced into a full-length se-
quence clone, then subcloned into a GFP-vector, and subsequently transfected into
ATG16L1 knock-down cells. The latter can be done by transfecting cells with RNAi, which is
specific for part of the ATG16L1 untranslated region. By not targeting the actual coding re-
gion of ATG16L1, transcribed mRNAs from the GFP constructs won’t be degraded and only
cellular transcript levels are reduced. First experiments with ATG16L1 knock-down cell lines,
which were subsequently not transfected with any other ATG16L1 constructs, have shown
that the viability of the cells is significantly reduced as autophagosomes keep accumulating.
Another good experiment would be to study the impact of the found ATG16L1 and NELL1
mutations in a mouse model. Knock-out mice for both genes (see 4.3 on page 135) exist, but
the loss-of function phenotypes do not adequately reflect the effect, which an altered protein
can have in the pathogenesis of IBD. Therefore, mice strains should be bred that are homozy-
gous for either wildtype or mutant allele of the respective homologous SNP. Afterwards, the
different strains could be exposed to mucosal-damaging reagents and subsequently com-
pared for different IBD incident rates and severity of the disease.
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it would be interesting to further examine this epistatic phenomenon in cell lines or mouse
models. For example, a variety of experiments could be carried out with four cell lines, each
having a different combination of CARD15/ATG16L1 risk or non-risk genotypes:
So far, associations with IBD have been shown to exist in the German and the British popu-
lation, but more populations with different ethnical backgrounds should be tested. It is
planned to test the associations in a Korean and a Norwegian IBD sample. Other groups will
certainly test their sample collections once the data is publicly available. As it is possible that
the IBD-associated mutations predispose to other chronic inflammatory diseases as well, e.g.
sarcoidosis, psoriasis, or tuberculosis, additional genotyping experiments should include
samples of these disorders.
CARD15 risk background CARD15 wildtype
ATG16L1 risk background cell line A cell line B
ATG16L1 wildtype cell line C cell line D
Table 4-2 Four cell lines with different combinations of genetic risk backgrounds.
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Two independent and hypothesis-free genome-wide association studies were carried out to
find novel susceptibility genes for Crohn’s disease (CD), which is a chronic inflammatory dis-
order of the bowel. In a first sequence-based and “direct” scan, approximately 20,000 non-
synonymous SNPs, which result in a change in protein sequence, were typed. The second
“indirect” map-based scan comprised about 100,000 evenly distributed SNPs.
SNP screen 1
A subset of 19,779 putatively functional SNPs was selected from over 60,000 candidate
nsSNPs compiled from public and private sources. Genotyping in 735 patients with CD and
368 controls by SNPlex™ technology identified 7,159 SNPs as being informative in this pop-
ulation, and the top 72 hits were genotyped in an independent German sample of 380 trios,
878 cases, and 1.032 controls. Besides the known CARD15 variant “SNP 12”, the hierarchic
analyses identified one significantly disease-associated non-synonymous SNP (p = 8.4 x 10-6
single point allelic case-control; p = 2.7 x 10-5 TDT) in the ATG16L1 gene on chromosome
2q37, namely rs2241880. The risk to develop CD was calculated to be 1.77-fold (95% CI: 1.43 –
2.18) higher for homozygous carriers of the “GG” genotype compared to homozygotes for
the rarer allele. The association was replicated in another British CD sample, but not in Ger-
man UC patients, thus classifying ATG16L1 as a CD-specific susceptibility gene. Full muta-
tion detection failed to detect any other cSNP that explained the association. The novel
susceptibility variant rs2241880 interacts genetically with known variants in CARD15
(Breslow Day test, p = 0.039 evaluating homozygous and compound heterozygous carriers of
CARD15 risk alleles). The predicted function suggests that the variant leads to an impairment
of the killing of intracellular bacteria and the identified novel disease gene adds to the under-
standing of CD as an innate immune disorder. Further studies are required to establish the
effect of this variant within the gastrointestinal tract and the role it plays in IBD behaviour
and response to treatment.
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116,161 SNPs were successfully genotyped in 399 controls and 393 CD cases using the
Affymetrix 100k GeneChip®. Among the top 150 significant lead SNPs that were typed in a
larger independent patient panel, SNPs in the NELL1 gene and a gene-free region upstream
of PTGER4 on chromosome 5p13 were replicated. The performed mutation detection for the
NELL1 gene led to the identification of four non-synonymous polymorphisms. CD and UC
patients heterozygous for the rs8176785 variant were found to have a 1.23-fold
(95% CI: 1.03 – 1.46) or 1.35-fold (95% CI: 1.12 – 1.64) increased risk, respectively, compared
to homozygous carriers of the rare allele. In summary, the LD-based screening led to the
identification of a genuine IBD susceptibility gene and a CD-predisposing region of yet un-
known function.
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Zwei unabhängige, genomweite Assoziationsstudien wurden durchgeführt, um prädispo-
nierende Genvarianten für Morbus Crohn (MC), eine chronisch entzündliche
Darmerkrankung (CED), zu finden. Zum einem wurde ein „direkter“ und sequenzbasierter
Scan mit circa 20.000 nicht-synonymen SNPs durchgeführt, zum anderen ein „indirekter“
Scan mit über 100.000 LD-basierten SNPs.
SNP screen 1
Von über 60.000 nicht-synonymen SNPs (nsSNP) aus öffentlichen und privaten Datenban-
ken wurden 19.779 ausgewählt. Die Genotypisierung von 735 MC-Patienten und 368 ge-
sunden Kontrollpersonen führte zur Identifikation von 7.159 in der Population informativen
SNPs. Die 72 am stärksten assoziierten Polymorphismen wurden in einer unabhängigen
deutschen Studiengruppe von 380 „Mutter-Vater-Kind Trios“, 878 MC Einzelpatienten und
1.032 unverwandten Kontrollen nachverfolgt. Neben der bekannten CARD15 Variante
„SNP 12“, wurde der hochsignifikante (p = 8,4 x 10-6 im allel-basierten χ2 Test; p = 2,7 x 10-5
im TDT) nsSNP rs241880 im ATG16L1 Gen auf Chromosom 2q37 identifiziert. Das Risiko für
homozygote Träger des Genotyps „GG“ an MC zu erkranken, ist dabei 1,77fach (95% KI:
1,43 – 2,18) höher als für Homozygote des seltenen Allels „A“. Das Assoziationssignal ließ
sich in einer Britischen MC-Probengruppe bestätigen, jedoch nicht in einer Gruppe aus
deutschen Patienten mit Ulcerativer Colitis (UC). Dieses Ergebnis bestätigte eine eindeutige
Assoziation der ATG16L1-Variante mit MC und nicht mit CED. Eine Resequenzierung der
ATG16L1-codierenden Regionen für 47 MC Proben führte zu keiner weiteren Identifikation
einer zusätzlichen Mutation. Die Suszeptibilitätsvariante rs2241880 zeigte auf genetischer
Ebene eine statistisch signifikante Interaktion mit den bekannten CARD15-Mutationen
(Breslow Day Test, p = 0,039 für untersuchte Homozygote oder kombinierte heterozygote
Träger der CARD15-Risikoallele). Die Schlüsselrolle von ATG16L1 bei der Autophagosomen-
bildung suggeriert eine Beeinträchtigung der Pathogenabwehr durch die Mutation und lief-
ert weitere Argumente für die Sichtweise von MC als eine Barrierekrankheit, die auf eine
Störung des angeborenen Immunsystems zurückgeht. Weitere Experimente sind notwendig,
um den Effekt der Mutation auf den Darm und die Rolle bei der Krankheitsentstehung zu un-
tersuchen.
Chapter 6: Zusammenfassung 147SNP screen 2
Bei diesem Experiment wurden 116.161 SNPs in 399 gesunden Kontrollen und 393 MC-
Proben mit Hilfe einer chip-basierten Methode typisiert. Unter den 150 am höchsten signifi-
kanten SNPs, die in einer größeren, unabhängigen Studienprobe typisiert wurden, ließen
sich Varianten im NELL1-Gen und in einer genfreien Region auf Chromosom 5p13.1 repliz-
ieren. Die durchgeführte Mutationsdetektion für NELL1 führte zur Identifikation von vier
nicht-synonymem Polymorphismen. Für heterozygote MC- bzw. UC-Patienten der Variante
rs8176785 konnte ein 1,23fach (95% KI: 1,03 – 1,46), bzw. 1,35fach (95% KI: 1,12 – 1,64) er-
höhtes Risiko berechnet werden, verglichen mit homozygoten Trägern für das seltenere Al-
lel. Zusammenfassend kann gesagt werden, dass der auf Kopplungsungleichgewicht
basierende Scan zur Identifikation eines echten CED-Suszeptibilitätsgenes und einer mit
MC assoziierten Region führte. Auch für diese Loci sind vor allem funktionelle Studien essen-
tiell, um die genaue Rolle bei der Pathogenese zu bestimmen.
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8.1 Kits, enzymes, and chemicals
Product Manufacturer
100 bp DNA ladder Invitrogen, Karlsruhe, Germany
15 ml reaction tubes Sarstedt, Nümbrecht, Germany
2.2 ml 96 deep well MTP ABgene, Epsom, UK
384 deep well storage plate (max. 300 µl) ABgene, Epsom, UK
384 well PCR MTP Eppendorf, Köln, Germany
384-well MT plates Greiner Bio-One GmbH, Frickenhausen, Germany
384-well MT plates Sarstedt, Nümbrecht, Germany
50 ml reaction tubes BD Biosciences, Heidelberg, Germany
96-well MT plates Costar Corning Incorporated, Cambridge, MA, USA
96-well MT plates Sarstedt, Nümbrecht, Germany
Advantage RT-for-PCR BD Clontech, Palo Alto, CA, USA
Agarose Eurogentec, Köln, Germany
AmpliTaq Gold® with GeneAmp 10x PCR Buffer II & 
MgCl2 solution
Applied Biosystems, Foster City, CA, USA
anti-ATG16L1 ABGENT, San Diego, CA
Bacillol® Bode Chemie, Hamburg, Germany
BigDye Terminator Ready reaction kit v1.1 Applied Biosystems, Foster City, CA, USA
Biosphere® Filter Tips (10/200/1000 µl) Sarstedt, Nümbrecht, Germany
Bromphenol blue Sigma, München, Germany
Cell culture flasks (250 ml; canted neck) BD Biosciences, Heidelberg, Germany
Cryotubes (2 ml) Greiner Bio-One GmbH, Frickenhausen, Germany
dNTP set (100 mM solutions, each 100 µM) GE Healthcare UK Limited, Buckinghamshire, UK
and Amersham, Piscataway, NJ
Easy peel heat seal foil ABgene, Epsom, UK
EDTA Sigma, München, Germany
EDTA blood vial 10 ml Sarstedt, Nümbrecht, Germany
EGF PeproTech, Rocky Hill, NJ, USA
epT.I.P.S Box 100-5000 µl Eppendorf, Köln, Germany
Ethanol pa Merck, Darmstadt, Germany
Ethidium Bromide solution (10 mg/ml) Invitrogen, Karlsruhe, Germany
Exonuclease I GE Healthcare UK Limited, Buckinghamshire, UK
Table 8-1 Kits, enzymes, and chemicals
Chapter 8: Materials 161Flagellin Invitrogen, Karlsruhe, Germany
GeneAmp PCR buffer system Applied Biosystems, Foster City, CA, USA
GenomiPhi v1, v2, and high yield WGA Kit GE Healthcare UK Limited, Buckinghamshire, UK
Glycerol Sigma, München, Germany
goat-anti-rabbit Vector Laboratory, Burlingame, CA
Human Multiple Tissue cDNA (MTC) Panel I BD Clontech, Palo Alto, CA, USA
Human Multiple Tissue cDNA (MTC) Panel II BD Clontech, Palo Alto, CA, USA
IFN-γ BIOSOURCE, Camarillo, CA, USA
Invisorb Blood Giga Kit Invitek, Berlin, Germany
Isopropanol Merck, Darmstadt, Germany
LiChrosolv® double distilled water Merck, Darmstadt, Germany
MicroAmp® optical 96-well reaction plate Applied Biosystems, Foster City, CA, USA
MicroAmp® single strips Applied Biosystems, Foster City, CA, USA
MicroAmp® single tubes Applied Biosystems, Foster City, CA, USA
Microtiter plates, 96-well, round bottom w/ lid Sarstedt, Nümbrecht, Germany
Multiscreen column loader GE Healthcare UK Limited, Buckinghamshire, UK
PicoGreen® Invitrogen, Karlsruhe, Germany
Proteinase K Molecular Research Center, OH, USA
Reaction tubes (0.5/1.5/2.0 ml) Eppendorf, Köln, Germany
SAP GE Healthcare UK Limited, Buckinghamshire, UK
Sephadex powder (G-50 superfine) GE Healthcare UK Limited, Buckinghamshire, UK
Sephadex spin column plates MAHVN 4550 GE Healthcare UK Limited, Buckinghamshire, UK
Serological pipettes with filter (5/10/25 ml) Sarstedt, Nümbrecht, Germany
SmartLadder Eurogentec, Köln, Germany
SNPlex™ System Core Kit Applied Biosystems, Foster City, CA, USA
TAE Buffer 25x ready pack Amresco, Solon, OH, USA
Taq DNA polymerase Qiagen, Hilden, Germany
TaqMan® Universal PCR Master Mix Applied Biosystems, Foster City, CA, USA
TBE Buffer 10x ready pack Amresco, Solon, OH, USA
TGF-β BIOSOURCE, Camarillo, CA, USA
Thermo-Fast® 384 PCR Plate ABgene, Epsom, UK
TNF-α BIOSOURCE, Camarillo, CA, USA
Tris Merck, Darmstad, Germany
Triton-X Sigma, München, Germany
Xylene Cyanol FF Sigma, München, Germany
Product Manufacturer
Table 8-1 Kits, enzymes, and chemicals
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8.2.1 Primers
Region Primer Sequence Amplicon
Promoter
ATG16L_p2_F
ATG16L_p2_R
ATG16L_p1_F
ATG16L_p1_R
5'-CACGAAAAGCAGCTTAACAATCAAAG-3'
5'-AGTGACGCCAGCCTGTAGCC-3'
5'-CACAGTGCTGACTGCATTACATGG-3'
5'-GCCTCAGGTTCCCGCTGAC-3'
828 bp
829 bp
Exon 01
(115 bp)
ATG16L_e01_F
ATG16L_e01_R
5'-TCCGGCCCTCTCGAAAATC-3'
5'-GGGAAAATCCTCCAAAGATAAAACG-3' 505 bp
Exon 02
(94 bp)
ATG16L_e02_F
ATG16L_e02_R
5'-GGGAAGACATTCTTGCAGGTG-3'
5'-TGAATCCTGGCAGGTTAGATGAG-3' 536 bp
Exon 03
(106 bp)
ATG16L_e03_F
ATG16L_e03_R
5'-CTGCTGGAGACACCCGAATG-3'
5'-TGGTGATGGGCCTCAATCTG-3' 445 bp
Exon 04
(74 bp)
ATG16L_e04-2_F
ATG16L_e04-2_R
5'-TGGCAGGGATAGTTCCCCTTTG-3'
5'-GCTGGTAGAAAAGGATCCCAGAGTG-3' 397 bp
Exon 05
(252 bp)
ATG16L_e05_F
ATG16L_e05_R
5'-TTTCCTCTCCTAATGGATTATCCTG-3'
5'-TTGTGGTGTATTTCCTTTTTCTAACTC-3' 600 bp
Exon 06
(66 bp)
ATG16L_e06_F
ATG16L_e06_R
5'-TGATGTTATGAGTTTGGGCTTGTG-3'
5'-CATTAGAAGCTATGATCACACCACTGC-3' 388 bp
Exon 07
(87 bp)
ATG16L_e07_F
ATG16L_e07_R
5'-TGGCAGCTCTTCCTTTTTCTCC-3'
5'-TGCTTCCCTCCCATTAAGCAG-3' 433  bp
Exon 08
(57 bp)
ATG16L_e08_F
ATG16L_e08_R
5'-AGGCTGGGTTTTCCCTTTCC-3'
5'-GCACGCAGCGAGATTAAGAGG-3' 437 bp
Exon 09
(103 bp)
ATG16L_e09_F
ATG16L_e09_R
5'-CTCATTTGAGTGAGGGTGCTTTTG-3'
5'-CCATCCCTCATGCTAGCAATCC-3' 537 bp
Exon 10
(106 bp)
ATG16L_e10_F
ATG16L_e10_R
5'-AGAATCTTAGTTGACCTGGGCTAGGAG-3'
5'-TGGTCAAACGATCCCTTACATAAAATG-3' 433 bp
Exon 11
(71 bp)
ATG16L_e11_F
ATG16L_e11_R
5'-TCATGTTCTCTTTGTCCTGCTATTTTG-3'
5'-GCAGAACCCAAGGGTTTATCAGAG-3' 427 bp
Exon 12
(72 bp)
ATG16L_e12_F
ATG16L_e12_R
5'-GCGAGTTGAAGCACACTCACG-3'
5'-GGAAACACAGATTTCCCCAAGG-3' 392 bp
Exon 13
(121 bp)
ATG16L_e13-14_F
ATG16L_e13-14_R
5'-GAGTCACTGTGCCTGACCTGTTTC-3'
5'-CAAGCAGAGGCACCAACGTG-3' 548 bp
Exon 14
(106 bp)
ATG16L_e15-2_F
ATG16L_e15-2_R
5'-GGCTTCATGTTTAGAGGGGCACTG-3'
5'-TTCATGGGAAAGAACAGCCAAGTG-3' 427 bp
Exon 15
(150 bp)
ATG16L_e16_F
ATG16L_e16_R
5'-TGTCTTAGGGTCTGTTGATGGGAAAG-3'
5'-GGGGGTGGGTCACTACTAACCTG-3' 515 bp
Exon 16
(48 bp)
ATG16L_e17-2_F
ATG16L_e17-2_R
5'-CCTGAGCTGCTCCCGTGATG-3'
5'-CAATAATGGTGGCCTGCAATTATGAAC-3' 385 bp
Exon 17
(102 bp)
ATG16L_e18_F
ATG16L_e18_R
5'-CGGACGGGGCTGAAATACTG-3'
5'-AGTGGCCCCAGCTTCTCTCC-3' 456 bp
Exon 18
(94 bp)
ATG16L_e19_F
ATG16L_e19_R
5'-AGTGAGCTCCTGCCTTGTCG-3'
5'-CCCATTCACGGCAAAGCTAC-3' 407 bp
Table 8-2 Primer sequences used for the mutation detection of the ATG16L1 gene.
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Exon 10-12
ATG16L10-12_F
ATG16L10-12_R
5'-AACGCTGTGCAGTTCAGTCCAG-3'
5'-CACAGTCCAGATTCGGCTTGC-3' 231 bp
β-Actin 3-4 b-Actin_F
b-Actin_R
5'-GATGGTGGGCATGGGTCAG-3'
5'-CTTAATGTCACGCACGATTTCC-3' 518 bp
GAPDH
GAPDH_s
GAPDH_a
5’-CCAGCCGAGCCACATCGC-3’
5’-ATGAGCCCCAGCCTTCTCCAT-3’ 360 bp
Table 8-3 Primer sequences used in the RT-PCR for ATG16L1.
Region Primer Sequence Amplicon
Fragment 1
ATG16L_ex1-9_F
ATG16L_1-9-1_R
5'-CGCCACATCTCGGAGCAAC-3'
5'-CCTGGGCTTTCTCAGCCATC-3'
depends on 
splice variant
Fragment 2
ATG16L_1-9-2_F
ATG16L_ex1-9_R
5'-AAATGCAGCGGAAGGACAGG-3'
5'-CAAGGCAGTAGCTGGTACCCTCA-3'
depends on 
splice variant
Table 8-4 Primer sequences used for splice variant detection of ATG16L1.
Region Primer Sequence Amplicon
Promoter
NEL_pro2_F
NEL_pro2_R
NEL_pro1_F
NEL_pro1_R
5'-TGTTAGTAGGACAAATAGGAAGTGGGA-3'
5'-GCCGAGTCGAAAAGCCG-3'
5'-TGACAGAGCGAATCCCGAGTAAT-3'
5'-AAGCTAGGTGGAAGCAAATGAGC-3'
673 bp
663 bp
Exon 01
(208 bp)
NELL1_ex01_F
NELL1_ex01_R
5'-CGCAACAAGCCACAGTAGCC-3'
5'-CGAGCAGGGCAAAGAGATCC-3' 517 bp
add. Exon
(84 bp)
NEL_ade_F
NEL_ade_R
5'-GGAGTGGTCTGGAGAACTGGTCT-3'
5'-GTGCCCTCAATCCAGAAAGTATTG-3' 423 bp
Exon 02
(129 bp)
NELL1_ex02_F
NELL1_ex02_R
5'-AGCGGGGTAAGGGAGCAAAG-3'
5'-TGATCTCTAATGCCTCCCTCCTG-3' 481 bp
Exon 03
(151 bp)
NELL1_ex03_F
NELL1_ex03_R
5'-GAAACTTGCAATCTGGATTCTTTGG-3'
5'-TGGTCCTTGGAGAGCAAACAAG-3' 515 bp
Exon 04
(171 bp)
NELL1_ex04_F
NELL1_ex04_R
5'-TGCCACGAGGGTTCTCAGAC-3'
5'-GCATGCCTAAGGTCCCATTTG-3' 515 bp
Exon 05
(97 bp)
NELL1_ex05_F
NELL1_ex05_R
5'-GCCCAGATGATGTGTCCAAG-3'
5'-AAACCAGTTTATTCATGTCAAGCAC-3' 464 bp
Exon 06
(73 bp)
NELL1_ex06_F
NELL1_ex06_R
5'-GCCAGCTCACCCTTTGAATG-3'
5'-TCTTTCACTATCTCCAGCACCTCAG-3' 331 bp
Exon 07
(83 bp)
NELL1_ex07_F
NELL1_ex07_R
5'-TCCAGACCTGAAATCCTCTGTG-3'
5'-GCATCAAAGACAGGAATGGTTATG-3' 430 bp
Exon 08
(135 bp)
NELL1_ex08_F
NELL1_ex08_R
5'-TGTGGGCTTGAATGGAAAGC-3'
5'-GTGGTCCTGGAGTGGACTGG-3' 589 bp
Exon 09
(103 bp)
NELL1_ex09_F
NELL1_ex09_R
5'-GTGGTCCTGGAGTGGACTGG-3'
5'-CATGTTAAGTGTCTGCCACATTGC-3' 433 bp
Table 8-5 Primer sequences used for the mutation detection of the NELL1 gene.
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(74 bp)
NELL1_ex10_F
NELL1_ex10_R
5'-AGGTCTGCCTGGGAGATTTAAGG-3'
5'-ATCCAACCCACCGCAGAGAG-3' 397 bp
Exon 11
(100 bp)
NELL1_ex11_F
NELL1_ex12_R
5'-TGTGGCATTATCGTTTTTAGTGGAATC-3'
5'-GGAGCAGCGCACAGAGTTTTG-3' 367 bp
Exon 12
(129 bp)
NELL1_ex12_F
NELL1_ex12_R
5'-GGAAAGCCTCTTACGCCTTGG-3'
5'-TTCAAAGGTCTTGCTTTCTCATGC-3' 526 bp
Exon 13
(126 bp)
NELL1_ex13_F
NELL1_ex13_R
5'-TCAGCTCAGGATGGGATCTAACG-3'
5'-TGGGAGTGGAAATCAATTATGCAG-3' 500 bp
Exon 14
(123 bp)
NELL1_ex14_F
NELL1_ex14_R
5'-GCGCATAGTAAGGTACTGACAAGTGG-3'
5'-TTTCCCTGACGCACAGTACCC-3' 408 bp
Exon 15
(96 bp)
NELL1_ex15_F
NELL1_ex15_R
5'-GCATGCCAGCCCTATGCTAAAC-3'
5'-AGCTCCATCCACCGTCACAAC-3' 467 bp
Exon 16
(141 bp)
NELL1_ex16_F
NELL1_ex16_R
5'-TGGGATTTGCTTCTTCCAGTGAC-3'
5'-GCATGATCCCTGGCCTAATCC-3' 461 bp
Exon 17
(194 bp)
NELL1_ex17_F
NELL1_ex17_R
5'-TCTCCCACACAGAGCAGAACTGAC-3'
5'-TCAAAGCAGGCTTCCCTACCC-3' 551 bp
Exon 18
(177 bp)
NELL1_ex18_F
NELL1_ex18_R
5'-CTGCTCTGCAAGCAAAATCAGG-3'
5'-CTTAGCCACAGGCCCCACAG-3' 492 bp
Exon 19
(225 bp)
NELL1_ex19_F
NELL1_ex19_R
5'-GATCAGCAAAAGCATTCTGAAAGAAG-3'
5'-GCCAGAGTTTCCACCATGTCC-3' 537 bp
Exon 20
(712 bp)
NELL1_ex20_F
NELL1_ex20_R
5'-GGGTCTGTCAGTCCTTCCTTTC-3'
5'-TGCAAATGATCTGATAAGGGAAAC-3' 534 bp
Region Primer Sequence Amplicon
Table 8-5 Primer sequences used for the mutation detection of the NELL1 gene.
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Assay_ID dbSNP ID Type Sequence
Hs99999903_m1 – GEX FAM 5’-GCCTCGCCTTTGCCGATCCGCCGCC-3’
Hs00250530_m1 – GEX FAM 5’-GCCTTGTGTGTCTTCGATGCACATG-3’
Hs00971083_m1 – GEX FAM 5’-TCTAAATCACACTTGCCCAACCTGC-3’
C___9095577_20 rs2241880 AoD
CCCAGTCCCCCAGGACAATGTGGAT
[A/G]
CTCATCCTGGTTCTGGTAAAGAAGT
– rs951199 AbD
F 5’-GATGCCATGTACTTTTTGTTACCTGTT-3’
R 5’-CCACTTCTCTGAGAGTAAAGCACAA-3’
VIC 5’-CATAGGCCACTTAACA-3’
FAM 5’-CATAGGCCAGTTAACA-3’
C__11472042_10 rs1992662 AoD
CCTAGACAACATACTATTCTCCTTA
[A/G]
CATTCCTTTATGTGTGCTCACAATG
C__11472026_10 rs1992660 AoD
GGTAGTATCACTCAAAAATTAGTTA
[C/T]
CATCTGCATGAGTTCTTCTTCATGG
C____392093_10 rs1793004 AoD
TGGATCAGGGCCACAATCTTGTATC
[C/G]
GCAGTCACCACCTCTATAAAGCTTG
– rs2075822 AbD
F 5’-CGGAGGGCATCGGGAA-3’
R 5’-CAAGGGCCATGGTCATGAGT-3’
VIC 5’-CTGGTCCATGGTGCCA-3’
FAM 5’-CTGGTCCATGATGCCA-3’
– rs2907748 AbD
F 5’-CCTGTACCTGGGCTCCTATTTC-3’
R 5’-GGAGGGTGGGCTCCTCTA-3’
VIC 5’-CAGGTAGCTGGGCTAA-3’
FAM 5’-CAGGTAGCTAGGCTAA-3’
– ND1+32656 selfD
F 5’-GTCCTTCTGGTGTACTGATGTATGAAA-3’
R 5’-GAACAGCAAATCAATCTCTGAGGTT-3’
VIC 5’-CGCCCCCCACACA-3’
FAM 5’-CCCCCCCCCACAC-3’
C___3203197_10 rs8176785 AoD
AGTGAGAAATTAATTCAGCTGTTCC
[A/G]
GAACAAGAGTGAATTCACCATTTTG
C__32647553_10 rs8176786 AoD
CCAGCGGATTTTAACCAAGAGCTGT
[C/T]
GGGAATGCCGAGTAAGTGTTAATTT
Table 8-6 TaqMan® assays. Primer/Probe sequences are listed if they were provided by Applied Biosystems. GEX = gene expression
assay; AbD = Assay-by-Design; AoD = Assay-on-Demand. In general, allele 1 is labelled with VIC and allele 2 with FAM.
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F 5’-GCATGGCAGATGGACAATGG-3’
R 5’-AGGAGATGAGAGGCGCTAACT-3’
VIC 5’-ACAAGGTTGCACTGTC-3’
FAM 5’-CACAAGGTTACACTGTC-3’
– NELL1_G-C AbD
F 5’-AGGGATGAGATTCGGTATCACTACA-3’
R 5’-TGCCATGCGGTAAGGAAGTG-3’
VIC 5’-CTCTGTCCTTGGCTTC-3’
FAM 5’-CTGTGCTTGGCTTC-3’
Assay_ID dbSNP ID Type Sequence
Table 8-6 TaqMan® assays. Primer/Probe sequences are listed if they were provided by Applied Biosystems. GEX = gene expression
assay; AbD = Assay-by-Design; AoD = Assay-on-Demand. In general, allele 1 is labelled with VIC and allele 2 with FAM.
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# Pool ID First SNP Description
1 Control A hCV9627665 Control Pool A
2 w1025013003_0001 hCV1767498 TaqMan® Verification Pool
3 w0506290359_0001 rs9290910 Affymetrix follow-up 1
4 w0506290539_0001 rs7681167 Affymetrix follow-up 2
5 w0506290539_0002 rs1488927 Affymetrix follow-up 2
6 w0506270719_0001 rs210465 Affymetrix follow-up X
7 w0506271309_0001 rs965306 Granuloma
8 w0506271309_0002 rs10499108 Granuloma
9 w0508020231_0001 rs4743484 Affymetrix follow-up As and Bs
10 w0508020231_0002 rs1429794 Chromosome 5 und NELL1 follow-up
11 w0508240811_0001 rs6699460 Genizon/ICMB overlaps
12 w0510100166_0001 rs10487428 Residual Affymetrix SNPs
13 w0510100167_0001 rs1063193 cSNP follow-up 1
14 w0510100167_0002 rs7259764 cSNP follow-up 1
15 w0510100167_0003 rs1785506 cSNP follow-up 1
16 w0510100167_0004 rs2361403 cSNP follow-up 1
17 w0510100167_0005 rs1320305 cSNP follow-up 1
18 w0512100656_0001 hCV11507064 cSNP follow-up 2
19 w0512100656_0002 hCV25995063 cSNP follow-up 2
20 w0512100663_0001 hCV15880968 cSNP follow-up 2
21 w0603102006_0001 rs327025 ATG16L1/NELL1 final fine mapping
22 w0603102006_0002 rs1519735 ATG16L1/NELL1 final fine mapping
23 w0603102006_0003 rs6431660 ATG16L1/NELL1 final fine mapping
24 w0603102006_0004 rs3792106 ATG16L1/NELL1 final fine mapping
Table 8-7 SNPlex™ pools. All used SNPlex™ pools are listed in this table. Corresponding assay information files (AIFs) can be found on
the attached DVD (folder: “AIF”). The 428 pools of the cSNP experiment are not listed in this table. AIFs of the latter are on the DVD in the
folder “AIFs_cSNP Project for ABI”.
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8.3.1 Centrifuges
8.3.2 Thermocyclers
8.3.3 Electrophoresis
Heraeus Biofuge fresco Kendro, Hanau, Germany
Heraeus Biofuge pico Kendro, Hanau, Germany
Heraeus Labofuge 400 Kendro, Hanau, Germany
Heraeus Multifuge 3S-R Kendro, Hanau, Germany
Heraeus Varifuge 3.2RS Kendro, Hanau, Germany
Micro Centrifuge Roth, Karlsruhe, Germany
ABI Prism™ 7700 Sequence Detector Applied Biosystems Inc., Foster City, CA, USA
ABI Prism™ 7900HT Sequence Detection System Applied Biosystems Inc., Foster City, CA, USA
Biometra® T Gradient Whatman Biometra GmbH, Göttingen, Germany
Biometra® T1 Thermocycler Whatman Biometra GmbH, Göttingen, Germany
GeneAmp® PCR System 9700 Applied Biosystems Inc., Foster City, CA, USA
BioDoc Analyzer Biometra, Göttingen, Germany
Gel Doc XR Bio-Rad, München, Germany
Gibco BRL Electrophoresis Power Supply 250 EX BioRad, München, Germany
Gibco BRL Horizontal Gel Electrophoresis Apparatus BioRad, München, Germany
High Performance UV Transilluminator VWR, Hamburg, Germany
Horizontal Electrophoresis Apparatus Bio-Rad, München, Germany
KERN 440-47N scale Kern & Sohn, Balingen, Germany
Microwave R-2V18 Sharp Electronics, Hamburg, Germany
Power Pac 300 Electrophoresis Power Supply Bio-Rad, München, Germany
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8.3.5 Other machines
Hydra 384 Robbins Scientific Dunn Labortechnik, Asbach, Germany
Hydra 96 Robbins Scientific Dunn Labortechnik, Asbach, Germany
Power Washer PW384 Tecan, Deutschland GmbH, Crailsheim, Germany
Tecan Carousel for Evo 150 Tecan, Deutschland GmbH, Crailsheim, Germany
Tecan Freedom Evo 150 Tecan, Deutschland GmbH, Crailsheim, Germany
Tecan Freedom Evo 200 Tecan, Deutschland GmbH, Crailsheim, Germany
Tecan Genesis RSP 150 Tecan, Deutschland GmbH, Crailsheim, Germany
Tecan Genesis Workstation 150 Tecan, Deutschland GmbH, Crailsheim, Germany
Tecan Genesis Workstation 200 Tecan, Deutschland GmbH, Crailsheim, Germany
Tecan Spectrafluor Plus Tecan, Deutschland GmbH, Crailsheim, Germany
Te-MO Tecan, Deutschland GmbH, Crailsheim, Germany
Te-MO with cooling rack Tecan, Deutschland GmbH, Crailsheim, Germany
WRC96 washing station Tecan, Deutschland GmbH, Crailsheim, Germany
3700 DNA Analyzer Applied Biosystems Inc., Foster City, CA, USA
3730xl DNA Analyzer Applied Biosystems Inc., Foster City, CA, USA
Axiocam Zeiss, Jena, Germany
Axiophot microscope Zeiss, Jena, Germany
Bambi Compressor DT/23Q Bambi, Birmingham, UK
GFL 1086 shaking waterbath GFL, Burgwedel, Germany
Heraeus 3 incubator Kendro, Hanau, Germany
Heraeus Kelvitron® t Kendro, Hanau, Germany
Mini Vortexer VM-3000 VWR, Darmstadt, Germany
PCR chambers Bä-RO® Technology, Leichlingen, Germany
Platesealer ALPS-300 Abgene, Epsom, UK
Thermomixer 5437 Eppendorf, Köln, Germany
TiMix Control incl. TH15 hood Edmund Bühler Labortechnik, Hechingen, Germany
Vortex-GENIE 2 G-560E Scientific Industries, Bohemia, NY, USA
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8.4.1 Laboratory information management system (LIMS)
An overview of the in-house LIMS is given in section 2.1 on page 24, Hampe et al. (2001), and
Teuber et al. (2005).
8.4.2 Software
FACTS 4.82 Tecan, Deutschland GmbH, Crailsheim, Germany
fastPHASE 1.1 http://www.uwopendoor.org/ViewSoftware.asp?softwareid=3/
Gemini 4.28 Tecan, Deutschland GmbH, Crailsheim, Germany
Genemapper 4.0 Applied Biosystems, Foster City, CA, USA
GENOMIZER http://www.ikmb.uni-kiel.de/genomizer/
Haploview 3.32 http://www.broad.mit.edu/mpg/haploview/
Daly lab, Broad institute, Cambridge, MA 02141, USA
novoSNP 2.0.3 http://www.molgen.ua.ac.be/bioinfo/novosnp/
Primer Express 2.0 http://www.applied-biosystems.com
Applied Biosystems, Foster City, CA, USA
R http://www.r-project.org
rcexact.exe for Fisher’s exact http://www.qimr.edu.au/davidD/
SAS/STAT http://www.sas.com/technologies/analytics/statistics/stat/
Cary, NC, USA
Sequence Detection System 2.1 Applied Biosystems, Foster City, CA, USA
Sequencher 4.2 and 4.5 http://www.genecodes.com
Gene Codes Corporation, Ann Arbor, MI, USA)
SNPbrowser 3.5 http://www.allsnps.com
Applied Biosystems, Foster City, CA, USA
SPSS 13.0 http://www.spss.com
Chicago, IL, USA
UNPHASED package:
COCAPHASE v2.403
TDTPHASE v2.403
http://portal.litbio.org/Registered/Help/unphased/
WHAP 2.09 http://pngu.mgh.harvard.edu/~purcell/whap/
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Statistical analyses
Protein structure prediction
SISA http://home.clara.net/sisa/
Tagger http://www.broad.mit.edu/mpg/tagger/
Arby http://arby.bioinf.mpi-inf.mpg.de/arby/jsp/index.jsp
BioInfoBank http://bioinfo.pl/meta/
DSSP database http://www.cmbi.kun.nl/gv/dssp/
Ensembl http://www.ensembl.org
FATCAT http://fatcat.ljcrf.edu
FFAS03 http://ffas.ljcrf.edu
Genedoc http://www.psc.edu/biomed/genedoc/
Jalview http://www.jalview.org
MUSCLE http://www.drive5.com/muscle/
Pfam http://www.sanger.ac.uk/Software/Pfam/
Porter http://distill.ucd.ie/porter/
POV-Ray http://www.povray.org
PROFsec http://www.predictprotein.org
Protein Data Bank http://www.pdb.org
PSIPRED http://bioinf.cs.ucl.ac.uk/psipred/
SCOP database http://scop.mrc-lmb.cam.ac.uk/scop/index.html
SeaView http://pbil.univ-lyon1.fr/software/seaview.html
Smart http://smart.embl-heidelberg.de
UniProt http://www.uniprot.org
WHAT IF http://swift.cmbi.kun.nl/WIWWWI/
Yasara http://www.yasara.org
YASPIN http://ibivu.cs.vu.nl/programs/yaspinwww/
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Dictionaries and Encyclopedias
Other used web resources
Celera http://www.celera.com
Genetic Association db http://geneticassociationdb.nih.gov/cgi-bin/index.cgi
HapMap http://www.hapmap.org
HGMD http://www.hgmd.cf.ac.uk/ac/index.php
JSNP http://snp.ims.u-tokyo.ac.jp
NCBI dbSNP http://www.ncbi.nlm.nih.gov/SNP/
American Heritage http://www.bartleby.com/61/
Wikipedia http://en.wikipedia.org
BLAST http://www.ncbi.nlm.nih.gov/BLAST/
CEPH http://www.cephb.fr
Genecards http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed
Google http://www.google.de
Google Scholar http://scholar.google.de
MatInspector http://www.genomatix.de/products/MatInspector/
MultAlin http://protein.toulouse.inra.fr/multalin/multalin.html
Primer3 http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi
PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed
RepeatMasker http://woody.embl-heidelberg.de/repeatmask/
SNPeffect http://snpeffect.vib.be/index.php
UCSC Genome Browser http://genome.ucsc.edu
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9.1 Summary of IBD linkage regions
Locus Location Reference Known and proposed candidate genes
– 1p12 Williams et al., 2002 (only UC)
– 1p13–1q3 Vermeire et al., 2004 DAP-3, IL-6R, MUC-1
IBD7 1p32–36 Cho et al., 1998 (UC and CD)
Cho et al., 2000
Vermeire et al., 2004
Ephrin A2, MFAP2, RNU1A, VCAM-1, IL-
12Rβ2, TNFRSF1B (TNFR2)
– 1q43–44 Hampe et al., 1999 (IBD)
– 2q24–32 Barmada et al., 2004 (only UC)
– 3p14 Rioux et al., 2000
IBD9 3p21–26 Satsangi et al., 1996
Hampe et al., 2001
Duerr et al., 2002
GNAI2, CCR2, CCR5, IL-4RA, IL-5RA, IFN-
α A2, 
– 3q24 Williams et al., 2002 (only UC)
– 3q26–28 Cho et al., 1998 (UC and CD)
van Heel et al., 2003
– 4q21–31 Cho et al., 1998 (UC and CD)
Hampe et al., 1999 (only UC)
Vermeire et al., 2004
IL-21, IL-15, IL-21, IL-15
– 5q14 Barmada et al., 2004 (only CD)
IBD5 5q31–33 Rioux et al., 2000 (only CD) SLC22A4/SLC22A5
SPINK5, IL-3, IL-4, IL-5, IL-13, CSF-2
IBD3 6p Satsangi et al., 1996 (only UC)
#2 Satsangi et al., 1996 (only UC)
Hampe et al., 1999 (IBD)
#2 Hampe et al., 1999 (UC and CD)
Stokkers et al., 1999 (metaanalysis)
Williams et al., 2002 (IBD)
van Heel et al., 2003 (only CD)
MHC region, TNF-α, complement C4, C2
– 6q16–27 IDDM-15
– 6q24–26 Barmada et al., 2004 (IBD)
– 7p13–15 Satsangi et al., 1996 CARD4; 7p21: AGR2 (Zheng et al., 2006)
– 7q21 Satsangi et al., 1996 MUC3, HGF, EGFR
– 8q12–13 Barmada et al., 2004 (IBD)
Table 9-1 Summary of IBD loci identified by linkage studies. Most of the IBD linkage literature was reviewed. A few examples of rep-
lication failures are listed for IBD1 on chromosome 16.This failure hints at a particular weakness of the method and genetic heterogeneity.
Chapter 9: Appendix 174– 10p12–15 Hampe et al., 1999 (only CD)
Vermeire et al., 2004
MRC-1, IL-2R, IL-15Rα
– 10q23 Hampe et al., 1999 DLG5 (Stoll et al., 2004)
– 11p15 (Cho et al., 1998)
Williams et al., 2002 (IBD)
– 11q22–23 Williams et al., 2002 (only CD)
Vermeire et al., 2004
MMP-1, MMP-3, MMP-12, MMP-13, MMP-
20, API1, API2
IBD2 12p13.2–q24.1 Satsangi et al., 1996
Duerr et al., 1998 (UC and CD)
Curran et al., 1998 (UC and CD)
Hampe et al., 1999
Barmada et al., 2004 (IBD and UC)
IFN-γ, NRAMP2, VDR, STAT6, ITGB7
– 12q12 Barmada et al., 2004 (IBD and UC)
IBD4 14q11–12 Ma et al., 1999
Duerr et al., 2000 (only CD)
Rioux et al., 2000
Vermeire et al., 2004
T cell receptor α/δ complex, ISGF3G, GZMB, 
LTB4R, DAD-1, MMP-14
– 15q26 Barmada et al., 2004 (IBD and CD)
IBD8 16p12 Hampe et al., 2002
IBD1 16p12–q13 Hugot et al., 1996 (only CD)
Ohmen et al., 1996
Parkes et al., 1996
Brant et al., 1998
Cavanaugh et al., 1998
Curran et al., 1998 (only CD)
Cho et al., 1998 (only CD)
Hampe et al., 1999
Annese et al., 1999
Williams et al., 2002
van Heel et al., 2003
NOT:
Satsangi et al., 1996 (other peak 
than Hugot et al.)
Rioux et al., 1998
Rioux et al., 2000
Barmada et al., 2004
Vermeire et al., 2004
CARD15
BRD7 (personal communications)
CD11 integrin cluster, CD19, IL-4R, SPN
– 16q23 Williams et al., 2002 (only CD)
– 17p12 Williams et al., 2002 (only CD)
Locus Location Reference Known and proposed candidate genes
Table 9-1 Summary of IBD loci identified by linkage studies. Most of the IBD linkage literature was reviewed. A few examples of rep-
lication failures are listed for IBD1 on chromosome 16.This failure hints at a particular weakness of the method and genetic heterogeneity.
Chapter 9: Appendix 175– 17q21–q23 Ma et al., 1999
Vermeire et al., 2004
– 18q21–22 Ma et al., 1999
Duerr et al., 2000
IBD6 19p13 Rioux et al., 2000 (UC and CD)
van Heel et al., 2003 (CD w/o 
CARD15)
ICAM1, C3, TYK2, JAK3, TBXA2R, LTB4H
– 20p12 Vermeire et al., 2004
– 22q11–12 Hampe et al., 1999 (IBD)
Barmada et al., 2004
– Xp21 Hampe et al., 1999 (IBD)
– Xq21–25 Hampe et al., 1999 (only UC)
Rioux et al., 2000
van Heel et al., 2003
Vermeire et al., 2004
IL-2Rγ, IL-13Rα2
Locus Location Reference Known and proposed candidate genes
Table 9-1 Summary of IBD loci identified by linkage studies. Most of the IBD linkage literature was reviewed. A few examples of rep-
lication failures are listed for IBD1 on chromosome 16.This failure hints at a particular weakness of the method and genetic heterogeneity.
Chapter 9: Appendix 1769.2 Construction of coding SNP set
9.2.1 SNP database for marker selection
SNP data were obtained from three sources:
1. The Celera Human RefSNP database (CRA, Kerlavage et al., 2002), version 3.4, which
included about 2.4 million SNPs discovered during the shotgun sequencing of the
Human genome by Celera Genomics (Venter et al., 2001), as well as 2.2 million imported
from public sources, mainly dbSNP (Sherry et al., 2001), JSNP (Hirakawa et al., 2002),
and HGMD (Stenson et al., 2003).
2. The Applera Corp. SNP Project (ASP) database, (Adams et al., 2002), which consists of
266,135 SNPs discovered in 20 European Americans and 19 African Americans by
Sanger sequencing of PCR amplicons overlapping the exons of 23,363 genes annotated
by Celera Genomics (Bustamante et al., 2005).
3. SNPs included in NCBI's dbSNP database (Sherry et al., 2001), release 117.
All SNPs were mapped to the Celera Human genome assembly Release 27 and only those that
mapped to unique locations, after removing redundancy, were advanced in the process
(Table 9-2).
Source Number of SNPs
Celera RefSNP database 4,039,783
Applera SNP Project database 266,135
NCBI dbSNP release 117 4,006,579
Total non-redundant, uniquely mapped 5,560,475
Table 9-2 Sources for SNPs used in marker selection.
Chapter 9: Appendix 1779.2.2 SNP selection and assay development
The SNP selection process was aimed at developing a comprehensive list of common puta-
tive functional cSNPs from all possible sources (Thomas et al., 2002), and to avoid putative
SNPs that are rare variants or potential sequencing or analysis artifacts (Marth et al., 2001).
We thus triaged SNPs based on their measured or expected heterozygosity in populations of
European and African descent. For this we used the allele frequency data obtained during the
ASP project and from the genotyping of 177,781 SNPs in about 45 samples each of European
American, African American, with TaqMan® Validated SNP Genotyping Assays (De La Vega
et al., 2002; De La Vega et al., 2005). When no allele frequency information in population pan-
els was available, we looked for evidence of independent discovery (so called "double-hit"
SNPs, Reich et al., 2003). We used as evidence the ASP project calls, the donor information of
the Celera shotgun reads, and the dbSNP submission handles. SNPs whose minor alleles
were observed in at least two distinct donors in either the ASP or Celera shotgun SNP discov-
ery were selected. We identified SNPs discovered independently by Celera or ASP and by the
public SNP discovery efforts. We also compared single-donor Celera SNPs to the NCBI hu-
man genomic assembly to find cases where the Celera minor allele was confirmed in the
public consensus sequence. Finally, for SNPs when the single source was dbSNP, SNPs with
at least 3 distinct submission handles were included. We compiled 1,601,782 SNPs that meet
these requirements. We then identified non-synonymous SNPs (nsSNPs), either missense or
nonsense, by mapping these SNPs to Celera (Kerlavage et al., 2002; Venter et al., 2001), Ref-
Seq/LocusLink (Pruit et al., 2001), and ENSEMBL (Hubbard et al., 2002) transcripts. At the
end of the process we obtained 28,709 nsSNPs in at least one transcript to be submitted for
assay design (Fig. 9-1). 
To avoid designing oligoprobes overlapping other common SNPs, we "masked" the context
sequence of target SNPs for other adjacent SNPs using only the list of triaged SNPs described
above. Masked context sequence and allele information was submitted to the assay design
pipeline of the SNPlex™ Genotyping System (Tobler et al., 2005), version 1.0, in batches no
larger than 2,500 SNPs. Design batches were organized to group SNPs belonging to a candi-
date gene lists related with immunity and inflammation, and by similar molecular function
as predicted by the PANTHER protein classification (Thomas et al., 2003), when possible. Af-
ter removing SNP assays that failed to meet the oligoprobe design or genome specificity
rules, we obtained and manufactured 19,779 SNPlex™ SNP genotyping assays distributed in
428 multiplexes with probes to type up to 48 SNPs each. Please refer to file
“Supplemental_Table_01.xls” on the DVD for details on the distribution and annota-
tions of SNPs for each SNPlex™ multiplex pool.
Chapter 9: Appendix 178Fig. 9-1 SNP selection and assay development system. For more details see description on page 177.
Chapter 9: Appendix 1799.2.3 Distribution and features of nsSNPs panel
Fig. 9-2 shows the distribution of the set of nsSNPs in our final panel across the human chro-
mosomes.
Fig. 9-2 Distribution of nsSNP panel across human chromosomes. The bars show the actual number of nsSNPs per chromosome, and
the lines represent the nsSNP/gene ratio, based on the Celera gene annotation (R27). The raw SNP to gene ratio (blue line) shows an
apparent higher than average (0.75 nsSNP/gene) value for chromosomes 5, 10, and 14, whereas chromosomes 7, 18, 20, 21, and X
show a lower SNP to gene ratio. However, this apparent distortion disappears if we normalize to count only genes with at least one nsSNPs
in our set (green line), where the genome average is 1.78 nsSNP/gene. The total number of Celera genes covered by nsSNP in our panel
is 9,672 (out of 25,030 genes in the Celera R27 annotation).
We then analyzed the distribution of genes with nsSNPs included in our set using the PAN-
THER protein function classification (Thomas et al., 2003). Of interest was to ascertain if par-
ticular functional classes are unrepresented (i.e. genes classes where common non-
synonymous SNPs are rare) or overrepresented (i.e. gene classes with frequent common vari-
ation). A binomial distribution test was used to calculate p-value for the observed vs. expect-
ed category representation as compared to the entire gene complement (Cho et al., 2000), as
per the Celera human gene annotation, Release 27. The analysis shown in table 9-3, page 180
shows that certain molecular function categories are over- or underrepresented in our panel
with statistical significance. Note that a large proportion of genes are not currently classified
(3373 out of 9672, i.e. 35%).
Chapter 9: Appendix 180Underrepresented in our panel are classes of genes known to be highly conserved and that
carry out several fundamental cellular processes (e.g. protein synthesis, chromatin packag-
ing genes), whereas overrepresented gene classes include some classes that are know for pre-
senting higher levels of genetic variation (e.g. olfactory receptors, cell surface/adhesion).
This suggest that selection pressure might limit common potentially deleterious polymor-
phisms in highly conserved genes participating in fundamental cellular processes, whereas
at the other extreme selection may favour common functional variation on certain classes of
genes that deal with environmental interactions and other functions.
Category
hCG R27
(n=25030)
nsSNP
(n=9672)
Expected
Over (+)
Under (-)
p-value
Protein biosynthesis 837 180 321.12 - 2.10E-18
Pre-mRNA processing 226 51 86.71 - 2.16E-05
Chromatin packaging and remodeling 185 43 70.98 - 2.28E-04
Protein folding 164 38 62.92 - 4.73E-04
Cell adhesion 533 313 204.49 + 6.18E-13
Olfaction 296 192 113.56 + 9.44E-12
Chemosensory perception 328 202 125.84 + 1.94E-10
Signal transduction 3387 1507 1299.46 + 7.20E-10
Cell surface receptor mediated signal transd. 1601 748 614.24 + 3.49E-08
Cell adhesion-mediated signaling 292 173 112.03 + 4.65E-08
Sensory perception 588 307 225.59 + 1.09E-07
Cell structure and motility 1064 502 408.21 + 2.45E-06
Proteolysis 734 360 281.61 + 2.93E-06
Cell structure 679 334 260.50 + 5.22E-06
G-protein mediated signaling 897 425 344.14 + 9.83E-06
Cell communication 1250 567 479.57 + 3.58E-05
Extracellular matrix protein-mediated sign. 54 40 20.72 + 1.08E-04
Lipid, fatty acid, and steroid metabolism 678 317 260.12 + 2.92E-04
Table 9-3 Gene representation of nsSNP panel. Highly significant p-values are marked with a yellow background. For further details of
the underlying statistics see description on page 179.
Chapter 9: Appendix 181We tailored our SNP selection towards variants that are common in the population, rather
than those that might have a potential deleterious impact in protein structure, as it is unclear
the importance of such SNPs in common-complex disease (Thomas et al., 2004). To show
this, we obtained the PANTHER position-specific evolutionary conservation score
(subPSEC) for 9,035 SNPs in our panel. The subPSEC score is the negative logarithm of the
probability ratio of the two variant amino acids arising from a cSNP in a particular gene con-
text. More negative values represent mutations with greater potential impact in protein
structure since they are strongly avoided in natural sequences. Fig. 9-3 shows that potentially
highly deleterious mutations with large negative subPSEC score values are somewhat rare in
our set and that, in fact, our panel includes SNPs with a wide range of subPSEC values (Tho-
mas et al., 2004). We hypothesized that this distribution would ensure that our panel have the
highest coverage possible of variants that might be involved in complex disease and which
are unlikely to be under strong purifying selection, in contrast with variants associated with
Mendelian diseases which are more deleterious and rare in the population (Thomas et al.,
2004).
Fig. 9-3 Distribution of subPSEC score for the nsSNPs in panel. For further details see text above.
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Fig. 9-4 Hit plot of a chromosomal region spanning 600 kbp. The corresponding standard UCSC genome browser view is automati-
cally retrieved using the respective physical map coordinates (NCBI build 34). Pairwise LD is displayed using a color scheme for rho (Morton
et al., 2001), where rho = 1 is depicted by purple and rho = 0 by light gray diamonds. Lines above the LD plot relate the physical marker
density to the equidistant LD plot. For every analysis type, a separate panel is plotted. HAP1-HAP4: WHAP haplotype analysis including
randomization test for the specified sliding window. CCA: χ2-statistic for alleles; CCG: χ2-statistic for genotypes; ORR: odds ratio for car-
riership of less frequent allele; CR: call rate in cases and controls; MAF: major allele frequency; HWE: χ2-statistic for Hardy-Weinberg
equilibrium test. This analysis (ncases = 20, ncontrols = 20) was generated from the sample data set that is provided with the software and
does not relate to any actual phenotype.
Chapter 9: Appendix 1839.4 Supplementary figures in silico protein analysis
Fig. 9-5 Protein sequence alignment ATG16L1. Structure-based multiple sequence alignment of the WD-repeat domains of ATG16L1
homologs and the related proteins CDC4, SIF2, TUP1, and TLE1 with known 3D structures. Each alignment row contains a single WD
repeat frequently characterized by GH and WD dipeptides (bottom annotation). CDC4 and SIF2 comprise eight WD repeats, whereas
TUP1 and TLE1 contain seven WD repeats. The secondary structure depicted at the top of each alignment rows is taken from CDC4 and
represents the β-strands characteristic of WD repeats. Physicochemically conserved amino acids are highlighted in blue boxes. Residue
numbering in the alignment is based on complete protein sequences (table 2-20, page 79). The position of the sequence variant T300A
of human ATG16L1 is marked (top annotation).
Chapter 9: Appendix 184Fig. 9-6 Exemplary output of a secondary structure prediction for human ATG16L1. Here, the PSIPRED web server produced the de-
picted prediction.
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# SNP ID position (build 35) MAF pTDT pTDT3
1 rs7942430 20,594,635 0.39 0.01 0.02
2 rs3740872 20,605,132 0.42 0.14 0.07
3 rs2000959 20,615,255 0.32 0.30 0.85
4 rs10766710 20,624,679 0.50 0.03 0.54
5 rs7122910 20,636,147 0.29 0.68 0.18
6 rs1792969 20,646,062 0.13 0.28 0.08
7 rs1793004 20,655,505 0.26 0.02 0.03
8 rs870194 20,663,881 0.20 0.35 0.62
9 rs1792983 20,674,751 0.20 0.31 0.17
10 rs11025705 20,688,454 0.15 0.35 0.23
11 rs7952174 20,695,492 0.15 0.05 0.47
12 rs7116986 20,711,993 0.13 0.07 0.67
13 rs1519727 20,721,594 0.37 0.39 0.16
14 rs1554368 20,732,334 0.16 0.07 0.04
15 rs327036 20,742,093 0.19 0.20 0.14
16 rs1949523 20,750,221 0.26 0.02 0.18
17 rs1158547 20,771,723 0.29 0.04 0.21
18 rs4923055 20,779,494 0.27 0.04 0.25
19 rs1519735 20,791,833 0.31 0.04 0.43
20 rs435001 20,800,510 0.12 0.45 0.70
21 rs2680989 20,809,773 0.11 0.60 0.91
22 rs11025788 20,829,897 0.22 0.60 0.87
23 rs1429794 20,838,013 0.19 0.63 0.77
24 rs7109004 20,849,339 0.26 0.90 0.50
25 rs1549717 20,867,190 0.14 0.65 0.81
26 rs4296038 20,878,420 0.21 0.69 0.87
27 rs2082080 20,891,024 0.22 0.84 0.61
28 rs2293241 20,905,691 0.28 0.76 0.47
29 rs1880088 20,915,761 0.26 0.85 0.98
30 rs1880084 20,927,365 0.30 0.76 0.93
31 rs952696 20,935,188 0.20 0.68 0.62
32 rs10833417 20,945,048 0.27 0.91 0.56
33 rs10500884 20,955,364 0.13 1.00 0.92
34 rs1400373 20,956,134 0.13 1.00 0.89
35 rs10766756 20,966,312 0.13 0.75 0.84
36 rs10500886 20,976,742 0.25 0.48 0.30
37 rs12791452 20,986,789 0.15 0.40 0.78
38 rs11025878 20,998,335 0.26 1.00 0.50
39 rs4922728 21,009,790 0.19 1.00 0.20
40 rs7937542 21,017,772 0.46 0.49 0.55
41 rs10833444 21,029,035 0.27 0.57 0.67
42 rs9666195 21,038,467 0.36 0.53 0.54
43 rs1543153 21,047,961 0.25 0.56 0.45
44 rs7932820 21,056,960 0.40 0.82 0.31
45 rs12417046 21,066,312 0.19 0.73 0.30
46 rs2403652 21,076,903 0.48 0.42 0.46
47 rs7933049 21,087,224 0.22 0.69 0.74
48 rs4922753 21,096,666 0.26 0.80 0.53
Table 9-4 Fine mapping of NELL1 in panel H (French-Canadian population). SNPs that are significant in the TDT are highlighted in
blue. MAF: minor allele frequency in control individuals. pTDT3: p-value obtained by a three-marker haplotype analysis using TDTPHASE.
Chapter 9: Appendix 18649 rs10766767 21,108,451 0.26 0.80 0.58
50 rs6483748 21,137,843 0.29 0.16 0.54
51 rs4475918 21,147,706 0.39 0.37 0.62
52 rs4923403 21,156,380 0.29 0.16 0.07
53 rs1453983 21,166,668 0.26 0.11 0.10
54 rs1454003 21,175,735 0.19 0.41 0.59
55 rs1823843 21,185,111 0.02 0.22 0.63
56 rs1945327 21,190,821 0.09 0.09 0.73
57 rs1453988 21,201,279 0.31 1.00 0.91
58 rs1670638 21,207,776 0.31 0.95 0.12
59 rs1670640 21,218,026 0.48 1.00 0.80
60 rs1454008 21,230,114 0.42 0.61 0.07
61 rs1791822 21,240,131 0.46 0.91 0.50
62 rs1453990 21,249,027 0.47 0.78 0.96
63 rs716577 21,262,140 0.37 0.74 0.40
64 rs6483756 21,267,196 0.38 0.70 0.44
65 rs10833498 21,277,881 0.32 0.61 0.82
66 rs4335544 21,286,758 0.41 0.55 0.67
67 rs1349818 21,292,747 0.47 0.36 0.28
68 rs4399327 21,302,941 0.50 0.36 0.08
69 rs2187522 21,313,688 0.48 0.25 0.74
70 rs11026036 21,323,317 0.35 0.27 0.85
71 rs7126959 21,333,727 0.28 0.17 0.07
72 rs1945404 21,343,840 0.34 0.57 0.46
73 rs10833520 21,352,936 0.21 0.75 0.89
74 rs1945443 21,365,895 0.38 0.56 0.88
75 rs4539321 21,375,322 0.47 0.33 0.09
76 rs11026072 21,385,901 0.34 0.58 0.63
77 rs7943922 21,394,268 0.48 0.79 0.25
78 rs11026079 21,406,963 0.29 0.77 0.45
79 rs7110569 21,418,064 0.13 0.45 0.81
80 rs1945408 21,428,394 0.17 0.71 0.58
81 rs7945802 21,438,700 0.42 0.48 0.75
82 rs4343021 21,446,511 0.16 0.71 0.99
83 rs10766821 21,458,271 0.37 0.65 0.93
84 rs7116826 21,472,159 0.17 0.72 0.96
85 rs10219188 21,479,105 0.48 0.60 0.67
86 rs6483774 21,491,019 0.48 0.32 0.26
87 rs10766829 21,499,146 0.45 0.70 0.23
88 rs6483779 21,509,362 0.06 0.12 0.17
89 rs7927068 21,516,670 0.45 0.70 0.14
90 rs7926887 21,523,755 0.44 0.52 0.43
91 rs4319515 21,534,943 0.43 0.06 0.35
92 rs4320947 21,544,279 0.45 0.08 –
93 rs4922850 21,557,214 0.11 0.26 –
# SNP ID position (build 35) MAF pTDT pTDT3
Table 9-4 Fine mapping of NELL1 in panel H (French-Canadian population). SNPs that are significant in the TDT are highlighted in
blue. MAF: minor allele frequency in control individuals. pTDT3: p-value obtained by a three-marker haplotype analysis using TDTPHASE.
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# SNP ID position (build 35) pTDT pTDT3
1 rs13161247 40,093,886 0.03 0.29
2 rs12516769 40,106,140 0.06 0.29
3 rs4957239 40,112,759 0.05 0.23
4 rs17819573 40,130,693 0.06 0.09
5 rs978281 40,134,404 0.22 0.11
6 rs2548166 40,178,916 0.08 0.20
7 rs4455605 40,184,520 0.08 0.33
8 rs17820911 40,191,019 0.17 0.25
9 rs1559992 40,198,499 0.15 0.22
10 rs453254 40,200,091 0.14 0.21
11 rs17821331 40,223,211 0.85 0.41
12 rs353339 40,237,557 0.95 0.35
13 rs353325 40,246,690 0.28 0.24
14 rs350069 40,256,884 0.21 0.10
15 rs353367 40,264,205 0.43 0.38
16 rs183046 40,269,981 0.02 0.21
17 rs17224401 40,275,446 0.44 0.16
18 rs17224723 40,287,513 0.49 0.13
19 rs1445010 40,304,133 0.07 0.09
20 rs1445011 40,315,959 0.08 0.14
21 rs348620 40,322,578 0.34 0.32
22 rs348584 40,329,072 0.22 0.30
23 rs180900 40,342,058 0.19 0.35
24 rs4957127 40,351,767 0.16 0.74
25 rs16869833 40,383,331 0.53 0.86
26 rs7725523 40,407,980 0.43 0.38
27 rs895123 40,419,818 0.67 0.30
28 rs16869934 40,433,109 0.14 0.28
29 rs1025969 40,438,670 0.12 0.41
30 rs10512737 40,445,800 0.66 0.29
31 rs4957288 40,459,597 0.13 0.09
32 rs6451507 40,494,445 0.06 0.21
33 rs7725052 40,523,027 0.02 0.04
34 rs6889990 40,536,424 1.00 0.01
35 rs7718309 40,564,656 0.002 0.03
36 rs7713972 40,588,231 0.001 0.03
37 rs6451525 40,590,026 0.002 0.02
38 rs6864749 40,604,350 0.004 0.12
39 rs6451529 40,611,106 0.03 0.09
40 rs4409138 40,639,362 0.01 0.08
41 rs924967 40,650,879 0.01 0.26
42 rs17238368 40,662,946 0.92 0.21
43 rs7714305 40,677,005 0.86 0.14
44 rs7726237 40,724,309 0.90 0.79
45 rs4957343 40,730,827 0.72 0.90
46 rs249413 40,757,195 0.98 0.97
47 rs2329353 40,784,025 0.70 0.93
Table 9-5 Fine mapping of 5p13.1 in a French-Canadian population (panel H). SNPs that are significant in the TDT are highlighted in
blue. MAF: minor allele frequency in control individuals. pTDT3: p-value obtained by a three-marker haplotype analysis using TDTPHASE.
Chapter 9: Appendix 18848 rs29743 40,791,037 0.87 0.50
49 rs257009 40,806,973 0.81 0.68
50 rs10074991 40,826,308 0.81 0.37
51 rs466108 40,832,503 0.76 0.62
52 rs1070446 40,874,985 0.69 0.51
53 rs16870407 40,888,805 0.86 0.24
54 rs16870425 40,901,620 0.44 0.45
55 rs10941526 40,909,835 0.43 0.19
56 rs1376178 40,944,658 0.50 0.62
57 rs9292793 40,952,442 0.26 0.54
58 rs16870528 40,972,426 0.90 0.77
59 rs2455309 40,979,012 0.60 0.27
60 rs1450657 40,985,533 0.49 0.42
61 rs1063499 40,991,318 0.42 0.28
62 rs1061429 41,017,446 0.21 0.10
63 rs2271707 41,033,753 0.08 0.13
64 rs10941529 41,041,548 0.77 0.05
65 rs1160833 41,046,944 0.60 0.02
66 rs325832 41,069,536 0.002 0.006
67 rs13167868 41,076,088 0.25 0.35
68 rs325872 41,089,680 0.06 0.18
69 rs17257858 41,096,124 0.93 0.11
70 rs1423391 41,106,597 0.47 0.16
71 rs325845 41,120,483 0.05 0.42
72 rs11958837 41,151,982 0.66 0.87
# SNP ID position (build 35) pTDT pTDT3
Table 9-5 Fine mapping of 5p13.1 in a French-Canadian population (panel H). SNPs that are significant in the TDT are highlighted in
blue. MAF: minor allele frequency in control individuals. pTDT3: p-value obtained by a three-marker haplotype analysis using TDTPHASE.
Chapter 9: Appendix 1899.7 Pharmacogenomics and current state of IBD therapy - from bench to bedside
Pharmacogenomics, previously called pharmacogenetics, describes the use of genetics in-
formation to predict pharmacological efficacy and toxic effects (Pierik et al., 2006). Examples
include the evidence associating failure of steroid treatment with variation in expression of
the multidrug resistance gene (MDR; Farrell et al., 2000), and responsiveness or resistance to
anti-TNF-α treatment with a polymorphism in the promoter region of TNF-α (Shanahan et
al., 2001). Mutations in the enzyme thiopurine methyltransferase (TPMT) change the thera-
peutic effect of purine analogue drugs, and thiopurine methyltransferase genotyping helps
ensure optimum drug dosing and to identify those at increased risk of toxis effects (Dubinsky
et al., 2000). Additionally, genetic factors affect expression of subclinical markers of CD such
as antibodies to Saccharomyces cerevisiae (ASCA), which have been proposed as diagnostic
markers and as a way to subclassify IBD (Shanahan et al., 2001; Shanahan et al., 2000). ASCA
is present in about 60% of CD patients and less than 5% in UC and non-IBD patients (Dubin-
sky et al., 2006; Quinton et al., 1998). It is generally agreed that the presence and level of im-
mune responses do not change in a given CD patient (Desir et al., 2004; Mow et al., 2004;
Dubinsky et al., 2006).
From a practical point of view, predisposed individuals may benefit from genetic findings be-
cause of the following reasons:
1. A more precise diagnosis allows for a more suitable therapy of affected persons.
2. Prophylactic measures might be made to prevent outbreak of disease.
3. Because different “genetic compositions” can lead to the same disease phenotype, but
result in distinct drug responses, individual therapies can be carried out.
This prospect of a “personalized medicine“ is also the main impulse of pharmaceutical com-
panies and with increasing knowledge of the inflammatory cascade and disease susceptibil-
ity genes, many emerging anti-inflammatory strategies are predictable. Every stage in the
inflammatory process can be interrupted with newly devised drugs including biological
agents (Sands et al., 2000), gene therapy (Shanahan et al., 2001), or in some cases with drugs
of low molecular weight. Only antagonism of TNF-α with the monoclonal antibody inflix-
imab is presently approved for use in treatment of CD. Infliximab is a chimeric antibody
composed of murine variable regions specific for human TNF-α, and human IgG1 constant
regions. The murine protein component of infliximab results in adverse immunological re-
sponses in some patients, e.g. formation of human anti-chimeric antibodies, infusion reac-
tions, and delayed hypersensitivity reactions (Sandborn et al., 1999; Schaible et al., 2000). A
general risk with systemic TNF-α inhibition is the activation of latent tuberculosis or other
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fliximab is uncertain but seems to include downregulation of the cytokine cascade, lympho-
cyte trafficking, and angiogenesis and induction of apoptosis in cells with membrane-bound
TNF-α (Feldmann et al., 2001).
Treatment of UC has been extensively reviewed by Hanauer et al. (2001), Sands et al. (2000),
and Sandborn et al. (1996). In brief, 5-aminosalicylates (5-ASA) remain the mainstay for in-
ducing remission of mild-to-moderate active UC, and for maintaining remission (Sutherland
et al., 2000). Glucocorticoids, a class of steroid hormones, reduce the production of pro-in-
flammatory cytokines (Sands et al., 2000; Angeli et al., 1999) and inhibit many leukocyte func-
tions, such as adherence, chemotaxis, phagocytosis, and eicosanoid production (Goulding et
al., 1998; Goppelt-Struebe et al., 1997). The long-term benefit of azathioprine and 6-mercap-
topurine in maintaining remission and avoiding steroid treatments (Sandborn et al., 1996;
Ardizzone et al., 1997; Adler et al., 1990) far outweighs potential risks by far (Farrell et al.,
2000).
A further pursued strategy in IBD treatment is therapeutic manipulation of the intestinal flo-
ra. This is done by probiotics, which are live organisms, usually lactobacilli or bifidobacteria
that are given as food supplements either alone or in combination (synbiotics) with certain
polysaccharides (prebiotics) that might independently affect the enteric flora. Probiotic
treatment seems to be efficacious in patients with UC and pouchitis, and trials in animals
with CD have been encouraging (Campieri et al., 1999). Possible mechanisms of probiotic ac-
tion in inflammatory bowel diseases include production of antimicrobial factors, competi-
tive interactions with pathogens, and signaling with the epithelium and mucosal immune
system (Shanahan et al., 2000 ).
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Patient(in)
Fragebogen zur Studie bei chronisch entzündlichen Darmerkrankungen (CED) 
Haben Sie bereits einmal Blut für eine genetische Studie an uns abgegeben?    
 Ja      Nein   unbekannt 
Haben Sie die Einwilligungserklärung unterschrieben?                             Ja      Nein 
Persönliche Daten 
 männlich  weiblich  
Geburtsjahr:  
Gewicht (kg):    
Körpergröße (cm):  
In verschiedenen Volksgruppen treten die CED  in verschiedener Häufigkeit und Ausprägung auf 
Ethnische Herkunft (z.B. deutsch, türkisch, italienisch, polnisch): 
Woran sind Sie erkrankt?  nicht erkrankt   
 Morbus Crohn   CED, aber zwischen M. Crohn/Colitis nicht entschieden 
 Colitis ulcerosa    Collagene Colitis   
 Dickdarmkrebs   andere Darmerkrankung, welche:  
Welcher Ihrer Verwandten (falls zutreffend) hat  Morbus Crohn oder Colitis ulcerosa? 
 unbekannt  keiner 
Welcher Ihrer Verwandten hat Symptome für eine chronisch entzündliche Darmerkrankung, 
ist aber bisher nicht untersucht worden? 
 unbekannt  keiner 
Wie viele Geschwister haben Sie?    
(Bitte mit Alter und Geschlecht angeben,   
wenn verstorben bitte Jahr und Lebensalter angeben) 
  
 unbekannt 
Wie viele Kinder haben Sie selbst?    
(Bitte mit Alter und Geschlecht angeben)   
 unbekannt     
Rauchen Sie oder haben geraucht?    Ja        Nein Wenn ja, 
wie viele Jahre: von..................bis...............  
Wie viele Zigaretten pro Tag: 
Rauchten Sie zum Zeitpunkt der Diagnose?   Ja       Nein 
Trinken Sie Alkohol?  Ja, regelmäßig jeden Tag  
   Unregelmäßig  
   Nie  
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In einer englischen Studie wurde ein Zusammenhang zwischen dem Stadtleben und dem Risiko an Morbus 
Crohn zu erkranken hergestellt:  
Wo sind Sie aufgewachsen ? Wo leben Sie heute?
 Dorf   Dorf  
 Kleinstadt   Kleinstadt  
 Großstadt   Großstadt  
 unbekannt  
In einem Haushalt mit wie vielen Personen wuchsen Sie auf?___________________ 
In einem Haushalt mit wie vielen Personen leben Sie heute? ___________________ 
Welcher Sanitärkomfort herrschte in Ihrer Kindheit?
Fließendes Wasser    Ja        Nein   unbekannt 
Fließendes Warmwasser   Ja        Nein  unbekannt 
Wasserklosett    Ja        Nein  unbekannt 
Zentralheizung    Ja        Nein  unbekannt 
Angaben zur allgemeinen Krankengeschichte: 
Besteht bei Ihnen eine Lungenerkrankung?    Ja   Nein  weiß nicht 
wenn ja, welche:  COPD (chronische Bronchitis)  
 Sarkoidose (Morbus Boeck)   
 Asthma bronchiale     
 Andere: _________________________________ 
Haben Sie Husten oder litten Sie innerhalb der letzten 5 Jahre an Husten? 
 Nein  unbekannt 
 Ja, wegen    Schnupfen, Nasennebenhöhlenentzündung    akutem Infekt   
 Sodbrennen/Refluxkrankheit     Herzschwäche 
 Pneumonie (Lungenentzündung)     Tumor 
                       unbekannt 
Dauer des Hustens?  tgl. >3 zusammenhängende Monate innerhalb 2 Jahren 
   > 2 Wochen 
   < 2 Wochen 
   unbekannt 
Besteht Auswurf?  Ja,  glasig-weißlich 
    gelblich/grünlich 
    bräunlich/rötlich 
   Seit wann?______________  Wie oft am Tag?____________ 
   Nein 
   unbekannt 
Es scheint einen  Zusammenhang zwischen chron. Zahnfleischentzündung („Parodontitis“) und CED zu geben. 
Ist bei Ihnen eine Zahnfleischerkrankung bekannt?  Ja  Nein  weiß nicht 
Haben Sie häufiger Zahnfleischbluten?     Ja  Nein  weiß nicht 
Haben Sie lockere, gewanderte oder gekippte Zähne?  Ja  Nein  weiß nicht 
Mussten Ihnen schon lockere Zähne gezogen werden?  Ja  Nein  weiß nicht 
Eine Verbindung zwischen CED  und entzündl. Hauterkrankungen wurde wiederholt vorgeschlagen. 
Ist bei Ihnen eine Hauterkrankung bekannt?  Ja    Nein  weiß nicht 
Wenn ja, welche: Neurodermitis (atopisches Ekzem)   Ja  Nein  weiß nicht 
 Ekzem      Ja  Nein  weiß nicht 
 Psoriasis (Schuppenflechte)    Ja  Nein  weiß nicht 
   andere: _______________________________   
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Haben/ hatten Sie eines der folgenden Hautprobleme? 
 trockene Haut 
 gestörtes Nagelwachstum 
 Kopfschuppen 
 rote schuppende Stellen (z.B. an den Ellenbogen oder am Haaransatz) 
 keines 
Leiden Sie häufiger unter Juckreiz? 
 Ja,   gelegentlich 
    vor allem bei starkem Schwitzen 
    unangenehmes Gefühl bei direktem Kontakt mit Wolle 
    juckende Bläschen an Handflächen/ Fußsohlen 
 Nein 
Hatten Sie Milchschorf als Säugling?  Ja   Nein  weiß nicht
Leiden Sie unter Allergien?       Ja       Nein  weiß nicht 
Wenn ja, welche: ________________________________________________________ 
Besteht bei Ihnen eine rheumatische Organerkrankung?   Ja       Nein  weiß nicht 
Wenn ja, welche: ___________________________________________________ 
Seit wann: 
Leiden Sie unter anderen Erkrankungen wie  
z.B. Zuckerkrankheit, Bluthochdruck u.a.    Ja       Nein   weiß nicht 
Wenn ja, welche: ________________________________________ 
Seit wann:___________________________ 
Nehmen Sie Tabletten gegen Diabetes      Ja       Nein  weiß nicht 
Wenn ja, welche ________________________________ 
Spritzen Sie Insulin?       Ja       Nein  weiß nicht 
Wenn ja, wieviel (ca.)? _____________________________
Wurden Sie gegen Tuberkulose (Tbc)  geimpft?   Ja       Nein   weiß nicht 
Wurden Sie gegen Masern geimpft?     Ja       Nein   weiß nicht 
Waren Sie als Kind an Masern erkrankt?    Ja       Nein   weiß nicht 
Nahmen oder nehmen Sie Medikamente ein (nur Medikamente, die nicht für die Behandlung 
von CED verwendet werden) ?   Ja       Nein 
Wenn ja, welche und wie lange: 
Die folgenden Fragen bitte beantworten, wenn Sie selbst an einer chronisch entzündlichen 
Darmerkrankung erkrankt sind:  
Welche Darmteile sind bei Ihnen betroffen?                        unbekannt 
 Dünndarm       
 Übergang vom Dünndarm zum Dickdarm    
 Teile des Dickdarms - welche: ______________________________________  
 gesamter Dickdarm (Pancolitis):      
 Enddarm       
genauere Angaben: 
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Haben sich während Ihrer Erkrankung Fisteln entwickelt?   Ja      Nein  weiß nicht 
Wenn ja, welche: 
Enddarm (Analfisteln)  Ja   Nein  
Fisteln zwischen Darmschlingen  Ja   Nein  
Fisteln vom Darm zur Haut  Ja   Nein  
Fisteln zu anderen Organen   Ja   Nein  
Haben sich bei Ihnen im Verlauf der Erkrankung Stenosen (Darmverengungen) ausgebildet? 
  Ja   Nein  weiß nicht 
Haben/Hatten Sie folgende Beschwerden?  
Gelenkschmerzen      Ja   Nein  
Hautentzündungen      Ja   Nein  
Augenentzündungen      Ja   Nein  
Gallengangsentzündungen     Ja   Nein  
Analfissur       Ja   Nein 
Abszesse       Ja   Nein 
Seit  welchem Kalenderjahr ist die Diagnose klar?  
Seit welchem Kalenderjahr hatten Sie erste Beschwerden?  
Hat sich die Diagnose während der Erkrankung schon einmal verändert?  
 Ja   Nein   weiß nicht 
Wenn ja,   von der Diagnose Morbus Crohn zu Colitis ulcerosa   Ja   Nein 
 Von der Diagnose Colitis ulcerosa zu Morbus Crohn   Ja   Nein  
Wie wurde Ihre Erkrankung bestätigt?
Feingewebeschnitt   Ja    Nein   Weiß nicht 
Darmspiegelung    Ja    Nein   Weiß nicht 
Darmröntgen    Ja    Nein    Weiß nicht 
Sind aufgrund Ihrer Erkrankung Operationen notwendig gewesen?    Ja   Nein 
Wenn ja, welche und in welchem Jahr? 
Haben Sie zur Zeit einen künstlichen Darmausgang?    Ja    Nein 
Hatten Sie einmal einen künstlichen Darmausgang?    Ja    Nein 
Wie viele stationäre Krankenhausaufenthalte sind bei Ihnen notwendig gewesen? 
 Nie   
 Weniger als alle 2 Jahre    
 ca. 1x pro Jahr     
 1-3 x pro Jahr     
 Mehr als 3 x pro Jahr   
Wie lange insgesamt im Krankenhaus? 
 weniger als 1 Monat
 1-3 Monate 
 3-6 Monate 
Mehr als 6 Monate 
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Wie lange haben Sie insgesamt Kortison  > 10mg pro Tag nehmen müssen?
 Mehr als ein Jahr  
 bis zu einem Jahr  
 3-6 Monate  
 1-3 Monate  
 Weniger als 1 Monat  
 Noch nie  
Wie viele Schübe haben Sie in etwa pro Jahr?
 Weniger als alle 2 Jahre  
 ca. 1x pro Jahr  
 1-3 x pro Jahr  
 Mehr als 3 x pro Jahr  
Wann war der letzte Schub? 
Sind Sie wegen Ihrer CED vorzeitig berentet worden?   Ja       Nein  
Wenn ja, in welchem Lebensalter? 
Welche Medikamente haben Sie bisher für Ihre chronisch-entzündliche Darmerkrankung 
erhalten?
Früher Aktuell 
Mesalazin (Salofalk, Claversal, Pentasa)  
Sulfasalazin (Azulfidine, Colo-Pleon)  
Cortison  
Budesonid (Entocort, Budenofalk)  
Azathioprin (Imurek, Zytrim, Azafalk, Azamedac, Colinsan)  
6-Mercaptopurin (Puri-Nethol)  
Infliximab (Remicade)  
Methotrexat (MTX)  
Cyclosporin  
Tacrolimus  
Mutaflor  
H15  
Studienmedikamente (bitte genauere Angaben):____________________________________ 
                             ___________________________________ 
Was würden Sie in der Betreuung von Patienten mit chronisch-entzündlichen 
Darmerkrankungen verändern? 
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Wären Sie bereit, an einer Studie zu den sozialen und psychischen Faktoren der chronisch 
entzündlichen Darmerkrankungen teilzunehmen? 
 Ja  Nein  
Nach Eingang der Proben wird jede Verbindung zu Ihrer Adresse und Ihrem Namen aus 
unseren Unterlagen gelöscht. Aufgrund vieler Rückfragen von Patienten haben wir eine 
separate Adressenkartei für die Zusendung allgemeiner Informationen zum Fortgang des 
Projekts.  
Ich möchte weiter über die allgemeinen Ergebnisse der Studie (die in ca. 3 Jahren zu 
erwarten sind) auf dem Laufenden gehalten werden und möchte daher, dass Sie meinen 
Namen und meine Adresse aufbewahren, um mich über die neuesten Forschungsergebnisse 
zu informieren. Diese Daten sollen bitte getrennt von den persönlichen Daten auf dem 
Fragebogen aufbewahrt werden. 
  Ja       Nein 
Ich habe kein Interesse an Informationen über die Studienergebnisse. Bitte löschen Sie 
meinen Namen und meine Adresse nach Eingang sofort. 
 Ja  Nein 
Vielen Dank für Ihre Mitwirkung! 
Bei Rückfragen melden Sie sich bitte gerne unter Telefon 0431-597 1084 (Fr. Timm)
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Patientenaufklärung / Einwilligungserklärung 
Im Rahmen eines Forschungsprojektes zur Entstehung chronisch entzündlicher Er-
krankungen (insbesondere Morbus Crohn und Colitis ulcerosa) bitten wir Sie um Zu-
stimmung  
 20 ml peripher venöses Blut
entnehmen zu dürfen. Wir wollen DNA aus Ihrem Blut gewinnen, um die genetischen 
Ursachen für eine Veranlagung zu chronisch entzündlichen Erkrankungen zu definie-
ren. Die dafür verantwortlichen Gene können sich im gesamten Chromosomenbereich 
befinden, andere als diese Entzündungsgene werden jedoch nicht untersucht.  Wir 
bitten Sie, Ihre Zustimmung durch Ihre Unterschrift zu bestätigen.  Es werden Ihnen 
keine Nachteile entstehen, falls Sie einer Probenentnahme nicht zustimmen sollten. 
Im folgenden möchten wir Ihnen die Vorteile und Risiken einer solchen Probenent-
nahme darstellen: 
Zu erwartende Vorteile für Ihre eigene Behandlung:
Keine unmittelbaren Vorteile.  Es werden sich aus den entnommenen Proben keine 
Rückschlüsse ableiten lassen, die unmittelbaren Einfluß auf Ihre persönliche Behand-
lung haben werden. Auch aufgrund der Anonymisierung können keine persönlichen 
Informationen zur Verfügung gestellt werden. In Zukunft erhoffen wir uns jedoch er-
hebliche Vorteile für alle Patienten Ihrer Krankheitsgruppe, da wir uns durch die weite-
re Aufklärung immunologischer Mechanismen Fortschritte in der Diagnostik bzw. The-
rapie versprechen.  Diese Erforschung von Krankheitsursachen und -mechanismen 
kann hier in Kiel erfolgen oder – im Rahmen von Forschungskooperationen – auch an 
anderen Orten. 
Risiken der Blutentnahme:
Wie zu einer Routineblutentnahme werden Ihnen unter sterilen Bedingungen 20 ml 
Blut aus einer peripheren Vene entnommen.  Die Risiken sind identisch mit denen 
einer Routineblutentnahme:  Lokale Infektion (“bakterielle Entzündung, Vereiterung”) 
und Fehlpunktion einer Schlagader.  Beide Risiken sind bei sachgemäßer Durchfüh-
rung extrem selten. 
Bitte eintragen: 
Name:___________________________________________________________
Adresse:_______________________________________________________________
______________________________________________________________________ 
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Speicherung von Daten:
Ihre persönlichen Daten getrennt von den genetischen Daten gespeichert – sie sind 
nur bis zur Verarbeitung der Blutprobe verfügbar und werden dann gelöscht  
Die gewonnenen Proben werden anonymisiert. Die mit der Probe verbundenen Infor-
mationen zur Krankheit (wie das Krankheitsstadium) werden von den persönlichen 
Informationen unwiderruflich getrennt. Diese Daten werden auf einem Kennwort-
geschützten Computer in einer separat abgesicherten Datenbank gespeichert. Eine 
Weitergabe an unberechtigte Dritte (insbesondere Arbeitgeber, Versicherungen) ist 
damit vollständig ausgeschlossen. Die Weitergabe von Proben und nicht-
personenbezogenen Informationen an wissenschaftliche Kooperationspartner, die zu 
einer schnelleren Beantwortung der wissenschaftlichen Fragestellungen führen kön-
nen, erfolgt ausschließlich in anonymisierter Form.  
Für diese spezielle Situation entbinde ich hiermit den behandelnden Arzt von der 
Schweigepflicht gegenüber Mitarbeitern des Forschungsvorhabens. Bei Beendigung 
der Forschungsaktivitäten werden die Proben und die dazu gehörenden Daten ver-
nichtet.  
Wir würden uns sehr freuen, falls Sie sich entschließen würden, zu diesem für alle 
Kranken mit Morbus Crohn/Colitis ulcerosa so wichtigen Forschungsprojekt durch Ihre 
Einwilligung beizutragen. 
Kommerzielle Nutzung/ Patent
Es kann sein, dass sich im Rahmen zukünftiger Forschung eine kommerzielle Nut-
zung der Forschungsergebnisse, basierend auf Ihrem individuellen biologischen oder 
genetischen Material, oder eine kommerzielle Nutzung des biologischen oder geneti-
schen Materials selbst ergeben wird. Für diesen Fall besteht kein persönlicher An-
spruch, dies gilt ebenfalls für Patentrechte. 
Benachrichtigung über die Ergebnisse des Gesamtvorhabens
Da alle Proben anonymisiert sind, kann Ihnen Ihr persönliches Ergebnis auch auf 
Nachfrage nicht mitgeteilt werden.  Auf Wunsch teilen wir Ihnen gerne die Gesamter-
gebnisse der Forschungslabor-Untersuchungen mit.  In diesem Fall würden wir Ihren 
Namen, Vornamen und Geburtsdatum separat ohne Verbindung zur Blutprobe erfas-
sen um Ihnen einen regelmäßigen Informationsbrief zusenden zu können.  
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Ich willige in die Entnahme von  
      Blut 
 ein 
 nicht ein.   
 Ich habe Zeit und Gelegenheit zur Entscheidung gehabt. Zusätzliche 
Fragen, falls vorhanden, sind mir ausreichend beantwortet worden. 
 Ich bin darüber belehrt worden, daß ich die Zustimmung jederzeit ver-
weigern oder widerrufen kann, ohne daß mir Nachteile in der weiteren 
Diagnostik oder Therapie entstehen.  
Dies ist nur vor der Anonymisierung der Proben möglich. 
 Ich möchte auf die Adressenliste für die Aussendung eines Informati-
onsbriefs zu den Gesamtergebnissen der Untersuchung gesetzt werden. 
  
Ort ............................. 
Datum ........................ 
Unterschrift: ..................................................................... 
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